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  I 
Abstract 
Tumour hypoxia has been linked to increased resistance to both radiotherapy 
and chemotherapy, especially in solid metastatic GI tumours.  Under hypoxic 
conditions, genes that promote tumour growth and survival are up-regulated, 
via the transcription factor hypoxia-inducible factor-1 (HIF-1).  The digestive 
hormone gastrin, which is often over-expressed in GI cancers, has also been 
shown to act as a pro-survival factor, up-regulating processes such as tumour 
proliferation, angiogenesis and migration, and down-regulating apoptosis.  Due 
to the high level of similarity between the downstream events mediated by the 
two proteins, the relationship between gastrin and HIF-1 was investigated.   
 
HIF-1α nuclear protein expression was inducible under hypoxic conditions, 
which led to an expected increase in VEGF gene expression, followed by a 12-
50 fold increase in hypoxic gastrin mRNA expression.  HIF-1α expression and 
transcriptional activity were not consistently affected by exogenous gastrin.  
RNA-interference-mediated knockdown of HIF-1α resulted in a 40-60% down-
regulation of gastrin gene expression under hypoxic conditions suggesting that 
HIF-1α is partially responsible for gastrin up-regulation in hypoxia.  Potential 
hypoxia-response elements (HREs) were identified within the gastrin 
promoter, but were only partially responsive to hypoxic incubation in GI 
carcinoma cells in luciferase-reporter assays.  Other possible mechanisms that 
may account for the increased gastrin gene expression induced under hypoxic 
conditions include interactions of gastrin with other transcriptional regulators, 
either in synergy with or independent from HIF-1, or the sequestration of 
gastrin within the cell by ‘P’-bodies or RNA-binding proteins. 
  II 
These findings may indicate that the addition of anti-gastrin agents such as 
CCK-2 receptor antagonists or gastrin immunogens to the treatment regime of 
patients with solid GI tumours may be clinically beneficial, especially if 
combined with agents used to reduce radiotherapy and chemotherapy 
resistance. 
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1.1 Background 
Cancer is considered as one of the leading causes of death in the developed 
world, second only to circulatory disorders such as heart disease and strokes, 
and therefore is a major burden on public health services in these countries.  In 
2005, there were 153,491 cancer deaths in the UK alone, which accounted for 
approximately 26% of the total deaths for that year (CancerStats Mortality – 
UK, 2008; Jemal, 2008).  There were approximately 284,560 cases of cancer 
diagnosed in 2004 in the UK (CancerStats Incidence – UK, 2008), with males 
and females being approximately equally affected, which was also seen in the 
cancer mortality data.  It has now been established that over one in three 
people will develop cancer at some point in their lives and approximately one 
in four will die from it (CancerStats Incidence – UK, 2008; Jemal, 2008).  
Factors influencing cancer risk involve both genetic and environmental 
components, such as family history and genetic inheritance, diet and smoking 
patterns (CancerStats Incidence – UK, 2008).  
 
There are over 200 known forms of cancer, although there are four types which 
account for approximately half of all cancer diagnosis (54%) and mortality 
(47%) in the UK and other developed countries; Lung, Colorectal, Breast and 
Prostate cancers (CancerStats Incidence – UK, 2008; CancerStats Mortality – 
UK, 2008).  Cancer is considered an age-dependent disease, with 64% of all 
cases occurring in patients aged 65 or over and approximately 76% of all 
cancer mortalities occurring in patients from the same age group (CancerStats 
Mortality – UK, 2008).  Cancer does however affect the younger patient as 
well, as approximately 1 in 10 cases of cancer are diagnosed in patients 
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between the ages of 25-50.  The overall risk of an individual developing cancer 
during their lifetime is one in three.  For patients under the age of 50 however, 
this risk is reduced to 1 in 27 (CancerStats Incidence – UK, 2008).  Cancer is 
responsible for a third of deaths in those under 65, outnumbering those caused 
by the circulatory system (heart disease / stroke) and respiratory system 
combined (CancerStats Mortality – UK, 2008).  The majority of tumours 
diagnosed in adults were solid in nature (CancerStats Incidence – UK, 2008). 
 
The overall incidence of cancer has increased by approximately 25% between 
the years of 1975 to 2004 (CancerStats Incidence – UK, 2008).  As the average 
life expectancy of a country in the Western world keeps increasing, the chance 
of developing cancer also increases.  It has been suggested that by 2025, the 
number of patients diagnosed with cancer will increase by around 100,000 new 
cases per year (CancerStats Incidence – UK, 2005).  The numbers of cancer 
deaths however are slowly decreasing, despite the increase in its incidence.  
During the thirty year period between 1976 and 2005, the number of cancer 
mortalities per 100,000 people dropped by approximately 20%, from 218 to 
180 (CancerStats Mortality – UK, 2008), with the majority of the decrease in 
cancer mortality occurring in the final ten years (i.e. 1996 to 2005).  
 
Tables 1.1 and 1.2 below describe the number of patients who were diagnosed 
with and died from cancers of the gastrointestinal (GI) tract in 2004 and 2005 
respectively.  Colorectal cancer was the most common form of GI cancer, 
accounting for between 12-14% of all cancer incidences and 10-11% of 
mortalities.  Colorectal cancer was responsible for over 16,000 deaths in 2005, 
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slightly affecting more men than women (23 per 100,000 deaths versus 14 per 
100,000 deaths respectively) (CancerStats Mortality – UK, 2008).  The actual 
incidence of colorectal carcinoma however has decreased by approximately 
10% since 1996, with mortality rates down by approximately 20%.  This is 
probably due to an improved diet in Western countries and the earlier 
diagnosis of the condition (CancerStats Incidence – UK, 2005; CancerStats 
Mortality – UK, 2008).  The current lifetime risk of developing colorectal 
cancer is still approximately 1 in 19 (Table 1.1). 
Lifetime risk of 
developing cancer 
Gender-specific cancer 
incidences 
 
Cancer 
Males Females 
Number 
of 
patients 
diagnosed 
in 2004 
Males Females 
Colorectal 1 in 18 1 in 20 
36,109 
(3rd most 
common) 
19,657 
cases 
(~14% of 
total) 
16,452 
cases (~12% 
of total) 
Oesophagus 1 in 75 1 in 75 
7,654  
(9th most 
common) 
4,943 
cases 
(~3% of 
total) 
2,711 cases 
(<1% of 
total) 
Pancreas 1 in 96 1 in 96 
7,654  
(10th most 
common) 
3,603 
cases 
(<1% of 
total) 
3,795 cases 
(~3% of 
total) 
Stomach 1 in 44 1 in 86 
8,178  
(8th most 
common) 
5157 
cases 
(~4% of 
total) 
3,021 cases 
(~2% of 
total) 
Table 1.1 – UK incidence rates and lifetime risk of common GI cancers 
(Information taken from CancerStats Incidence – UK, 2008). 
 
 
 
Stomach cancer is another common GI cancer, making up approximately 3% 
of all cancer diagnoses and 4% of cancer mortalities (CancerStats Incidence – 
UK, 2008; CancerStats Mortality – UK, 2008).  The incidence of this cancer 
however has decreased by 25% since 1992 and mortality by over 30%, which 
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is one of the largest decreases seen in both cancer incidence and mortality, and 
continues the trend seen over the last fifty years (CancerStats Incidence – UK, 
2005; CancerStats Mortality – UK, 2008; Jemal 2008).  Despite the decrease in 
both incidence and mortality, the lifetime risk of developing stomach cancer is 
1 in 44 and 1 in 86 for males and females respectively (Table 1.1).   
Gender-specific cancer mortalities 
 
Cancer Number of 
mortalities in 2005 
Males Females 
Colorectal 16,092  (2nd most common) 
8,637 deaths 
(11% of total) 
7,455 deaths 
(10% of total) 
Oesophagus 7,419  (5th most common) 
4,847 deaths  
(6% of total) 
2,572 deaths  
(3% of total) 
Pancreas 7,238  (6th most common) 
3,455 deaths  
(4% of total) 
3,783 deaths  
(5% of total) 
Stomach 5,672  (7th most common) 
3,523 deaths  
(5% of total) 
2,149 deaths  
(3% of total) 
Table 1.2 – UK mortality rates in common GI cancers (Information taken from 
CancerStats Mortality – UK, 2008). 
 
 
Despite the number of cancer-related deaths being on the decrease, due to 
earlier detection and advances in cancer treatment, the actual numbers of 
cancer cases are still increasing, and with an ever-aging population, cancer 
incidence will continue to rise.  The five-year survival rates for the GI cancers 
discussed above are all under 50%, and apart from colorectal cancer are 
considerably lower than the average cancer five-year survival rate of 43% 
(men) and 56% (women) (CancerStats Survival – UK, 2008).  Table 1.3 details 
the overall five-year survival rates for the four GI cancers in England and 
Wales from 2001, which considered cancers diagnosed between the years 
1996-1999 (CancerStats Survival – UK, 2008).  This data in Table 1.3 does not 
consider the ultimate cause of death of the patients, or any recent advancement 
in cancer treatment, but does highlight how the battle against GI cancer is not 
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yet over. 
Five year survival rate in 2001 
 
Cancer 
Males Females 
Colorectal 47% 48% 
Oesophagus 7% 8% 
Pancreas 2% 2% 
Stomach 13% 14% 
Table 1.3 – England and Wales five-year survival rates in common GI cancers 
(Information taken from CancerStats Survival – UK, 2008). 
 
 
For a cancer to become fully metastatic and invasive, it must acquire six 
characteristic phenotypes (Hanahan and Weinberg, 2000), which are as 
follows: 
• Self-sufficient in providing growth signals (e.g. mutation in oncogenes 
produces a constitutively active component of a growth-promoting 
signalling pathway, such as Akt (also known as Protein kinase B)). 
 
• Show insensitivity to inhibiting signals (e.g. mutation in tumour suppressor 
genes, such as PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) gene, which normally suppressors phosphatidylinositol 3-
kinase (PI3-kinase) /Akt pathways). 
 
• Reduction in cell apoptosis (e.g. down-regulation of pro-apoptotic signals, 
or up-regulation of anti-apoptotic signals). 
 
• Able to continue with DNA synthesis (e.g. up-regulation of telomerase, 
allows for preservation of the full sequence). 
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• Initiates angiogenesis (e.g. up-regulation of vascular endothelial growth 
factor (VEGF)). 
 
• Show metastatic properties allowing for tissue invasion. 
 
The mutations that transform the cells lining the normal mucosa of a tissue 
through hyperplasia, into dysplasia and eventually into a fully formed cancer, 
occur over a long period of time (Hanahan and Weinberg, 2000).  There are 
mutations that occur early during carcinogenesis and are often specific to a 
particular cancer, such as p16 and p53 in oesophageal cancer (reviewed in 
Jenkins et al, 2002) and APC (adenomatous polyposis coli), K-ras and p53 in 
colorectal cancer (Ichii et al, 1993).  Tumours generally require three or more 
mutations in different key pathways to induce a malignant phenotype 
(Vogelstein and Kinzler, 2004). 
 
1.2 Gastrin 
The initial idea that gastric acid secretion was controlled by both nervous and 
hormonal signals arose in 1902, when Bayliss and Starling suggested the 
hormone secretin influenced the levels of pancreatic secretions.  Evidence for 
the same style of control occurring in the stomach was proposed in 1905 by 
Edkins, who suggested that the digestive hormone gastrin played a role in 
stomach acid secretion (Reviewed in Modlin et al, 1997). 
 
The digestive hormone gastrin is produced and released into the circulation by 
G cells, which are located in the antrum of the stomach lining, in the base of 
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the glands.  Gastrin is mainly responsible for the production of gastric acid 
from parietal cells and the proliferation of enterochromaffin-like (ECL) cells.  
The parietal cells are located in the neck of the glands in the fundus of the 
stomach, whereas the ECL cells are located in the base of the glands 
throughout the entire stomach (reviewed in Watson et al, 2006).  G cells are 
mainly located in the antrum of the stomach and in the duodenum, but 
negligible expression has also been described in the pituitary gland and 
pancreas (reviewed in Dockray, 2004).  The ECL cells are stimulated by the 
serum gastrin to proliferate.  This induces the cells to secrete histamine, which 
then acts at histamine receptors on the surface of parietal cells, initiating 
gastric acid secretion (reviewed in Watson et al, 2006).   
 
Gastrin also causes the proliferation of the parietal cells located in the glands 
of the stomach lining.  The use of a gastrin-knockout mouse model revealed 
that the loss of gastrin gene diminished both parietal and ECL cell 
development and number, abolishing gastric acid secretion (Friis-Hansen et al, 
1998).  The introduction of exogenous gastrin reversed these effects, restoring 
the integrity of the stomach lining (Friis-Hanson et al, 1998). 
 
Normal fasting plasma gastrin levels are approximately 30-50pmol/l; however, 
the presence of food in the stomach increases the levels by three-fold 
(Dockray, 2004).  The presence of food is detected by microvilli on the surface 
of G cells, initiating the gastrin-histamine-gastric acid secretion pathway.  To 
prevent the overproduction of gastric acid, a negative-feedback loop is also 
activated.  Histamine, produced by the ECL cells also induces the release of 
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somatostatin from D cells, which are located throughout the stomach, at the 
base of the glands (reviewed in Watson et al, 2006).  The somatostatin inhibits 
G cell function in a paracrine fashion via reducing gene transcription.  
Inhibiting gastric acid secretion via the gastric H+/K+-ATPase inhibitor 
omeprazole decreased somatostatin mRNA expression 3-fold and as a result 
increased plasma gastrin expression 4-fold.  This effect was reversed by 
exogenous treatment with a somatostatin analogue, therefore confirming its 
inhibitory effect on gastrin expression (Brand and Stone, 1998).  Therefore, the 
release of gastrin from G cells is inhibited in a negative feedback loop (Brand 
and Stone, 1998).   
 
Gastrin release from the G cell is also positively modulated via gastrin-
releasing peptide, which is released by neurones present in the stomach, acting 
on its receptor located on the surface of the G cell (Nishi et al, 1985). 
 
1.3 CCK-2 receptor 
Gastrin acts via cholecystokinin-2 receptors (CCK-2 or CCKB-receptors), 
which are 74kD seven-transmembrane G protein-coupled receptors expressed 
within the baso-lateral border of ECL and parietal cells (Figure 1.1)  (Haigh et 
al, 2003).  Low CCK-2 receptor expression can also be found on smooth 
muscle, the pancreas and the brain (Innis et al 1980; Menozzi et al, 1989).  
Gastrin binds to its receptor via a small five amino acid region within the 
second extracellular loop (Silvente-Poirot and Wank, 1996), which induces its 
proliferative effect.  The C-terminal amide group found on the mature gastrin 
peptide is required for it to act at the CCK-2 receptor.  If it is removed, the 
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proliferative and secretory effects normally seen are no longer detectable 
(reviewed in Dockray, 2004).   
CCK-2 receptor structure 
Plasma
membrane
Extracellular
Intracellular
Seven 
Transmembrane
Domains 
Gastrin binding site
N-terminus
C-terminus
 
 
Figure 1.1 – The structure of the CCK-2 receptor, which is a classic seven 
transmembrane domain G protein-coupled receptor. 
 
 
 
There is also a CCK-1 isoform of the receptor, which has approximately 50% 
homology to the CCK-2 receptor isoform, but which gastrin can only bind to 
with low affinity (Silvente-Poirot and Wank, 1996). 
 
Gastrin shares a similar structure to cholecystokinin, as both molecules express 
the C-terminal pentapeptide amide group required for receptor activation.  
Cholecystokinin can bind to both receptors with high affinity, whereas gastrin 
is selective for the CCK-2 receptor (Reubi and Waser, 1996).  As the plasma 
gastrin concentrations increase following the presence of food in the stomach, 
its expression is often becomes 5-10 fold higher than that of cholecystokinin 
(reviewed in Dockray, 2004). 
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1.4 Gastrin synthesis 
The gastrin gene is located on chromosome 17q21.  It is 4kb long and consists 
as a single gene of three exons, with two introns (Ito et al, 1984).  Only the 
second and third exons are transcribed to produce the final gastrin protein (Ito 
et al, 1984).  The expression of this gene is regulated at both the transcriptional 
and translational level.   
 
Post-translational cleavage and peptide modifications allow for multiple 
peptides to be produced from the same gastrin gene and released into the 
plasma as individual biologically active proteins.  These proteins include the 
processing-intermediates progastrin and C-terminal glycine-extended gastrin 
(gly-gastrin) and the final mature amidated gastrin hormones.  The fully 
processed gastrin molecules can either be found as 17 and 34 amino acid 
peptides, with an amide group attached at their C-terminus; they are known as 
G17 and G34 respectively.  It is this C-terminus amidation that is vital for 
gastric acid secretion (Morley et al, 1965). 
 
Within the G cells, the original gastrin transcript is formed from two of the 
three exons of the gastrin gene as a 0.7kb mRNA product.  The transcript 
passes through into the endoplasmic reticulum, where its N-terminal sequence 
is removed to yield progastrin (see Figure 1.2), via the cleavage between 
amino acid residues 21 and 22 (Wang et al, 1996).   
 
This intermediate then continues through into the Golgi apparatus, where it is 
stored in secretory vesicles (Varro et al, 1994).  Here, it is cleaved into gly- 
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gastrin via the actions of two enzymes.  Subtilisin-like prohormone 
convertases, a family of endopeptidases, cleave at pairs of basic residues 
(Arg57/58 and Arg94/95) (Bishop et al, 1998; Dickinson et al, 1993; Varro et 
al, 1994), before carboxypeptidase E removes further basic residues from the 
C-terminus, revealing the glycine group.  This gly-gastrin intermediate is 34 
amino acids in length and is often modified further via processes such as serine 
residue-96 phosphorylation and sulphation of tyrosine residues, which occur 
within the Golgi apparatus (Varro et al, 1994).   
Pathway of gastrin synthesis 
 
Prepro-
gastrin
Progastrin
Lys74Lys75 Gly93Arg94Arg95
Arg57Arg58 Lys74Lys75 Gly93Arg94Arg95
Arg57Arg58 Lys74Lys75 Gly93Arg94Arg95
Cleavage of signal peptide
Prohormone convertase
Carboxypeptidase E
PAM
Lys74Lys75 Gly93 Gly-G34
Prohormone convertasePAM
Lys74Lys75 NH2 Gly93 Gly-G17
NH2 Amidated G17
Prohormone convertase
NH2Amidated G17
Amidated 
G34
 
Figure 1.2 – The pathway of gastrin synthesis (information taken from 
Dockray, 2004 and Stepan et al, 2002). 
 
 
The G34 gly-gastrin is then either hydroxylated at the N-terminus, before 
being amidated via the enzyme peptidyl-alpha-amidating mono-oxygenase 
(PAM) to form the G34 final gastrin product, or cleaved into a 17 amino acid 
gly-gastrin (Stepan et al, 2002; Varro et al, 1995), which then can be amidated 
via PAM.  Only once this processing has occurred, are the G17 or G34 gastrin 
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peptides released from the vesicles.  Amidated G34 and G17 share a common 
C-terminal peptide sequence, which is required for binding to the CCK-2 
receptor (reviewed in Dockray, 2004). 
 
Under optimum conditions, the production of the fully mature amidated gastrin 
(G17) takes approximately 2hrs.  The progastrin intermediate is produced 
within 30mins.  The 34-amino acid amidated or gly-gastrin is detectable within 
60mins and the final G17 gastrin molecules (either the amidated or gly-gastrin 
isoform) by 120mins (Varro et al, 1995). 
 
The final amidated gastrin produced is regulated by the pH of the processing 
vesicle.  The pH of the stomach is approximately 5.6.  Under these conditions, 
the cleavage of the G34 molecule into the G17 gastrin products is favoured, as 
the prohormone convertase enzymes involved are pH sensitive.  (Blackmore et 
al, 2001).  Any increase of pH, via the uptake of amines into the vesicle 
inhibits the cleavage of G34 into G17, resulting in the accumulation of G34 
peptide.  Physiologically, G34 is often produced in duodenal G cells as the pH 
is higher than that found in the antral G cells, where G17 molecule is 
preferentially secreted (reviewed in Dockray, 2004).  G34 peptide has a lower 
metabolic clearance rate than G17 and therefore is held in the plasma for 
longer, leading to increased concentrations of total plasma gastrin levels. 
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1.5 Expression of gastrin in GI tumours 
The digestive hormone gastrin has been suggested to play a role in the 
development of GI cancers, although its exact role is still being elucidated, and 
is a matter of some debate.   
 
There is evidence that suggests that the presence of gastrin is important for 
carcinoma progression in the early stages of carcinogenesis.  The expression of 
both gastrin and its CCK-2 receptor were found within non-metastatic gastric 
carcinoma samples (Henwood et al, 2001), which ranged in nature from 
atrophic gastritis samples, through intestinal metaplasia to epithelial dysplasia 
samples.  Pre-carcinogenic colonic polyps were also found to co-express the 
gastrin and CCK-2 receptor genes (Smith and Watson, 2000).  Only half the 
polyps that expressed the gastrin gene however translated it into the fully 
mature amidated gastrin, which would induce CCK-2-receptor-mediated 
tumour progression.   
 
In gastric and colonic tumour xenograft mouse models, exogenous treatment 
with gastrin increased tumour volume and DNA content (Sumoyoshi et al, 
1984; Winsett et al, 1986).   
 
Gastrin was shown to be expressed in several human gastric and colorectal 
carcinoma cells (McWilliams et al, 1998), pancreatic carcinoma cells (Harris 
et al, 2004) and oesophageal carcinoma cells (Harris et al, 20042). 
 
Increased amidated gastrin levels have also been linked to increased incidence 
of colorectal carcinoma cases in a number of human studies (Ciccotosto et al, 
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1995; Seitz et al, 1991; Thorburn et al, 1998), and has even been linked to 
increasing histological grade of the tumours (Mao et al, 2008).  Gastrin protein 
was shown to be expressed in colonic tumours and their associated resection 
margins (Hartwich et al, 2001), but not in normal colonic mucosa (Hartwich et 
al, 2001; Smith and Watson, 2000).  This evidence however has been disputed 
by further clinical and animal studies in a number of GI carcinomas (Graffner 
et al, 1992; Pinson et al, 1995, Siddheshwar et al, 2001; Yuan et al, 2008).  
The exact association between hypergastrinaemia and colorectal cancer is still 
under investigation.  The initial research into the expression of gastrin in 
colorectal cancers did not correct for confounding factors, such as 
Helicobacter pylori (H. pylori) infection (Ciccotosto et al, 1995) and only 
considered the amidated versions of gastrin and not its processing 
intermediates.  So far, these transitional gastrin peptides have been detected in 
all colorectal tumours tested, often being favoured over the fully mature 
peptide, and are up-regulated when compared to control samples (Ciccotosto et 
al, 1995; Siddheshwar et al, 2001; Thorburn et al, 1998). 
 
Gastrointestinal tumours show increased growth in response to an application 
of gastrin via the CCK-2 receptor.  The majority also express the gastrin gene, 
and therefore can produce both amidated, progastrin and occasionally gly-
gastrin (40-50% of tumours), which could encourage further proliferation of 
the tumour in an autocrine or paracrine fashion (Ciccotosto et al, 1995; Wang 
et al, 1996).  An example of autocrine growth has been demonstrated with the 
rat pancreatic cell line, AR42J, which endogenously expresses both gastrin and 
its CCK-2 receptor, leading to high basal activation (Harris et al, 2004). 
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The presence of excess gastrin would increase the rate of cellular proliferation, 
therefore increasing the chance of spontaneous mutations within the cells.  As 
a result, the excess gastrin would aid the progression of a pre-cancerous lesion 
into full malignancy (reviewed in Smith and Watson, 2000; Watson and Smith, 
2001). 
 
A number of non-cancerous medical conditions can also induce an increase in 
serum gastrin concentrations.  These include: 
 
1) An infection of the antrum by H. pylori, a bacterium which is linked with 
increased risk of the host developing a gastric ulcer.  Infection with H. 
pylori increases the number and activity of G cells and reduces the 
inhibitory effects of D cells (Liu et al, 2005; Zavros et al, 2002).  As a 
result, infection with H. pylori, especially CagA positive strains, induces an 
increase in both gastric acid production (which would lead to peptic ulcers) 
and serum gastrin levels, which may up-regulate gastric cell proliferation, 
therefore increasing the chance of carcinoma development.  
 
2) Zollinger-Ellison syndrome, which induces acid hypersecretion and 
stomach ulceration, leads to high plasma concentrations of the amidated 
gastrin peptide (both G17 and G34) (Gregory et al, 1969).  Tumours from 
patients with this condition were the first to link gastrin with mucosal 
transformation of normal tissue to a hyperplasia state during the 1960s 
(Gregory et al, 1960).   
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3) Pernicious anaemia, where gastric acid secretion is reduced to a level 
where somatostatin-inhibition of the G cells becomes redundant.  This 
allows free transcription and translation of the gastrin gene, inducing an 
increase in serum gastrin levels, in an attempt to induce gastric acid 
secretion (reviewed in Dockray, 2004). 
 
4) Prolonged treatment with proton pump inhibitors, which are the standard 
treatment of stomach ulcers (reviewed in Dockray, 2004).  They reduce the 
level of gastric acid production, therefore removing the feedback inhibition 
of G cell activity, allowing free transcription and translation of the gastrin 
gene. 
 
1.6 Expression of CCK-2 receptors in GI tumours 
A number of epithelial cell tumours have been shown to express the CCK-2 
receptor.  These include gastric, colonic and pancreatic tumours, where 75-
90% expressed both amidated gastrin and the CCK-2 receptor, as identified in 
both human tumour samples and carcinoma cell lines (Goetze et al, 2000; 
McWilliams et al, 1998).  This data however has also been disputed by some 
studies, which suggest that only a low percentage of gastric and colorectal 
tumours expressed the CCK-2 receptor (Ahmed et al, 2004). 
 
Within oesophageal carcinomas, approximately 60% of tumours show an 
increased level of CCK-2 receptor expression (Haigh et al, 2003), however, 
patients with the pre-cancerous condition Barrett’s oesophagus, where the 
oesophagus was damaged due to reflux of stomach acid, leading to chronic 
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pain and inflammation, revealed CCK-2 receptors to be expressed in all 
samples tested (Haigh et al, 2003).  Gastrin would act to increase cellular 
proliferation in an attempt to repair the damaged tissue, but may be less 
important for more advanced stages of carcinogenesis. 
 
Further isoforms of the gastrin receptor have also been demonstrated to exist, 
formed from the original CCK-2 receptor gene as alternate splice variants 
(Biagini et al, 1997; McWilliams et al, 1998; Miyake et al, 1995).  A truncated 
CCK-2 receptor isoform (CCK-2) has been isolated from human stomach, 
being derived from the original CCK-2 gene using a novel exon 1 splice 
variant.  This produces a receptor with no extracellular N-terminus (Miyake et 
al, 1995).  In one study, the CCK-2 receptor was shown to be expressed in 
75.6% of colonic tumours and 100% of resultant metastatic samples, compared 
to 23% and 43% expression for the original CCK-2 receptor isoform in colonic 
tumours and metastases respectively (Biagini et al, 1997).  It has also been 
found to be expressed on gastric carcinoma cell lines (McWilliams et al, 
1998), being co-expressed with gastrin, suggesting that the truncated isoform 
may have a role in the progression and invasion of carcinoma. 
 
Retention of intron IV of the CCK-2 receptor gene gives rise to a further 
isoform of the gastrin receptor, the CCK-C (Cancer) receptor (Smith et al, 
2002).  CCK-C receptor mRNA is expressed within pancreatic carcinomas, but 
not within normal tissue (Smith et al, 2002), suggesting a role in the 
progression of carcinogenesis.  Unlike the normal CCK-2 receptor, the CCK-C 
receptor can bind both the processing intermediates and the final, mature 
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gastrin molecule (Biagini et al, 1997).  It has been suggested that this receptor 
may result in autocrine up-regulation of cell proliferation (Biagini et al, 1997). 
A further CCK-2 receptor splice variant is the CCK2i4 receptor, which also has 
retained intron IV of the CCK-2 receptor gene, giving it 69 extra amino acids 
within the third intracellular loop of the receptor (Hellmich et al, 2000).  
Expression of this receptor in a HEK-293 xenograft model induced constitutive 
tumour growth, in a Src-dependent manner (Chao et al, 2006). 
 
1.7 Gastrin gene regulation 
A number of growth factors and cytokines are responsible for up-regulation of 
gastrin at the transcriptional level (Marks et al, 1996; Shiotani and Merchant, 
1995; Suzuki et al, 2001).  These include epidermal growth factor (EGF), 
tumour necrosis factor-1α (TNF-α), and interleukins 1β and 8 (IL-1β, IL-8), 
which are all frequently expressed in tumours (Hartwich et al, 2001; Konturek 
et al, 2006).  EGF interacts within the gastrin promoter (from -68bp to -54bp) 
at a GC-rich EGF-response element (5’ – GGGGCGGGGTGGGGGG – 3’) via 
the transcription factor Sp-1 (Specificity protein 1) (Merchant et al, 1995), 
which up-regulates gastrin mRNA expression (Merchant et al, 1991). 
 
These growth factors have also been suggested to up-regulate the expression of 
the transcription factor, c-Fos, by a mitogen-activated protein kinase (MAPK)-
dependent or protein kinase C (PKC)-dependent signalling pathway, allowing 
it to bind to the gastrin promoter at a separate site to that of EGF and again 
induce gastrin expression (Marks et al, 1996; Suzuki et al, 2001).   
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Gastrin gene expression is also regulated by the β-catenin/TCF (T-cell factor) 
pathway, especially in colorectal carcinomas (Koh et al, 2000).  A mutation in 
the APC gene, which is normally responsible for the degradation of β-catenin, 
removes its ability to inhibit β-catenin activity.  This allows β-catenin binding 
to the TCF transcription factor, translocation to the nucleus, binding to target 
sequences within the promoter of target genes and as a result, increased 
transcription of gastrin.  Transfection of a constitutively active β-catenin 
protein up-regulates the gastrin promoter activity three-fold (Koh et al, 2000).   
 
Gastrin gene expression is also highly regulated at the level of translation into 
protein therefore its abundance within the cell is very tightly controlled (Bate 
et al, 1996).  A recent study by Grabowska et al (2008) has identified an 
alternative gastrin transcript, which originates within intron one of the gastrin 
gene and is probably driven by a promoter that is present further upstream 
within intron one.  The alternative transcript showed increased activity, when 
inserted into a luciferase-expressing construct, which was further increased in 
conditions of ‘stress’, such as treatment with cytotoxic agents (Grabowska et 
al, 2008). 
 
1.8 Gastrin – Cell survival and proliferation 
Once gastrin has bound to the CCK-2 receptor, PKC becomes activated, and 
via a signal transduction pathway utilising both calcium and MAPK, the 
receptors are internalised and translocated to the nucleus, where they may play 
a role in gene transcription via up-regulating expression of transcription factors 
such as c-fos and Elk-1 (ETS-like transcription factor 1) (Wroblewski et al, 
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2002; Todisco et al, 1997; Todisco et al, 19972).  Inhibition of PKC or MAPK 
activity via specific inhibitors initiated an 80% decrease in gastrin activity, as 
shown in rat AR42J cells (Todisco et al, 1997).  Similar results were achieved 
via the use of gastrin-specific inhibitor CI-988 (Moody and Jensen, 2001).  The 
actions of gastrin allow the production of growth factors, such as heparin-
binding growth factor (HB-EGF) and amphiregulin.  The mRNA expression of 
both of these growth factors was up-regulated in male Sprague-Dawley rats 
within hours of a gastrin infusion.  They act at the EGF receptor, enhancing the 
proliferative effects of gastrin on the gastric mucosa (Tsutsui et al, 1997) and 
possibly even of tissues that do not express the CCK-2 receptor.  H. pylori 
infection further increases the expression and shedding of HB-EGF in the 
gastric mucosa, in a gastrin / CCK-2 receptor-dependent fashion (Dickson et 
al, 2006), which would further increase the transactivation capacity of gastrin.   
 
Within the ECL cells, gastrin up-regulates the expression of genes involved in 
histamine synthesis and secretion, via initiating cellular signalling pathways 
that up-regulate transcription factors such as Sp-1 and CREB (cAMP-
Response Element Binding Protein) (Höcker et al, 1998), which then activate 
target genes.  These include histidine decarboxylase (responsible for the 
conversion of histidine to histamine) and vesicular monoamine transporter type 
2 (VMAT2) (allows storage of freshly manufactured histamine) (reviewed in 
Dockray, 2004), which would lead to increased gastric acid production.  The 
promoter of VMAT2 has been shown to express a gastrin response element (5’ 
– CCGCCCCCTC – 3’) from -56bp to -47bp (Catlow et al, 2007).  Similar 
gastrin response elements have been identified in the promoters of histidine 
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decarboxylase (Raychowdhury et al, 1999) and the Reg1 growth factor (Steele 
et al, 2007), which are responsible for histamine production and ECL 
proliferation respectively.  
 
Amidated gastrin induced cell proliferation and DNA synthesis in a number of 
human carcinoma cell lines, including colonic (Colucci et al, 2005), pancreatic 
(Smith et al, 1995), oesophageal (Haigh et al, 2003) and thyroid medulla 
(Bläker et al, 2004).  In the human gastrin-transgenic mouse model (INS-GAS 
(Insulin-gastrin)), the presence of hypergastrinemia resulted in increased 
proliferation and thickening of the gastric mucosa, when compared to the 
control animals (Wang et al, 1996; Wang et al, 2000), which eventually led to 
the development of gastric carcinoma (Wang et al, 2000).  The INS-GAS 
mouse over-expresses human amidated gastrin due to the insertion of the 
human gastrin gene within the promoter of the insulin gene; this allows for 
human gastrin to be produced from the β-cells of the INS-GAS mouse 
pancreas (Wang et al, 1996).  The excess amidated gastrin would act via the 
CCK-2 receptor, which has also been shown to be over-expressed in the INS-
GAS mouse model (Ottewell et al, 2006).  The effects induced by the over-
expression of human gastrin in the INS-GAS were further accelerated by H. 
pylori infection or treatment with proton pump inhibitors, which are both 
known to induce hypergastrinemia (Wang et al, 1996; Wang et al, 2000).  The 
presence of excess gastrin was also shown to aid gastric mucosal regeneration 
after damage with cytotoxic agents, suggesting that gastrin is also responsible 
for maintaining the integrity of the GI tract (Ottewell et al, 2006).  Similar 
positive growth effects of gastrin were also seen in colonic and pancreatic 
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xenograft mouse models, where exogenous gastrin treatment significantly 
increased tumour volume (Smith and Solomon, 1988; Smith et al, 1995). 
 
The growth responses induced by gastrin were specifically inhibited by the use 
of gastrin antisense, gastrin-specific siRNA (small-interfering ribonucleic acid) 
and CCK-2 receptor antagonists (but not CCK-1 receptor antagonists) in both 
in vitro and in vivo models (Bläker et al, 2004; Grabowska et al, 2007; Haigh 
et al, 2003; Harris et al, 2004; Moody and Jensen, 2001; Smith 1995), 
confirming the idea that gastrin plays a role as a growth factor.  Treatment of 
GI carcinoma cells with gastrin siRNA reduced cell growth by approximately 
60%.  Cells that expressed highest levels of endogenous gastrin, such as the 
colonic C170HM2 carcinoma cells (Grabowska et al, 2007) and pancreatic 
PANC1 carcinoma cells (Smith et al, 1995) were most affected by growth 
inhibition treatment, suggesting that gastrin acts in both an autocrine and 
endocrine manner.   
 
The up-regulation of β-catenin has been shown to increase the transcription of 
the gastrin gene.  There is also evidence however that suggests that gastrin 
plays a role in regulating β-catenin expression (Cao et al, 2006), leading to 
increased tumour growth and survival, via the up-regulation of β-catenin/TCF 
target gene expression.  Gastrin was shown to increase the expression and 
translocation of β-catenin in the colorectal cell line Colo320WT in a CCK-2 
receptor-dependent fashion (Cao et al, 2006).  Exogenous treatment with 
gastrin induced the translocation of β-catenin into the nucleus in a p21-
activated kinase-dependent fashion (He et al, 2008), inducing the expression of 
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β-catenin/TCF transcription factor target genes including c-myc and cyclin D1, 
which have roles in cell proliferation, migration and cell cycle regulation (Cao 
et al, 2006; He et al, 20082).  Mutation of the p21-activated kinase inhibited 
gastrin-induced β-catenin translocation from the cell membrane into the 
nucleus, and its resultant association with TCF (He et al, 2008). 
 
1.9 Gastrin - Apoptosis 
The evasion of apoptosis (or programmed cell death) is a further property that 
is acquired by tumours, to prevent targeted and controlled destruction of cells 
that contain pro-survival mutations.  In a recent study, the levels of apoptosis 
in colorectal cancer were correlated to the level of gastrin expression.  High 
gastrin expression was associated with low levels of apoptosis, whereas low 
gastrin expression suggested high levels of apoptosis (Mao et al, 2008). 
 
Gastrin is responsible for the induction of cyclooxygenase-2 (COX-2) 
expression in a CCK-2 receptor-dependent mechanism.  COX-2 is the 
membrane-associated enzyme that catalyses the rate-limiting step in the 
production of prostaglandins, such as prostaglandin E2.  As a result of 
prostaglandin production, tumour proliferation is induced (Wang and DuBois, 
2006).  Colorectal and gastric carcinomas have been shown to express COX-2, 
which is also expressed in pre-malignant conditions, such as Barrett’s 
oesophagus (Abdalla et al, 2004; Hartwich et al, 2001).  In one study, 90% 
colorectal tumour samples were shown to express COX-2 mRNA, whereas the 
adjacent normal mucosa lacked COX-2 expression (Hartwich et al, 2001). 
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COX-2 is responsible for the propagation of many pro-survival processes, 
which includes the inhibition of apoptosis.  The up-regulation of COX-2 
expression can lead to the increased expression of anti-apoptotic proteins, such 
as Bcl-2 and the decreased expression of the pro-apoptotic proteins, such as 
Bax (Hartwich et al, 2001).  The resultant increase in the ratio between anti- 
and pro-apoptotic proteins reduces the risk of the tumour cell entering 
apoptosis, as cytochrome c is prevented from being released from the 
mitochondria and therefore cannot initiate the effector caspase cascade, 
required for the organised destruction of the cell organelles and proteins 
(reviewed in Hanahan and Weinberg, 2000). 
 
The activity of the Bcl-2 anti-apoptotic protein was also increased after 
treatment with gastrin, via signalling through the Rac/cdc42 G protein, which 
in turn activates the p21-activated kinase (He et al, 2008).  The p21 kinase then 
interacts with β-catenin, enhancing gene transcription via association with the 
TCF transcription factor (He et al, 2008), as previously described above, 
further inducing the inhibition of apoptosis.  Gastrin has also been associated 
with the death receptor ligand Fas in colorectal cancer, which regulates 
apoptosis via inducing the caspase cascade (Mao et al, 2008). 
 
The up-regulation of COX-2 protein by gastrin also involved the PI3-kinase 
/Akt pro-survival signalling pathway.  In rat AR42J cells, which show high 
levels of endogenous gastrin, there were also high levels of phosphorylated 
(activated) Akt (Harris et al, 2004).  Akt was also shown to be phosphorylated 
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in oesophageal carcinoma cell lines, after exogenous treatment with gastrin 
(Harris et al, 2004; Todisco et al, 2001). 
 
Inhibition of gastrin signalling using gastrin antisense, gastrin siRNA, CCK-2 
receptor antagonist or simply removing the serum from the growth media 
increased the level of apoptosis, and more specifically of cytotoxic caspase 
expression, whilst decreasing the level of Akt phosphorylation (Harris et al, 
2004; Grabowska et al, 2007; Todisco et al, 2001).  This confirms that gastrin 
also plays a role as an anti-apoptotic protein. 
 
1.10 Gastrin - Invasion and malignancy 
Gastrin is known to play a role in tumour cell invasion and extracellular 
membrane remodelling.  The presence of hypergastrinemia has previously 
been associated with liver metastasis in colorectal cancer patients (Kameyama 
et al, 1993).   
 
Gastrin actions via the CCK-2 receptor cause a number of genes to be up-
regulated, such as matrix metalloproteinases (MMPs) and extracellular 
protease inhibitors, which are responsible for the degradation of the 
extracellular matrix and the remodelling of tissue.  Gastrin was shown to 
stimulate the invasion of AGS cells through an artificial basement membrane, 
via the activation of MMP-9 (Wroblewski et al, 2002).  The up-regulation of 
MMPs, such as MMP-2, MMP-3 and MMP-9 also aids tumour malignancy via 
increasing the shedding of HB-EGF, allowing for the induction of further 
signalling pathways (Clarke et al, 2006).  Therefore, gastrin may be involved 
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in the processes of invasion and metastasis in carcinogenesis.  Gastrin also 
induced the expression of focal adhesion kinase, a key molecule in tumour 
malignancy in a CCK-2 receptor-dependent manner (Yu et al, 2006).  The 
expression of CCK-2 receptor has also been suggested to be involved in tissue 
repair after injury, as the receptor was associated with areas of regeneration 
(Schmassmann et al, 2000).  The induction of hypergastrinemia increased the 
rate of ulcer healing in a rat oxyntic mucosa model (Schmassmann et al, 2000). 
 
1.11 Gastrin - Angiogenesis 
Angiogenesis, the development of new blood vessels, is another key property 
required for the survival of solid tumours.  This process is highly regulated in 
adults and is normally only required in wound healing / reproduction 
(reviewed in Folkman and Shing, 1992).  Angiogenesis is a major component 
of several pathological conditions, such as cancer, and is often seen in 
advanced tumours where it enhances growth and the ability to metastasise via 
ensuring a constant blood supply, due to the increased microvessel density. 
 
The effects of gastrin on angiogenesis have been investigated using both in 
vitro and in vivo models.  Amidated gastrin was shown to induce human 
umbilical vein endothelial cell (HUVEC) tubule and node formation in two 
separate studies, in a CCK-2 receptor-dependent manner (Clarke et al, 2006; 
LeFranc et al, 2004).  The use of CCK-2 receptor antagonists, such as 
L360,260 significantly inhibited the HUVEC cell angiogenesis (Clarke et al, 
2006; LeFranc et al, 2004).  The pro-angiogenic effect was also suggested to 
be transmitted in a PI-3 kinase/Akt-dependent signal transduction pathway 
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(LeFranc et al, 2004).  The HUVEC cells were also shown to express the 
cancer-specific CCK-C receptor (LeFranc et al, 2004) and increased HB-EGF 
expression / shedding (Clarke et al, 2006), suggesting the possibility that 
gastrin was also inducing other pro-survival processes within the cells.  
Exogenous gastrin treatment was also shown to induce the migration of 
HUVEC cells when grown on gelatine (LeFranc et al, 2004); further 
suggesting that gastrin plays a role in tumour invasion and malignancy. 
 
Microvessels derived from human glioblastomas were also shown to express 
CCK-2 and CCK-C receptors mRNA (LeFranc et al, 2004), and again were 
found to be responsive to gastrin treatment in a pro-angiogenic manner.  
Similar results were also observed via the use of a chorioallantonic membrane 
assay (Clarke et al, 2004), where angiogenesis was promoted after treatment 
with gastrin. 
 
Finally, in a study involving the pre-malignant APCMin mouse model, tumour 
microvessel density was increased after treatment with gastrin (Clarke et al, 
2006), again confirming the early involvement of gastrin in the process of 
carcinogenesis, promoting not only tumour growth, but also angiogenesis in a 
CCK-2 receptor-dependent manner.   
 
Another key molecule involved in the regulation of angiogenesis is COX-2, 
whose expression has been suggested to be induced by the actions of gastrin 
(Ansorge et al, 2007), which, via the stimulation of the CCK-2 receptors 
activates both PI3-kinase/Akt and MAPK pathways, enhancing COX-2 
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transcription and activity (Abdalla et al, 2004; Colucci et al, 2005).  The 
signalling is mediated via the binding of USF-1 (upstream stimulatory factor-
1) and USF-2 transcription factors to a cAMP response element-E box at -56bp 
to -48bp, within the COX-2 promoter (Ansorge et al, 2007).  The level of 
gastrin expression can be positively correlated to the degree of COX-2 present 
(Abdalla et al, 2004).  As a result of gastrin-induced COX-2 expression, a 
number of cell survival processes are up-regulated, including angiogenesis, 
cellular proliferation and invasion, whilst apoptosis is inhibited.   
 
Although normal colonic mucosa does not express COX-2 mRNA, the mucosa 
directly surrounding the tumour has been shown to express both COX-2 and 
the CCK-2 receptor (Hartwich et al, 2001).  The expression of both these 
proteins in non-tumourigenic tissue is another indication that gastrin plays a 
role in the initiation and progression of tumours.  The effects of COX-2 
activity were abolished by the use of CCK-2 receptors antagonists, such as 
YM022 and L-365,260 (Abdalla et al, 2004; Colucci et al, 2005), which 
suggested that gastrin was responsible for the cellular proliferation seen in the 
colon carcinoma cells.  The use of COX-2-specific non-steroidal anti-
inflammatory drugs however, which prevent the actions of the COX-2 enzyme 
only partially inhibited the effects of gastrin.  This indicated that gastrin acts 
via a number of mechanisms (Abdalla et al, 2004; Colucci et al, 2005). 
 
1.12 Hypoxia 
The pro-survival properties induced by gastrin in GI carcinomas are vital for 
the growth and viability of the tumour.  Problems occur however when the rate 
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of cell proliferation exceeds tumour angiogenesis.  The established tumour 
vasculature becomes unable to maintain sufficient oxygen and nutrient supply 
to the tumour, due to the increasing molecular diffusion distances being 
generated.  Any pre-existing vasculatures that do evolve become malformed 
and irregular in nature, resulting in an unbalanced oxygen supply to the tumour 
(reviewed in Vaupel et al, 1989).  This leads to the generation of regions of 
low oxygen tension, or hypoxia; a key feature of solid tumours.  Therefore, the 
cancer must adapt to survive under low oxygen conditions.   
 
The presence of hypoxia is responsible for modulating gene expression in solid 
tumours, inducing both tumour growth and angiogenesis (Maxwell et al, 
1997), via the activity of the transcription factor ‘Hypoxia-Inducible Factor-1’ 
(HIF-1), which was originally postulated as the regulator of hypoxic 
erythropoietin expression (Wang and Semenza, 1993). 
 
A side effect of tumour hypoxia is the development of resistance to both 
radiotherapy and chemotherapy regimes.  Radiotherapy requires oxygen to 
induce DNA breaks (Roots and Smith, 1974), whereas most chemotherapy 
regimes use existing vasculature to reach the internal tumour cells, which in 
large solid tumours is usually inadequate (reviewed in Vaupel et al, 1989).  
The idea that the success of radiotherapy was dependent on the level of tumour 
oxygenation was first described by Gray et al in 1953 (reviewed in Brown, 
1999).  The higher the level of tumour oxygenation, the more likely it is to be 
susceptible to radiotherapy (Brizel et al, 1997; Nordsmark et al, 1996) and 
chemotherapy (Hussein et al, 2006; Teicher et al, 1990).  Teicher et al (1990) 
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tested a panel of chemotherapeutic agents and radiation on both ‘normally 
oxygenated’ and hypoxic tumour cells.  They determined that the majority of 
agents/treatments tested were 2-6-fold more cytotoxic towards the oxygenated 
cells, when compared to the hypoxic equivalents.  Only a few of drugs tested 
had any affect on the hypoxic cells, suggesting that the cells originating the 
furthest away from the vasculature would be the least affected by 
chemotherapeutic agents. 
 
1.13 Hypoxia-inducible factors (HIFs) 
The transcription factor, Hypoxia-Inducible Factor-1 (HIF-1) plays a 
fundamental role in the cellular adaptation to reduced physiological oxygen 
levels (hypoxia).  Its expression was first determined in 1995 in Hep3B cells 
(Wang et al, 1995), as a protein present under reduced oxygen tension that 
regulated the expression of the erythropoietin gene.  It has since been 
established however that HIF-1 is expressed throughout the majority of 
mammalian cells, regulating the expression of key target genes. 
 
HIF-1 is composed of two distinct subunits, the 120kDa inducible alpha 
subunit (HIF-1α) and the 91-94kDa constitutively expressed beta subunit (HIF-
1β), which is also known as ARNT (aryl hydrocarbon receptor nuclear 
translocator) (Wang and Semenza, 1995; Huang et al, 1996).  Both subunits 
are members of the basic helix-loop-helix (bHLH) PER-ARNT-SIM (PAS) 
family of proteins, (Wang et al, 1995), with HIF-1α sharing more homology 
with the drosophila ‘singled-minded’ (SIM) protein, over that of ARNT (Wang 
et al, 1995).  The HIF-1β subunit can form dimers with other bHLH-PAS 
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proteins, whilst HIF-1α is unique to HIF-1. 
 
There are two other isoforms of the HIF-α subunit, HIF-2α and HIF-3α.  The 
HIF-2α isoform also plays a role in regulating gene transcription via 
undergoing dimerisation with the HIF-1β subunit and binding to the promoters 
region of target genes under hypoxic conditions (Tian et al, 1997).  Whilst the 
expression of the HIF-1α subunit is ubiquitous amongst mammalian cells, the 
HIF-2α subunit is limited to vascular endothelial cells, the kidney, heart, lung, 
astrocytes and the epithelium of the small intestine (reviewed in Gordan and 
Simon, 2007).  HIF-1α and HIF-2α proteins share similar structural motifs, 
such as the ODD (oxygen-dependent degradation) domain, dimerisation 
domain, DNA binding motifs and conserved regulatory elements, and both 
bind to the same sequence within the promoter regions of target genes. 
 
The HIF-3α isoform is the least understood of the three proteins.  It is believed 
however that HIF-3α is responsible for the antagonism of HIF-1 or HIF-2-
dependent gene expression (reviewed in Heidbreder et al, 2003; Ratcliffe, 
2007), by reducing the ability of the other isoforms to bind to the DNA and 
therefore reducing their transcriptional activity (Maynard et al, 2007). 
 
1.14 HIF-1α regulation under normal physiological 
conditions 
The HIF-1 transcription factor is responsible for the up-regulation of the 
expression of a number of pro-survival target genes, which are not required for 
normal cellular processes; therefore, the expression of the HIF-1α subunit is 
down-regulated at physiological oxygen concentrations (i.e. between 20-
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100mmHg, which relates to approximately 7% oxygen (Adams et al, 1999)), 
via proteomic degradation, but is highly inducible under hypoxic conditions.  
The HIF-1α protein is constitutively transcribed and translated, however, is 
subjected to rapid degradation (i.e. has a half life of less than 5mins) via an 
ubiquitin-proteasomal-dependent pathway (Wang et al, 1995).   
 
The inducible subunit HIF-1α becomes hydroxylated on proline residues 402 
and 564, within its ODD domain (Chan et al, 2002; Ivan et al, 2001; Jaakkola 
et al, 2001).  This hydroxylation occurs rapidly via the actions of three oxygen 
(plus iron, 2-oxoglutarate and ascorbate)-dependent HIF-1α prolyl hydroxylase 
enzymes, which are active only under physiological oxygen concentrations 
(Jaakkola et al, 2001).  Each proline hydroxylation is considered as an 
independent event (i.e. the hydroxylation of one proline residue does not affect 
the hydroxylation of the other) (Chan et al, 2000). 
 
Prolyl hydroxylase enzymes are homologous to egl-9 (egg-laying defect gene) 
in C. elegans, where they were first identified.  They are also known as ‘HIF 
prolyl hydroxylases’ (Bruick and McKnight, 2001). 
 
The hydroxylation of HIF-1α allows for the von-Hippel-Lindau tumour 
suppressor protein (pVHL), in complex with several other proteins, including 
Cul2 and Elongin C and B, to bind to the HIF-1α.  The binding of pVHL was 
confirmed via precipitation studies, where both HIF-1α and pVHL were shown 
to co-immunoprecipitate together under normoxic conditions (Maxwell et al, 
1999).  pVHL is the recognition component of an E3 ubiquitin ligase, therefore 
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causing the polyubiquitination of HIF-1α, which is then degraded via the 26S 
proteasome (Huang et al, 1998; Maxwell et al, 1999; Salceda and Caro, 1997) 
(Figure 1.3). 
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Figure 1.3 – Normoxic degradation of Hypoxia-Inducible Factor-1α. 
 
 
 
The regulation of the HIF-1α subunit under normoxic conditions was 
determined using mutational analysis and inhibition studies.  Mutation of 
either of the proline residues (402 or 564), or the inhibition of either the 
ubiquitination or proteasomal degradation processes allowed for the 
accumulation of HIF-1α expression under normoxic conditions (Chan et al, 
2002; Chachami et al, 2004).   
 
The inactivation of pVHL activity under normoxic conditions causes HIF-1α 
accumulation, as seen in in vitro models using renal carcinoma cells.  HIF-1α 
becomes constitutively expressed and therefore promotes unregulated growth, 
even if prolyl enzymes are present and functional (Gunaratnam et al, 2003).  If 
the pVHL becomes inactivated, the HIF-1α protein is still subjected to 
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hydroxylation.  HIF-1α can also become over-expressed under normoxic 
conditions due to the presence of other oncogenic mutations, other than those 
that inactivate pVHL.  This would allow HIF-1α to become functionally active, 
despite the presence of the fully operational degradation pathway (Hofer et al, 
2001).   
 
HIF-1α expression is also induced by CoCl2 (cobaltous ions), DFO 
(deferoxamine) and dimethyloxalylglycine (both iron chelators) under 
normoxic conditions (Semenza et al, 1995, Chan et al, 2002; Chachami et al, 
2004).  All three molecules act via pharmacologically competing with prolyl 
hydroxylases, which are iron-dependent enzymes (Chan et al, 2002).   
 
The inhibition of HIF-1α under normoxic oxygen concentrations is also 
regulated via an oxygen-dependent asparagine hydroxylase, known as ‘factor-
inhibiting HIF-1 (FIH-1), which acts as a second oxygen sensor in the HIF-1α 
regulation pathway (Lando et al, 20021).  This enzyme was originally 
identified in 2002 and is responsible for hydroxylating asparagine residue 803, 
in the COOH-terminal transactivation domain of HIF-1α (Lando et al, 20022; 
McNeill et al, 2002).  This hydroxylation reduces the ability of HIF-1α to bind 
to its co-activator p300/CBP (CREB-binding protein) at its CH1 (cysteine-
histidine) domain (McNeill et al, 2002).  FIH-1 prevents HIF-1α accumulation 
in the nucleus under hypoxic conditions, therefore inhibiting its activity, 
although it does not affect its degradation (Lando et al, 20021).  Under hypoxic 
conditions however, FIH-1 activity is inhibited, allowing HIF-1α to form a 
transcriptional complex with p300/CBP and other accessory co-activators, 
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such as Redox-factor 1 (Lando et al, 20022).  Mutation of the conserved 
asparagine induces constitutive p300 interaction, which leads to increased 
transcriptional activation of the HIF-1 transcription factor (Lando et al, 
20021&2). 
 
As a result, the expression of HIF-1α under normoxic conditions is tightly 
regulated via two different mechanisms; degradation by prolyl hydroxylase 
enzymes and inhibition of transcriptional activity by FIH-1.  Therefore the 
expression of HIF-1α is very unstable at physiological oxygen concentrations, 
having a half-life of less than 5mins (Wang et al, 1995).  HIF-1α mRNA is 
constitutively expressed under normoxia within the cytoplasm, to ensure rapid 
up-regulation of the protein if the cell enters hypoxic conditions (Heidbreder et 
al, 2003; Huang et al, 1996). 
 
1.15 HIF-1α and cancer 
HIF-1α is over-expressed in over 70% of human tumours, including those 
found in the brain (especially the cerebral cortex and hippocampus), breast, 
cervical, colon, gastric, lung, ovarian, pancreatic, prostate and renal cancers, as 
shown using multiple in vitro and in vivo models, as well as within primary 
biopsies from patients, when compared to the equivalent normal control 
(Palayoor et al, 2003; Zhong et al, 2002; Zhong et al, 1999).  HIF-1α 
expression in the heart, liver and kidney under hypoxic conditions was low, 
suggesting further mechanisms were required to allow the cell to survive in 
hypoxia (Heidbreder et al, 2003).  HIF-1α protein was mainly expressed in the 
nucleus of tumour cells, often concentrated around areas of neovascularisation, 
  37 
on the periphery of necrotic regions and at invading edges of tumours (Acs et 
al, 2003; Beasely et al, 2002; Büchler et al, 2003; Griffiths et al 2007; Jiang et 
al, 2004; Kuwai et al, 2003; Zagzag et al; 2000; Zhong et al, 1999).  HIF-1α 
has been suggested to play a role in cancer progression, as a number of studies 
investigating different tumour types have linked increasing HIF-1α expression 
with increasing histological tumour grade.  These studies included breast (Bos 
et al, 2001; Bos et al, 2003; Zhong et al, 1999), colorectal (Jiang et al, 2004; 
Kuwai et al, 2003), gastric (Griffiths et al, 2007; Mizokami et al, 2006) and 
ovarian (Nakayama et al, 2002) human carcinoma samples.  Higher HIF-1α 
expression was observed in more advanced tumour samples (i.e. poorly-
differentiated tumours), compared to those of a well-differentiated phenotype.  
Its full role in cancer progression however is still under debate, as the 
expression of HIF-1α within human tumour samples has been correlated with 
both increased and decreased treatment success and overall patient survival.  
For example, in breast, cervical and gastric carcinomas, the expression of HIF-
1α has been associated with increased disease reoccurrence and shorter overall 
patient survival (Birner et al, 2000; Bos et al, 2003; Griffiths et al, 2007; 
Mizokami et al, 2006; Oh et al, 2008; Vleugel et al, 2005).  Improved 
treatment outcome and reduced patient mortality was however noted in head 
and neck, lung and oesophageal tumour samples (Beasely et al, 2002; 
Koukourakis et al, 2001; Lee et al, 2003; Volm et al, 2000).  This may suggest 
that the role of HIF-1α is dependent on the location of the tumour within the 
body and therefore further research is required to determine the full role of 
HIF-1α in carcinogenesis. 
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The constitutive expression of HIF-1 causes the tumours to show a more 
aggressive phenotype, with increased rates of proliferation, angiogenesis 
(shown by increased microvessel density) and invasion / malignancy (Kuwai et 
al, 2003; Oh et al, 2008; Zhong et al, 1999).  This allows the cancer to be more 
resistant to treatment, both using chemotherapy and radiotherapy (Hussein et 
al, 2006) and is therefore linked to a poor prognosis.  The expression of HIF-
1α is more prominent in solid tumours, which have taken time to establish, 
increasing their rate of glycolysis and neovascularisation, therefore ensuring 
their survival (Zhong et al, 2000).  Often, the expression of HIF-1α protein 
increases as the pathological stage increases (i.e. higher expression is present 
in poorly differentiated tumour samples, compared to well differentiated 
tumours) (Bos et al, 2001).   
 
The early expression of HIF-1α also protects cells against apoptosis initially as 
HIF-1 is responsible for the transcription of genes that are anti-apoptotic.  As 
hypoxia continues however, the expression of anti-apoptotic genes is replaced 
by pro-apoptotic versions, such as IAP-2 (inhibitor of apoptosis protein-2) 
(Dong et al, 2001). 
 
1.16 HIF-1α regulation under hypoxic conditions 
Under hypoxic conditions, (where tissue oxygen levels range between 0-
10mmHg, which equals approximately 1.5% oxygen concentration (Adam et 
al, 1999)) the actions of the HIF-1 transcription factor are initiated via the 
inhibition of the regulatory ubiquitin-proteasomal signalling pathway that 
controls the expression of normoxic HIF-1α protein.  The inhibition of prolyl 
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hydroxylases allows for the stabilisation of HIF-1α; therefore, pVHL is 
prevented from binding, allowing the cell to survive with the stress exerted on 
it by hypoxia (Chan et al, 2002) (Figure 1.4).   
Hypoxic regulation of HIF-1α 
Nucleus
Cytoplasm
HIF1α
HIF1α HIF1α
HIF1β
HIF1α
VHL
VHL
PHDs
PHDs
HypoxiaResponse element
Target Genes
HIF1β
 O2 / Fe
2+
HIF1α
 
 
Figure 1.4 – Hypoxic regulation of Hypoxia-Inducible Factor-1. 
 
 
 
HIF-1α protein levels are dramatically increased under hypoxic conditions, 
whereas the mRNA levels remained approximately the same under both 
normoxic and hypoxic conditions (Heidbreder et al, 2003; Huang et al, 1996; 
Kuwai et al, 2003).  The induction of HIF-1α under hypoxic conditions 
requires de novo protein translation, but not transcription (Chachami et al, 
2004).  HIF-1α protein is detectable within 30mins and becomes stabilised for 
several hours (Büchler et al, 2003; Wang et al, 1995). 
 
Under hypoxic conditions, the non-hydroxylated HIF-1α protein translocates to 
the nucleus (Chan et al, 2002).  HIF-1α protein contains a nuclear translocation 
signal within the C-terminus, allowing entry through the nuclear membrane 
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(Kallio et al, 1998).  A single amino acid mutation within this signal was 
shown to prevent HIF-1α from entering the nucleus, and prevented p300/CBP 
binding (Kallio et al, 1998; McNeill, 2002).   
 
Nuclear localisation of HIF-1α has been confirmed on several occasions using 
cell immunofluorescent staining (Mabjeesh et al, 2003, Mottet et al, 2003).  
Once in the nucleus, HIF-1α forms a dimer with the HIF-1β subunit (Figure 
1.4).  The bHLH domain of both HIF-1α and HIF-1β, located at the N-
terminus of the peptides is required for both heterodimerisation and DNA 
binding (Wang et al, 1995). 
 
The fully formed HIF-1 transcription factor can then bind within the major 
groove of the DNA (Wang and Semenza, 1995).  Both subunits make contact 
with the DNA, with HIF-1α forming the strongest bond (Wang and Semenza, 
1995).  HIF-1 binds to conserved hypoxia-response elements (HRE) within the 
promoter region of target genes, along with further regulatory sequences 
(reviewed in Wenger et al, 2005). 
 
Under hypoxic conditions, the HIF-1α subunit is no longer hydroxylated at 
aparagine-803 and is able to interact with its co-activator p300/CBP, at its 
COOH-terminal transactivation domain (Lando et al, 20021&2).  The 
interaction with p300/CBP increases the transcriptional activity of the HIF-1 
transcription factor, via recruitment of co-activating protein complexes to the 
promoter of the target gene (Lando et al, 20021&2). 
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1.17 Intracellular signal transduction control of HIF-1α 
expression 
The expression of the transcription factor HIF-1 is also regulated at the protein 
level via intracellular signalling pathways.  This normally occurs under 
normoxic conditions, although the exact pathway involved appears to be both 
cell-type-specific and dependent on mutations in oncogenes, unlike the 
hypoxic response which is ubiquitous (Hudson et al, 2002; Laughner et al, 
2001).  The cell signalling often leads to HIF-1α phosphorylation, causing its 
stabilisation (Richard et al, 1999).  HIF-1α expression is also stabilised via 
nitric oxide and reactive oxygen species, generated in an inflammatory 
environment (Chachami et al, 2004; Griffiths et al, 2007).  Despite the 
suggestion that normoxic signalling pathways can induce HIF-1α 
accumulation, the actual expression levels achieved are lower than that induced 
via hypoxia (Li et al, 2005). 
 
A number of growth factors and small molecules are responsible for activating 
the signalling pathways that regulate HIF-1α expression.  These include 
insulin, EGF, TNF-α, insulin-like growth factors (IGFs), IL-1β, prostaglandins, 
angiotensin II, endothelin and thrombin (reviewed in Wenger et al, 2005).  
There is a level of redundancy in the signalling induced by these molecules, as 
they seem to converge onto two main signalling pathways; the PI3-kinase/Akt 
pathway and MAPK pathway, after binding to their tyrosine kinase receptors 
(e.g. HER2 (human epidermal growth factor receptor 2) /neu receptor).  The 
inhibition of these receptors removes the ability to stimulate HIF-1α 
stabilisation and therefore function (Gunaratnam et al, 2003).   
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The PI3-kinase/Akt pathway is involved in the activation of HIF-1, via 
stabilising HIF-1α expression (Chachami et al, 2004), but its exact role has not 
been fully elucidated, although it is understood that HIF-1α is not a direct 
substrate for Akt, but is a downstream target of Akt signalling (Mottet et al, 
2003).  PI3-kinase is responsible for converting phosphatidylinositol-4, 5-
bisphosphate to phosphatidylinositol-3, 4, 5-trisphosphate, which activates 
phosphoinositide-dependent kinase-1.  This then phosphorylates Akt on 
Serine-473 (on the regulatory domain) and Threonine-308 (on the catalytic 
domain), causing its activation and its ability to phosphorylate further proteins 
on serine or threonine residues (reviewed in Vara et al, 2004).  Inhibition of 
PI3-kinase using LY294002 decreased the expression of normoxic HIF-1α 
protein (Zhou et al, 2004). 
 
A suggested target of the PI3-kinase /Akt signalling involved in the 
stabilisation of HIF-1α is mTOR (mammalian target of rapamycin).  mTOR is 
responsible for phosphorylating 4E-BP1 (eukaryotic initiation factor 4 – 
inhibiting binding protein-1), causing the dissociation of the eukaryotic 
initiation factor, which leads to the stabilisation of HIF-1α mRNA translation 
(Lang et al, 2007) and the up-regulation of transcription of target genes.  
Treating cells with the mTOR inhibitor rapamycin would inhibit the mTOR 
activity and as a result, prevent the accumulation of HIF-1α, even under 
hypoxic conditions (Hudson et al, 2002; Treins et al, 2002). 
 
A further target of Akt phosphorylation is FRAP (FKBP (FK506-binding 
protein)-rapamycin associated protein), which also acts on multiple targets, 
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such as the ribosomal protein p70S6K (p70 S6 kinase 1) (Laughner et al, 2001 
Zhong et al, 2000).  Autocrine activation of FRAP was shown to up-regulate 
HIF-1α protein expression via inducing its translocation to the nucleus, as seen 
in the myeloma cell line A431 (Fukuda et al, 2003; Zhong et al, 2002).  Using 
rapamycin, an inhibitor of FRAP, hypoxic induction of HIF-1α was shown to 
be greatly reduced in vitro, whilst tumour growth and angiogenesis was 
inhibited in vivo, suggesting FRAP plays an important role in the activation of 
HIF-1 via intracellular signalling (Zhong et al, 2000).  FRAP was shown to up-
regulate HIF-1α protein expression only, as the mRNA levels were not affected 
by rapamycin inhibition (Fukuda et al, 2003).   
 
The PI3-kinase/ Akt pathway is also responsible for the up-regulation of heat 
shock protein (Hsp) expression, which also aids the stabilisation of the HIF-1α 
protein under normoxic conditions (Zhou et al, 2004).  Hsp70 has been shown 
to interact directly with ODD domain of the HIF-1α subunit, whereas Hsp90 
interacts with the bHLH domain (Zhou et al, 2004).  Targeting Hsp90 for 
inhibition also decreased the expression of HIF-1α protein (Zhou et al, 2004). 
 
Hypoxia can induce the PI3-kinase pathway via an autocrine mechanism, as 
growth factors transcribed by HIF-1 can act at tyrosine kinase receptors on the 
cell surface (Mottet et al, 2003). 
 
The MAPK signalling pathways (e.g. MEK-ERK pathway (MAPK-ERK 
kinase – extracellular-regulated kinase pathway)) have also been shown to up-
regulate the HIF-1α protein, suggesting a further, non-hypoxic mechanism of 
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HIF-1 regulation (Fukuda et al, 2003).  The MAPK pathway, as with the PI3-
kinase pathway, can be activated via growth factors that act at tyrosine kinase 
receptors, such as the IGF-receptor, causing their autophosphorylation.  This 
attracts the protein SHC (Src homology collagen-like protein), which through 
interaction with Grb2 (Growth factor receptor-bound protein 2) and mSOS 
(mammalian sons of sevenless), initiates the phosphorylation of the G protein 
Ras.  This then phosphorylates Raf-1, which in turn phosphorylates MEK 
(reviewed in Fang and Richardson, 2005).  The kinase MEK phosphorylates 
ERK, which then directly phosphorylates the HIF-1α subunit (Sang et al, 
2002).  It has been suggested that when HIF-1α becomes phosphorylated via 
MAPK signalling, then it can form a dimer with HIF-1β and up-regulate gene 
transcription.  A dephosphorylated version of HIF-1α promotes apoptosis, due 
to its ability to bind to p53 (Suzuki et al, 2001).  The actions of the HIF-1α co-
activator p300 also require the presence of an active MAPK, which indirectly 
stimulates the transactivation of HIF-1α (Sang et al, 2003).   
 
Inhibition of MEK using PD98059 prevents ERK phosphorylation and 
therefore blocks HIF-1α expression, whereas a constitutively active ERK 
pathway continually induces HIF-1α protein.  The inhibition of other MAPKs, 
such as p38 had no effect on HIF-1α expression (Sang et al, 2002; Richard et 
al, 1999).  The inhibition of MAPK also prevented the p300 protein from 
associating with HIF-1α, reducing its ability to translocate to the nucleus and 
up-regulate gene expression (Sang et al, 2003).  As a result, the transcription of 
HIF-1α target genes is dependent on MAPK signalling (Hofer et al, 2001). 
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As a result of receptor activation and intracellular signalling, the activity of 
multiple transcription factor activities, such as c-fos and NF-κB (nuclear factor 
κB) are up-regulated (Fukuda et al, 2003; Gunaratnam et al, 2003; Zhong et al, 
2002), which would increase both cell survival and proliferation.   
 
These normoxic signalling pathways are up-regulated within a number of 
cancers, due to mutations that occur within either key oncogenes, such as c-
Src, Ras or HER2/neu receptor, or key tumour suppressor genes, such as 
pVHL, PTEN or p53.  Oncogenes only require a mutation in one allele before 
they become constitutively active, whereas tumour suppressor genes require 
the mutation in both alleles before their expression is knocked out.  The up-
regulation of oncogenes or down-regulation of tumour suppressor genes allows 
for the constitutive activity of a number of growth promoting signalling 
pathways, including the PI3-kinase/Akt pathway (reviewed in Hanahan and 
Weinberg, 2000; Vogelstein and Kinsler, 2004).  This induces an over-
expression of HIF-1α, even under normoxic conditions (Chan et al, 2002).  As 
a result, key pro-survival processes are induced, such as increased rate of 
tumour proliferation, induction of angiogenesis or inhibition of apoptosis 
(Maxwell et al, 1997; Zhong et al, 1999).  The inactivation of PTEN, a 
phosphatase that reverses the actions of PI3-kinase, is often seen in cancer, to 
aid its progression and the process of angiogenesis.  The expression of PTEN 
decreases as the tumour advances.  The over-expression of HIF-1α has been 
significantly linked to PTEN inactivation.  HIF-1α expression has been shown 
to increase as the levels of PTEN decreases (Jiang et al, 2003; Zundel et al, 
2000), allowing the PI3-kinase/Akt pathway to up-regulate both expression 
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and activation of HIF-1 (Li et al, 2005).  The over-expression of HER2/neu 
receptor leads to the constitutive expression of Akt, even in the presence of a 
functional PTEN protein (Li et al, 2005).  This also leads to the induction of 
HIF-1α protein under normoxic conditions.  Inhibitors of PI3-kinase, Akt and 
FRAP, or the reintroduction of PTEN, removed HIF-1α expression from the 
cell, reducing both growth and angiogenesis (Jiang et al, 2003; Treins et al 
2002; Zhong et al, 2000), making them all possible targets for cancer 
therapies. 
 
1.18 Downstream transcriptional effects of HIF-1 
activation 
HIF-1 is responsible for the induction of multiple target genes, which aid both 
tumour survival and progression in a hypoxic environment, producing a more 
metastatic phenotype.  Once bound HIF-1 causes the transcription of multiple 
target genes, responsible for a whole range of biological activities such as cell 
proliferation, metabolism and angiogenesis / oxygen transport (See Table 1.4 
for a list of key target genes and list of functions.)  The expression of these 
genes enables the cell to adapt and endure hypoxic conditions.  HIF-1 is 
suggested to regulate the expression of up to 200 genes in hypoxia (Wenger et 
al, 2005), accounting for 1-5% of the entire human genome (Semenza, 2003). 
 
HIF-1 binds to the DNA at promoter regions of target genes at consensus 
hypoxia-response elements (HRE), ranging from -50bp to -5000bp upstream of 
the coding sequence (reviewed in Wenger et al, 2005).  HIF-1 recognises the 
sequence 5’ – (C/G/T)RCGTGC(G/T) – 3’, where R is any purine residue.  In 
approximately 75% of HRE sequences, the purine is an adenine residue, with 
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the rest being guanine residues (reviewed in Wenger et al, 2005).  The HIF-1α 
subunit binds tightly to the entire HRE sequence, whereas the HIF-1β subunit 
only recognises the final GTG residues (Wenger et al, 2005).  The HRE 
sequence was originally determined in the erythropoietin promoter, prior to the 
discovery of the HIF-1 transcription factor (Semenza et al, 1994). 
 
One of the major targets of HIF-1 transcriptional activity is VEGF, which is 
one of the most investigated genes in relation to HIF-1 activity.  VEGF plays a 
major role in neovascularisation and cellular proliferation, acting via one of 
three VEGF receptors.  Under physiological conditions, VEGF signalling is 
required for both wound healing and the reproductive cycle; however, it has 
been implicated in a number of pathological conditions, such as cancer, 
rheumatoid arthritis and diabetes (reviewed in Byrne et al, 2005).  VEGF 
expression is predominantly up-regulated by hypoxia; however, its expression 
can also be regulated via growth factor signalling, such as IGF-1 and EGF 
under normoxic conditions (reviewed in Mikhopadhyay and Datta, 2004), via a 
NF-κB-dependent manner (reviewed in Pradeep et al, 2005).  VEGF 
expression was associated with HIF-1α expression in a number of cancer 
phenotypes, including colon, pancreatic and breast cancer (Bos et al, 2001; 
Büchler et al, 2003; Currie et al, 2004; Kuwai et al, 2003), which was further 
correlated with increased microvessel density and  reduced patient survival 
(Bos et al, 2001; Kuwai et al, 2003).  VEGF was co-expressed with HIF-1α 
within tumour cells, but in the cytoplasm instead of the nucleus (Büchler et al, 
2003; Griffiths et al, 2007).  Inhibition of VEGF via HIF-1α down-regulation 
resulted in reduced tumour weight and vascularisation, where tumours were 
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smaller, weaker and less branched (Stoeltzing et al, 2004), suggesting that 
VEGF plays a role in angiogenesis and vessel maturation.   
Gene: Cellular function: 
Endothelin-1 Vasoconstrictive peptide 
Erythropoietin Glycoprotein hormone responsible for 
red blood cell production 
Heme oxygenase 
Inhibits the production of reactive 
oxygen species and regulates 
vasodilation 
Vascular Endothelial Growth Factor 
(VEGF) 
Growth factor responsible for blood 
vessel formation 
Inducible and Endothelial Nitric 
Oxide Synthase 
Enzymes responsible for synthesis of 
Nitric oxide , a vasoactive compound 
Glycolytic enzymes: 
• Aldose A and C (muscle and 
brain isoforms) 
• Enolase-α 
• Phosphofructokinase (liver and 
platelet isoforms) 
• Hexokinase 
• Lactate dehydrogenase (LDH) 
• Phosphoglycerate kinase 
• Glucose phosphate isomerase I 
• Triosephosphate isomerase 
• Pyruvate kinase 
• Glyceraldehyde-3-phosphate 
dehydrogenase 
Provide energy source for cells via 
anaerobic respiration 
Glucose transporter 1 (GLUT1) 
Transmembranal glucose transporter, 
which helps regulate glucose uptake into 
cells 
BNIP3 (Bcl-2/adenovirus EIB 
19kD-interacting protein 3) 
Member of the Bcl2 apoptosis protein 
family, which up-regulates apoptosis 
Galactokinase Enzyme involved in maintaining energy levels within cells 
Galectin-3 Anti – apoptotic lectin which promotes 
cell survival and migration 
RhoA Causes F-actin polymerisation and 
cytoskeletal rearrangement 
Glycogen synthase 1 Responsible for the synthesis of energy 
stores from glucose 
Human telomerase reverse 
transcriptase A telomerase 
Transferrin and its receptor An iron-binding protein 
Matrix metalloproteinases (MMPs) Proteases that are required for invasion 
Table 1.4 – Key target genes transcribed as a result of HIF-1 activity 
(Information taken from Greijer et al, 2005; Wenger et al, 2005). 
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HIF-1 is also responsible for transcribing genes involved in glycolysis and 
glucose transport (Semenza et al, 1994).  The lack of oxygen prevents cells 
from performing normal metabolic processes; however, the transcriptional 
activity of HIF-1 results in an energy source (adenosine triphosphate (ATP)) 
being provided for the tumour, even under low oxygen tension, via anaerobic 
respiration (Semenza et al, 1994).  Examples of metabolic genes that are 
induced by HIF-1 include glucose transporter 1 (GLUT1) and lactate 
dehydrogenase (LDH), acting to increase glucose entry into cells and to 
maintain cellular energy levels (see Table 1.4 for further examples).   
 
Initially, HIF-1 also transcribes anti-apoptotic genes, such as Galectin-3 to 
enhance cell survival, but as hypoxia progresses, gene expression alters 
towards expression of pro-apoptotic molecules, such as BNIP3 (Bcl-
2/adenovirus EIB 19kD-interacting protein 3) (Greijer et al, 2005).  The 
induction of hypoxia is only expected to be temporary, therefore after a period 
of extended hypoxia the cells are unable to sustain the non-physiological 
conditions, therefore undergo apoptosis.  However, after longer periods of 
hypoxia, invasive genes are also up-regulated, which would alter cell 
differentiation and migration properties, enhancing chances of survival (Greijer 
et al, 2005; Zhong et al, 2002).   
 
A number of genes are also down-regulated by hypoxic conditions as shown 
by Greijer et al (2005) via microarray (a total of 114 genes, which is 
approximately 15% of total genome).  These include genes involved in 
cytoskeletal motility (e.g. / RhoA kinase), mRNA processing, DNA repair and 
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histone interactions but only a small proportion (<20%) are regulated by HIF-1 
directly (Greijer et al, 2005). 
 
Surprisingly, genes encoding components of prolyl hydroxylases are also 
transcribed under hypoxic conditions (Greijer et al, 2005), suggesting an 
autoregulatory mechanism, anticipating the presence of oxygen, and therefore 
initiating HIF-1α degradation.  Once normoxia resumes, the prolyl hydroxylase 
enzymes reassemble and target HIF-1α to the proteasome (Mottet et al, 2003).   
 
The removal of cells from hypoxic conditions will result in the degradation of 
HIF-1α after only a few minutes, but the effects of hypoxia will last longer as 
the target genes, such as VEGF and GLUT1 continue to be translated 
(Palayoor et al, 2003). 
 
The central role that HIF-1 plays in tumour development makes it a possible 
target of anti-cancer therapy.  As HIF-1β is constitutively expressed within the 
cell, targeting the inducible HIF-1α subunit would be more successful at 
inhibiting the carcinogenic properties of the HIF-1 transcription factor.  
Targeting HIF-1α expression has been previously been shown to inhibit cancer 
progression in vivo.  For example, HIF-1α inhibition via the use of dominant-
negative HIF-1α constructs or HIF-1α-null cell lines in xenograft mouse 
models inhibited the expression of HIF-1 target genes, the level of tumour 
vascularisation and overall tumour growth (Ryan et al, 2000; Stoeltzing et al, 
2004). 
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1.19 Project hypothesis and objectives 
In normoxia, the effect of gastrin on angiogenesis is well-defined to be 
indirectly mediated through (i) COX-2 and (ii) amphiregulin/HB-EGF via 
VEGF.  We hypothesise that in hypoxia to maintain this pro-angiogenic role, 
gastrin-HIF interactions occur to either: 
• maintain the expression of gastrin to act on GI cancer cascades,  
 
• or for gastrin to have an inherent ability to switch to increasing HIF-1α 
expression (see Figure 1.5).   
 
The objectives for this project were therefore, 
1) Investigation into the effect of exogenous gastrin treatment of GI 
carcinoma cell lines on HIF-1α protein expression and transcriptional 
activity under both normoxia and hypoxia. 
 
2) Investigation into the effect of hypoxia-induction on gastrin mRNA 
expression.  
 
3) Effect of gastrin depletion on HIF-1α and downstream biological events 
linked to hypoxia. 
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Figure 1.5 – Project hypothesis investigating the relationship between gastrin 
and HIF-1. 
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2.1 Basic cell culture 
Human GI carcinoma cell lines were routinely cultured in RPMI-1640 medium 
(Sigma Aldrich, Poole, UK), supplemented with heat-inactivated foetal bovine 
serum (FBS) and 2mM L-glutamine (both Sigma Aldrich).  The cell lines were 
grown at 37ºC, in a humidified 5% CO2 (carbon dioxide) atmosphere. 
 
The epithelial cell monolayers were routinely sub-cultured when they reached 
80% confluency in T75cm2 flasks (Corning, Fisher Scientific, Loughborough, 
UK), using 0.025% ethylenediamine tetra-acetic acid (EDTA) in phosphate-
buffered saline (PBS) (Oxoid, Basingstoke, UK), at a ratio of 1:6 through the 
addition of fresh cell culture medium.  The GI carcinoma cell lines that were 
used are shown in Table 2.1. 
 
The majority of experiments were conducted in three key cell lines; HCT116, 
MGLVA1 and PAN1 carcinoma cells.  The key characteristics for these 
carcinoma cell lines are described in Table 2.2. 
 
2.2 Induction of hypoxia 
Hypoxia was induced in the GI carcinoma cell lines listed in Table 2.1, using 
the following methods: 
1) Cobalt chloride (CoCl2 (Sigma Aldrich)).  CoCl2, an iron antagonist, was 
used to inhibit prolyl hydroxylase activity.  Growth medium was aspirated 
from the cell lines and replaced with fresh medium containing 150M 
CoCl2.  Cells were incubated at 37ºC, in a humidified 5% CO2 atmosphere 
for between 2-24hr. 
  55 
Cell line: Tissue of origin: ECACC number: 
AGS Human gastric 
adenocarcinoma 
89090402 
BxPC3 Human pancreatic 
adenocarcinoma 
93120816 
C170HM2 Human colonic 
adenocarcinoma 
Derived from parental cell 
line C170 (ECACC number 
97071507). 
HCT116 Human colonic 
adenocarcinoma 
91091005 
MGLVA1 Human gastric 
adenocarcinoma 
Derived within the Division 
of Pre-Clinical Oncology 
OE19 Human oesophageal 
adenocarcinoma 
96071721 
OE21 Human oesophageal 
squamous carcinoma 
96062201 
OE33 Human oesophageal 
adenocarcinoma 
96070808 
PAN1 Human pancreatic 
adenocarcinoma 
Derived within the Division 
of Pre-Clinical Oncology 
PANC1 Human pancreatic 
adenocarcinoma 
87092802 
ST16 Human gastric 
adenocarcinoma 
Derived within the 
University of Nottingham. 
Table 2.1 – Human GI carcinoma cells lines used to determine HIF-1α protein 
expression, HIF-1α gene expression and gastrin gene expression. 
 
 
2) Deferoxamine (DFO (Sigma Aldrich)).  DFO, an iron chelator was used to 
inhibit prolyl hydroxylase activity.  Growth medium was aspirated from 
the cell lines and replaced with fresh medium containing 200M DFO.  
Cells were incubated at 37ºC, in a humidified 5% CO2 atmosphere for 
between 2-24hr. 
 
3) Atmospheric hypoxia.  True hypoxic conditions were maintained using the 
Invivo2 400 Hypoxia workstation (Biotrace Fred Baker, Bridgend, UK), to 
facilitate the stabilisation and up-regulation of the HIF-1α subunit.  The 
hypoxia workstation was able to maintain a humidified 1% oxygen, 5% 
CO2, 94% nitrogen environment, at a constant 37ºC.  Cells and equipment  
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Cell line Cell line characteristics 
HCT116 cells • Derived from a poorly-differentiated human colonic 
carcinoma. 
• High level of endogenous gastrin gene expression. 
• Expresses both the standard and alternative 
transcripts of the gastrin gene. 
• Inhibition of gastrin gene expression resulted in 
reduced cell survival and increased apoptosis. 
• Cell growth was inhibited after exogenous gastrin 
treatment. 
• Gastrin treatment induces cAMP expression. 
• Does not endogenously express the CCK-2 receptor. 
• Treatment with glycine-extended gastrin induced cell 
proliferation. 
MGLVA1 cells • An ascitic variant of the gastric cell line MGN45G. 
• Relatively low level of basal gastrin gene expression. 
• Expresses both the standard and alternative 
transcripts of the gastrin gene. 
• Inhibition of gastrin gene expression resulted in 
reduced cell survival, which was restored after 
treatment with exogenous amidated gastrin and 
glycine-extended gastrin. 
• Does not endogenously express the CCK-2 receptor. 
• Secretes both progastrin and glycine-extended 
gastrin, but not amidated gastrin. 
PAN1 cells • Derived from a poorly-differentiated pancreatic 
adenocarcinoma. 
• Relatively low level of basal gastrin gene expression. 
• Expresses both the standard and alternative 
transcripts of the gastrin gene. 
• Expresses gastrin at both the gene and protein level, 
at levels similar to those found in pancreatic tumours. 
• Inhibition of gastrin gene expression resulted in 
reduced cell survival and increased apoptosis. 
• CCK-2 receptor status unknown. 
Table 2.2 – Key gastrin-related cell characteristics for the HCT116, MGLVA1 
and PAN1 carcinoma cell lines.  (Information taken from Bold et al, 1994; 
Colucci et al, 2008; Ferrand et al, 2006; Grabowska et al, 2007; Grabowska et 
al, 2008; Harris et al, 2004; Ishizuka et al, 1994; Watson et al, 1998; Watson 
et al, 1999). 
 
 
 
were placed into the hypoxia workstation via an air-lock system.  Cells 
were harvested between 1-16hr hypoxic incubation (for Western blotting, 
RT-PCR (reverse transcriptase polymerase chain reaction) and luciferase 
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assays) and lysed (for Western blotting and luciferase assays) within the 
workstation, before the assays were continued within a class II cell culture 
hood.  When possible, the reagents required for harvesting the assays were 
placed in the hypoxia workstation for 30-60mins prior to use, to allow 
them to equilibrate to the hypoxic environment and remove any traces of 
oxygen from the solutions.  Equivalent normoxic controls remained at 37ºC 
in a humidified 5% CO2 environment. 
 
2.3 Exogenous treatment of cells with amidated gastrin 
The GI carcinoma cell lines were treated with exogenous gastrin, prior to being 
harvested for Western blotting, RT-PCR and luciferase assays.  Serum-starved 
cells were treated with 1nM, 10nM or 100nM exogenous amidated human 
gastrin (G17) (Aphton Corporation, Philadelphia, USA), 1nM, 10nM or 
100nM AK-80 scrambled control (Aphton Corporation), or untreated control 
(serum-free medium only).  The scrambled control contained the same first 
five amino acids as the amidated gastrin (methionine-glutamine-arginine-
leucine-cysteine), but in a randomised sequence.  The exogenous gastrin-
treated carcinoma cells were incubated under normoxic or hypoxic conditions 
for a known time point (4-72hr), before being harvested as described below.   
 
2.4 Exogenous treatment with epithelial growth factor 
(EGF) 
The GI carcinoma cell lines were treated with exogenous EGF, prior to being 
harvested for luciferase assays.  The EGF would bind to known EGF reporter 
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elements within the transfected plasmid and therefore act as a positive control, 
up-regulating the luciferase activity. 
 
Approximately 24hr after plasmid transfection, the growth medium was 
aspirated and replaced with fresh serum-free medium +/- 10g/ml EGF (Sigma 
Aldrich).  The GI carcinoma cell lines were incubated under normoxic 
conditions for 24-48hr, with the EGF treatment being refreshed every 12hr, 
before being harvested as described below. 
 
2.5 Western blotting 
Specific expression of nuclear HIF-1α and HIF-1β protein after the induction 
of hypoxia or exogenous amidated gastrin treatment (HIF-1α expression only) 
was determined using target-specific primary antibodies by the process of 
Western blotting.   
 
2.5.1 Nuclear lysate preparation 
Carcinoma cell lines were plated into six-well plates at a density of 3 x 105 – 5 
x 105 cells/well (cell line-dependent), to achieve a 50-60% confluency after 
24hr incubation at 37ºC, in a humidified 5% CO2 atmosphere.  Cells were then 
serum-starved, by replacing the normal growth media with fresh serum-free 
equivalent for approximately 24hr, before being exposed to hypoxia or treated 
with exogenous gastrin as described above, for a known time point.   
 
Nuclear lysates were prepared using BioVision Nuclear/Cytosol Fractionation 
Kit (Cambridge Bioscience, Cambridge, UK).  Briefly, cells were harvested 
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using 0.25% trypsin/EDTA and centrifuged to form a pellet, which was then 
resuspended in ice-cold ‘cytosol extraction buffer A’.  The extraction buffer 
contained additional protease inhibitors and DTT (Dithiothreitol), to prevent 
protein degradation and aid disulphide-bond reduction respectively.  The cells 
were incubated on ice for 10mins, before ice-cold ‘cytosol extraction buffer B’ 
was added.  After further incubation on ice, the samples were centrifuged at 
14000g for 5mins at 4ºC, to separate the cytoplasmic fraction from the nuclear 
cell pellets.  The cytoplasmic supernatant was removed and the remaining cell 
pellets resuspended in ice-cold ‘nuclear extraction buffer’, with additional 
protease inhibitors and DTT.  The lysates were incubated on ice for 40mins, 
with occasional agitation, before being centrifuged at 14000g for 10mins at 
4ºC.  The resultant supernatant contained the nuclear fraction of the samples.  
The protein concentrations of the nuclear lysates were determined using the 
Nanodrop ND-100 spectrophotometer according to the manufacturer’s 
instructions.  The samples were stored at -80ºC until required. 
 
2.5.2 Protein gel electrophoresis 
10g protein per nuclear sample was separated using SDS-PAGE (sodium 
dodecyl sulphate polyacrylamide gel electrophoresis).  The nuclear protein 
samples were diluted in a 1:1 ratio with Tris-Glycine 2X SDS (sodium dodecyl 
sulphate) sample buffer (Invitrogen, Paisley, UK), prior to being denatured by 
heating at 99ºC for 5mins.   
 
Precast 8-16% gradient Tris-Glycine gels (Invitrogen) were used for gel 
electrophoresis.  After rinsing in distilled water and 1X Tris-Glycine SDS 
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running buffer (25mM Tris Base, 192mM Glycine and 3.5mM SDS (all Sigma 
Aldrich)), the gels were locked into the XCell SureLock Novex Mini-Cell 
electrophoresis system (Invitrogen).  The inner chamber of the Mini-Cell 
electrophoresis system (containing the electrode) and half of the outer chamber 
were filled with 1X SDS running buffer, before 10g nuclear protein samples 
were loaded per gel lane.  The gel was also loaded with two protein markers; 
5l SeeBlue Plus2 pre-stained (1X) protein standards (Invitrogen) and 2l 
MagicMark XP (1X) Western protein standards (Invitrogen), which provided 
an accurate molecular weight scale, to aid with protein size determination.  The 
SeeBlue Plus2 was visible throughout the protocol, whereas the MagicMark 
XP was only visible during the development stage.  The gels were run for 
90mins at 125V. 
 
2.5.3 Gel transfer onto PVDF membrane 
The separated nuclear proteins were transferred onto polyvinylidene difluoride 
(PVDF) 0.2m pore membranes (Invitrogen), which were pre-soaked in 100% 
methanol (Fisher Scientific) and 1X Tris-Glycine transfer buffer (12mM Tris 
Base and 96mM Glycine).  The proteins were transferred from the Tris-
Glycine gels to the membranes using the XCell II Blot Module (Invitrogen), 
which was designed to fit into the XCell SureLock Novex Mini-Cell 
electrophoresis system.  The Tris-Glycine gels and PVDF membranes were 
assembled into the XCell II Blot module, alongside pre-soaked filter paper and 
blotting pads (Invitrogen), according to the manufacturer’s instructions (as 
detailed in Figure 2.1).  The XCell II Blot module was locked into the XCell 
SureLock Novex Mini-Cell electrophoresis system.  The blot module and half 
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of the outer chamber were filled with fresh 1X transfer buffer, before the gels 
were transferred for 90mins at 30V. 
The assembly of the electrode for Western blotting transfer. 
Cathode plate
Pre-soaked blotting pads
Pre-soaked filter paper
Tris-Glycine gel 
(contains nuclear proteins)
Pre-soaked PVDF membrane
Pre-soaked filter paper
Pre-soaked blotting pad
Pre-soaked filter paper
Tris-Glycine gel 
(contains nuclear proteins)
Pre-soaked PVDF membrane
Pre-soaked filter paper
Pre-soaked blotting pads
Anode plate
↑ Protein flow ↑
↑ Protein flow ↑
 
 
Figure 2.1 – The assembly of the XCell II Blot Module to allow the transfer of 
the nuclear proteins in the correct direction.  The electrical circuit flows from 
the cathode to the anode, allowing the separated proteins to flow from the Tris-
Glycine gel onto the PVDF membrane. 
 
 
 
The PVDF membranes were briefly rinsed in 1X TBST (Tris-buffered saline 
(20mM Tris Base (pH 7.6) and 137mM sodium chloride), with 0.05% Tween-
20 (all from Sigma Aldrich)), before non-specific protein binding was blocked 
for 2hr at room temperature, using 2% ECL (Enhanced Chemi-Luminescence) 
Advance blocking buffer (Amersham Bioscience, Buckinghamshire, UK), 
prepared in 1X TBST.   
 
2.5.4 Probing with antibodies 
The PVDF membranes were then probed with a target-specific primary 
antibody, diluted in 2% ECL Advance blocking buffer overnight, at 4ºC (see 
Table 2.3 for a list of the primary antibodies used, and their specifications).  
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The β-actin was used to confirm equal loading of the proteins, whilst the 
mouse anti-bromodeoxyuridine antibody was used as a negative control, to 
ensure the immune complexes generated after being probed with the test 
antibody were specific. 
Target 
protein 
detected: 
Target 
molecular 
weight: 
Antibody 
dilution 
required: 
Antibody 
raised in: 
Supplier: Notes: 
HIF-1α  120kDa 1:250 
 
Mouse 
(monoclonal) 
BD 
transduction 
labs 
Test 
antibody 
HIF-1β  92kDa 1:2000 Rabbit 
(polyclonal) 
Novus 
Biologicals 
Test 
antibody 
 
Bromodeoxy-
uridine 
Dependent 
on test 
antibody 
1:1000 
 
Mouse 
(monoclonal) 
DAKO 
Cytomation 
 
Negative 
control 
β-Actin 42kDa 1:5000 Mouse 
(monoclonal) 
Abcam Loading 
control 
 
Table 2.3 – Specification for the target-specific primary antibodies for Western 
blotting. 
 
 
 
The PVDF membranes were thoroughly washed with 1X TSBT, before being 
probed for 1hr at room temperature with a biotin-conjugated secondary 
antibody, raised against the species of the primary antibody: 
• Rabbit α-mouse for HIF-1α, actin and bromodeoxyuridine mouse negative 
control (DAKOCytomation, Ely, UK). 
 
• Swine α-mouse for HIF-1β (DAKOCytomation). 
 
The secondary antibodies were used at a 1:1000 dilution and were also 
prepared in 2% ECL Advance blocking buffer.   
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The PVDF membranes were thoroughly washed with 1X TBST, before they 
were probed with Strept/ABComplex HRP (Streptomycin/avidin-biotin 
complex horseradish peroxidase)-conjugated (DAKOCytomation), for 30mins 
at room temperature.  The Strept/ABComplex HRP was prepared in 1X TBST, 
at a 1:20 dilution, approximately 60mins prior to use, to allow the avidin/biotin 
complexes to form. 
 
The PVDF membranes were developed using ECL Advance Western blotting 
detection kit, following the manufacturer’s instructions.  Briefly, equal 
amounts of ECL Advance solutions A and B were mixed together, before 
being poured onto the freshly washed PVDF membranes.  The immune 
complexes were visualised and densitometrically-analysed using the Syngene 
ChemiGenius BioImaging system GeneTools and GeneSnap programs.   
 
Equal loading was confirmed by stripping the PVDF membranes to remove the 
test antibody, and then reprobing with a β-actin loading control antibody.  The 
membranes were sealed into glass tubes, containing 30ml of Western blotting 
stripping buffer (62.5mM Tris-HCl (pH 6.7), 70mM SDS and 100mM 2-
mercaptoethanol).  The PVDF membranes were incubated in the stripping 
buffer for 30mins at 50ºC, with constant agitation to ensure the removal of all 
previous immune complexes from the membrane.  The membranes were then 
thoroughly washed with 1x TBST wash buffer, before being blocked with 2% 
ECL Advance blocking buffer for 2hr and probed with the primary antibody as 
previously described. 
 
  64 
2.6 Immunofluorescent cell staining 
Specific expression of nuclear HIF-1α protein or gastrin protein after the 
induction of hypoxia was determined using target-specific primary antibodies, 
by the process of immunofluorescent cell staining. 
 
Carcinoma cell lines were plated into eight-well chamber slides at a density of 
5 x 104 cells/well, to achieve a 60-80% confluency after 24hr incubation at 
37ºC, in a humidified 5% CO2 atmosphere.  Cells were then serum-starved, by 
replacing the normal growth medium with fresh serum-free equivalent for 
approximately 24hr, before being exposed to hypoxia (as described above) for 
approximately 6hr. 
 
The carcinoma cell lines were washed in PBS (Oxoid), before being fixed in 
4% paraformaldehyde (diluted from 16% stock (Science Services, London, 
UK)) for 10mins at room temperature.  The aldehyde was quenched with 
10mM 2-aminoethanol (Sigma Aldrich) (prepared in PBS) for 5mins, before 
the cells were washed in PBS.  The cells were then permeabilised in 0.1% 
Triton X-100 (Sigma Aldrich) (prepared in PBS) for 1min, before being rinsed 
in PBS.   
 
Non-specific antibody binding was blocked by incubating the cells in PBS + 
1% BSA (bovine serum albumin) for 30mins, followed by a second 30min 
incubation in 10% goat serum (diluted in PBS + 1% BSA 
(DAKOCytomation)).  The carcinoma cells were then incubated in their 
primary antibody as described below: 
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• 1:250 mouse anti-HIF-1α (BD Transduction Labs) overnight at 4ºC, with 
mouse anti-bromodeoxyuridine (DAKOCytomation) as a negative control. 
 
•  1:200 rabbit anti-gastrin (DAKOCytomation) for 10mins at room 
temperature, with universal rabbit negative control (DAKOCytomation) as 
a negative control. 
 
The carcinoma cells were washed thoroughly in PBS + 1% BSA, before being 
incubated in a 1:500 dilution of the secondary antibody; Alexa-Fluor Goat α-
mouse IgG 488 (HIF-1α expression) or Alexa-Fluor Goat α-rabbit IgG 488 
(gastrin expression) (Molecular probes, Invitrogen) for 1hr at room 
temperature.  The chambers were then removed, before the cells were 
thoroughly washed in PBS.  The nuclei were then counterstained using 
0.5g/ml Hoescht dye (Molecular Probes, Invitrogen) for 10mins, before being 
washed in PBS.  The slides were then coverslipped using CitiFluor (Science 
Services).  The slides were viewed and images taken using a Leica DMLB 
fluorescent microscope. 
 
2.7 Gene expression assays 
Specific expression of HIF-1α, VEGF and gastrin genes, after the induction of 
hypoxia, specific target mRNA inhibition, or exogenous amidated gastrin 
treatment was determined using quantitative real time RT-PCR. 
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2.7.1 RNA extraction 
Carcinoma cell lines were plated into six-well plates at a density of 3 x 105 – 5 
x 105 cells/well (cell line-dependent), to achieve a 50-60% confluency after 
24hr incubation at 37ºC, in a humidified 5% CO2 atmosphere.  Cells were then 
serum-starved, by replacing the normal growth media with fresh serum-free 
media for approximately 24hr, before being exposed to hypoxia or treated with 
exogenous gastrin as described above, for a known time point.  Cells were 
harvested using 0.25% trypsin/EDTA and centrifuged to form a pellet.  The 
cell pellets were stored at -80ºC until required. 
 
RNA was then extracted from the frozen cell pellets, using one of two 
reagents; RNABee (Biogenesis, Poole, UK) or TRI-reagent (Sigma Aldrich).  
Initial experiments (e.g. hypoxic time course studies) used the RNABee 
reagent for RNA extraction, however this reagent was discontinued during the 
course of this study, so was replaced by TRI-reagent for the later experiments 
(e.g. siRNA transfection studies).  Both reagents use the phenol/chloroform 
method of RNA extraction, and had virtually identical protocols. 
 
Frozen cell pellets prepared after the induction of hypoxia or exogenous 
amidated gastrin treatment, which contained approximately 3 x 105 – 5 x 105 
cells, were resuspended in 1ml RNABee or TRI-reagent, before 200l 
chloroform (Sigma Aldrich) was added and the cell suspension shaken for 
several seconds.  An extraction control was prepared alongside the RNA.  This 
contained RNABee or TRI-reagent and chloroform, but no cells, to ensure that 
the gene expression produced was derived from the RNA and not from any 
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genomic contamination.  Frozen cell pellets prepared after transfection with 
siRNA only contained up to 5 x 104 cells.  Therefore, the RNA was extracted 
from these samples using half volumes of reagents.  
 
The samples were incubated on ice or at room temperature for 5mins (for 
RNABee and TRI-reagent respectively), before being centrifuged at 13,000g 
for 15-30mins at 4ºC.   
 
The resultant clear, aqueous phase, which contained the RNA was transferred 
into 500l isopropanol (Sigma Aldrich) and incubated for 10mins at room 
temperature (for TRI-reagent samples) or 20mins at -20ºC (for RNABee 
samples).  This allowed for RNA precipitation, which was collected by 
centrifugation at 13000g for 10-15mins at 4ºC.  The isopropanol was removed 
and the remaining RNA pellet was washed in 1ml 70% ethanol (Sigma 
Aldrich, diluted using RNase (ribonuclease)-free distilled water from absolute 
stock), before being centrifuged at 13000g for 5mins at 4ºC.  The ethanol was 
removed and the RNA pellet was allowed to air dry, before being resuspended 
in RNase-free distilled water (Sigma Aldrich). 
 
2.7.2 cDNA synthesis 
Complementary DNA (cDNA) was synthesised from the RNA samples using 
the Superscript II RNase H- Reverse Transcriptase kit (Invitrogen).  Briefly, 
10l RNA was incubated with 1.2l random hexamers (pd(N)6 Amersham 
Biosciences) at 70ºC for 10mins, before the samples were immediately 
transferred to ice, to stop the reaction.   
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Control samples were also prepared, to ensure that any signal produced from 
each cDNA positive sample was specific to the RNA, and not as a result of 
genomic contamination or from primer dimers.  The controls included: 
• cDNA negatives, which used water in the place of the random hexamers 
and reverse transcriptase. 
 
• Reagent control, which contained no RNA, but all other reagents to ensure 
that they did not generate any signal in their own right.   
 
Table 2.4 shows the reagents required for the cDNA mastermix for one RNA 
sample.  All reagents for the cDNA mastermix were provided in the reverse 
transcriptase kit, except for the deoxynucleotides (dNTPs) (Sigma Aldrich).   
Reagent: Volume required per sample: 
DNase / RNase-free distilled water 3l 
5X buffer 4l 
0.1M DTT 2l 
dNTPs 0.6l 
Reverse transcriptase 0.4l 
Table 2.4 – The amount of reagents required per sample (cDNA mastermix). 
 
10l cDNA mastermix was added to each RNA/primer sample and the cDNA 
was synthesised using the following programme; 10mins at 25ºC, 60mins at 
42ºC, followed by 5mins at 95ºC.  The resultant cDNA was diluted 1:5 using 
RNase-free distilled water and stored at -20ºC until required. 
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2.7.3 Real time RT-PCR 
Quantitative real time RT-PCR was performed on each cDNA sample.  Table 
2.5 shows the reagents required for the RT-PCR mastermix for each cDNA 
sample.  All reagents for the mastermix were obtained from the qPCR Core kit 
for Sybr Green I, except for the UNG (Uracil DNA Glycosylase) and primers 
(all from Eurogentec).   
Reagent: 
 
Volume required per sample: 
DNase / RNase – free distilled water 
 
12.6l 
10X reaction buffer 
 
2.5l 
50mM MgCl2 (magnesium chloride) 
 
1.75l 
 5mM dNTPs  
 
1l 
1:2000 dilution of Sybr Green 
 
0.75l 
HotGoldStar Taq (5U/l) 
 
0.125l 
UNG (1U/l) 
 
0.25l 
Primer (1:20 dilution of 100M 
stock) 
1l 
Table 2.5 – The amount of reagents required per sample (RT-PCR mastermix). 
 
 
Gene-specific primers were designed using the Applied Biosystems Primer 
Express program (version 2.0).  The primers were complimentary to regions 
with the gene cDNA sequence, and were restricted by the following 
parameters: 
• Have a Tm (annealing temperature) between 58-60ºC. 
• Be approximately 20 nucleotides in length. 
• Have a guanine / cytosine content of 30-80% (and not contain more 
guanine bases than cytosine bases). 
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The DNA sequences of the test and endogenous control primers used are 
shown in Table 2.6. 
Primer: Sequence: 
HIF-1α  Forward: CCTCTGTGATGAGGCTTACCATC 
 
Reverse: CATCTGTGCTTTCATGTCATCTTC 
 
VEGF Forward: ACGAGGGCCTGGAGTGTGT 
 
Reverse: TTTGTTGTGCTGTAGGAAGCTCAT 
 
HPRT 
(endogenous control) 
Forward: ATTATGCTGAGGATTTGGAAAGGG  
 
Reverse: GCCTCCCATCTCCTTCATCAC 
 
Gastrin Forward: CCACACCTCGTGGCAGAC 
 
Reverse: TCCATCCATCCATAGGCTTC 
 
HPRT (for use with 
gastrin primers) 
Forward: GACCAGTCAACAGGGGACAT 
 
Reverse: CGACCTTGACCATCTTTGGA 
 
ARNT (HIF-1β) Forward: AACTTCGTGAGCAGCTTTCCA 
 
Reverse: GCTGACCTTCCTTTTTCACTGTTC 
 
Table 2.6 – Oligonucleotide primer pairs used during real-time RT-PCR. 
 
20l of the RT-PCR mastermix was added to each well of a 96-well optical 
plate (Applied Biosystems, Warrington, UK), before 5l of the diluted cDNA 
samples were added per well.  Each cDNA sample was run in triplicate.  The 
plate was then sealed with an optical adhesive cover (Applied Biosystems) and 
run using the Applied Biosystems 7500 Real Time PCR System, with the 
following protocol; 50ºC for 2mins (annealing stage), 95ºC for 10mins 
(denaturing stage) and then 40 cycles of 95ºC for 15secs (denaturing stage), 
followed by 60ºC for 1min (annealing/extension stage).  The program finished 
with a dissociation step, which lasted 45mins. 
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Alongside the test cDNA samples, the negative control samples generated 
from each stage of their synthesis were included in the RT-PCR (i.e. extraction 
control, cDNA negative samples, cDNA reagent control and also RT-PCR 
water control), to ensure that the signal generated were specific to the RNA / 
cDNA samples, and not from other genomic contamination, protocol reagents 
or primer dimers. 
 
The level of gene expression was quantified by the level of Sybr Green present 
in the sample.  The RT-PCR data was analysed by the relative quantification 
method using the 2-Ct equation (from Livak and Schmittgen, 2001).  This 
method allows the relative change in gene expression to be compared between 
the test gene and the endogenous housekeeping gene, HPRT (hypoxanthine 
phosphoribosyl transferase).  The Ct value of each gene (i.e. the number of 
cycles required to reach a Sybr Green fluorescence threshold, during the 
exponential phase of the RT-PCR), was determined for both the test and HPRT 
gene.  
 
The 2-Ct for the samples could then be calculated using the following 
equation: 
  2-Ct = 2- [Ct
 
(test gene) – Ct (HPRT)] 
 
The Ct can be defined as the difference in the threshold cycles between the 
test gene and the endogenous control, from the same sample.  This allowed for 
a direct comparison of gene expression between the test gene and its control.  
For each cycle, there is a doubling in the amount of template generated; 
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therefore, a single Ct difference represents a two-fold difference in the gene 
expression.  Converting the Ct to 2-Ct, allowed for the differences seen in 
expression levels to be compared between different cell lines (Livak and 
Schmittgen, 2001). 
 
2.8 siRNA transfection 
Target-specific mRNA expression was down-regulated after the transfection of 
small-interfering RNA (siRNA).  These are short (21-25 nucleotides in length), 
double-stranded RNA molecules with a two nucleotide overhang, which utilise 
a naturally-occurring mechanism to repress gene expression (reviewed in Gong 
et al, 2005; Sklan and Glenn, 2007).  During transfection, siRNA molecules 
are taken up into cells and are incorporated into RISC (RNA-induced silencing 
complex), which contains an endonuclease.  The ‘sense’ strand of the siRNA is 
degraded, leaving the ‘antisense’ strand associated with RISC, which is 
complementary to the target mRNA.  The siRNA-RISC complex is then free to 
target and degrade specific mRNA sequences.   
 
Carcinoma cell lines were plated into 24-well plates at a density of 5 x 104 
cells/well, to achieve 30-80% confluency after 24hr incubation at 37ºC, in a 
humidified 5% CO2 atmosphere.  The following day, the growth medium was 
removed and replaced with 200l fresh medium.  For each well that was 
transfected, 4l siPORT Amine transfection reagent (Ambion, Warrington, 
UK) was mixed with 45l Opti-MEM (minimal essential media) 1 medium 
(Invitrogen), before being incubated for 20mins at room temperature.  The 
siPORT Amine/ Opti-MEM 1 mixture was added to 40M target-specific 
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siRNA (see Table 2.7 for details) and gently mixed via pipetting, before being 
incubated for a further 20mins at room temperature.  50l of siRNA/siPORT 
Amine complex was added per well in a drop-wise fashion, with constant 
rocking.  The final concentration of siRNA per well was 20nM.  All 
transfections were completed in duplicate. 
siRNA target: siRNA target sequence: 
ARNT (HIF-1β) GAGACUUGGCCAUAAAGAUUU 
HIF-1α  AAUGUGAGUUCGCAUCUUGAU 
Gastrin AAGAAGAAGCCUAUGGAUGGA 
Scrambled gastrin control AAGCGAAGAAACGAGGUGUAU 
Table 2.7 – Sequence-specific mRNA targets for siRNA repression. 
 
To confirm that the down-regulation of the mRNA was specific to the target 
siRNA, the carcinoma cell lines were also transfected with one of three 
controls: 
• Non-targeting siRNA control (Eurogentec, Southampton, UK), as a 
negative control (for both the HIF-1α and ARNT siRNA).  Sequence 
unavailable. 
 
• Mock control, which contained the siPORT Amine transfection reagent, 
but no siRNA. 
 
• Untreated control, which only contained the Opti-MEM I, and no siRNA or 
transfection reagent. 
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For the gastrin siRNA, a target-specific scrambled control siRNA was 
available, which contained the same nucleotides, but in a randomised 
sequence.  This was transfected in place of the non-targeting siRNA control. 
 
The transfected cells were incubated for approximately 6hr at 37ºC, in a 
humidified 5% CO2 atmosphere, before a further 1ml growth medium was 
added per well.  At this point, the transfected cells were either exposed to 
hypoxia, or retained under normoxia for approximately 16hr, before being 
harvested using 0.25% trypsin/EDTA and centrifuged to form a pellet.  The 
cell pellets were stored at -80ºC until required. 
 
2.9 Construction of hypoxia-response element 
sequence-expressing reporter plasmid 
 
2.9.1 Sequence analysis 
The DNA sequence upstream of both the Homo sapiens gastrin and VEGF 
gene coding regions (-3500bp to + 77bp and -2000bp to + 50bp respectively) 
were obtained from the Ensembl genome browser (http://www.ensembl.org, 
exon information section, genes ENSG00000184502 and ENSG00000112715 
respectively).  The two sequences were compared for any consensus sequences 
using the ClustalW Multiple Alignment Program within the SDSC (San Diego 
Supercomputer Centre) Biology WorkBench software 
(http://workbench.sdsc.edu).   
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2.9.2 DNA extraction 
A gastrin luciferase reporter plasmid was synthesised using a PGL4-basic 
luciferase reporter vector (Promega, Southampton, UK), which was a 4242bp 
plasmid that contained a synthetic firefly luciferase reporter construct, but 
lacked any promoter or enhancer elements (Figure 2.2).  The DNA insert that 
included the putative gastrin HRE sequence was prepared from freshly 
extracted HCT116 carcinoma cell DNA.   
 
The DNA was extracted from the HCT116 carcinoma cell line using the 
Wizard SV Genomic DNA purification system (Promega).  Briefly, the 
HCT116 cells were plated into six-well plates at a density of 5 x 106 cells/well.  
After an overnight incubation at 37ºC, in a humidified 5% CO2 atmosphere, 
the growth medium was aspirated and the cells were rinsed in PBS (Oxoid).  
The cells were harvested using 150l Wizard SV lysis buffer, before being 
applied to a Wizard SV Minicolumn assembly.  The sample was centrifuged at 
13,000g for 3mins, to collect the DNA sample into the column ‘binding 
matrix’.  The DNA was then washed four times using 650l Wizard SV wash 
solution (which contained additional ethanol (Sigma Aldrich)) per wash, 
followed by centrifugation at 13,000g for 1min.  The binding matrix was dried, 
before the DNA was eluted into DNase (deoxyribonuclease) / RNase-free 
distilled water.  The DNA concentration was determined using the Nanodrop 
ND-100 spectrophotometer according to the manufacturer’s instructions.  The 
DNA was stored at -20ºC until required. 
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PGL4-basic luciferase reporter vector 
                        
Figure 2.2 – A plasmid map of the PGL4-basic luciferase reporter vector, 
detailing key constructs and restriction enzyme sites. 
 
 
 
2.9.3 Polymerase chain reaction (PCR) 
Primers were designed using PRIMER3 software from the SDSC Biology 
WorkBench software.  The forward primer was complimentary to a sequence 
upstream of both the putative gastrin HRE sequence and an endogenous XhoI 
restriction enzyme site.  The reverse primer was complimentary to a sequence 
in the gastrin coding region and was designed to contain a BglII restriction 
enzyme site.  Both primers were restricted by the following parameters: 
• Have a Tm between 57-63ºC. 
• Be approximately 20 nucleotides in length. 
• Have a guanine / cytosine content of 20-80%. 
 
The DNA sequences of the primers used to prepare the putative gastrin HRE 
sequence are as follows: 
• Forward primer – ATCAGTTCCTGGTACACGGC 
 
  77 
• Reverse primer –  
  CCTCCTCCTTCTAGAGGTTTTCTCACCTGCAGAGC 
 
2.9.4 PCR amplification 
Table 2.8 showed the reagents required for the PCR mastermix.  All reagents 
for the mastermix were obtained from the HotStarTaq MasterMix Kit (Qiagen, 
Crawley, UK), except for the deoxynucleotides (Sigma Aldrich) and primers 
(Eurogentec). 
 
17l of the PCR mastermix was added to every 8l of HCT116 DNA or water 
negative control.  The PCR was run on the PTC-200 Peltier Thermal Cycler 
(MJ Research, GRI, Braintree, UK) using the following protocols: 
• Original PCR protocol; 40 cycles of 95ºC for 1min (denaturing stage), 
60ºC for 1min (annealing stage) and 72ºC for 3mins (extension stage).   
 
• Putative gastrin HRE long-product PCR protocol; 94ºC for 15mins, then 35 
cycles of 94ºC for 30secs (denaturing stage), 55ºC for 1min (annealing 
stage) and 68ºC for 3.5mins (extension stage), for the first 10 cycles, plus 
an additional 10secs per cycle for the remaining 25 cycles. 
 
The negative control sample ensured that the PCR product was generated from 
the specific DNA added to the sample and not from other genomic 
contamination. 
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Reagent: 
 
Volume required per sample: 
DNase / RNase – free distilled water 
 
6.75l 
10X reaction buffer 
 
2.5l 
5X Q-Solution 
 
5l 
10mM dNTPs 
 
0.5l 
HotStarTaq (5U/l) 
 
0.25l 
Forward primer (5M) 
 
1l 
Reverse primer (5M) 
 
1l 
Table 2.8 – The amount of reagents required per sample (PCR mastermix). 
 
 
 
2.9.5 Agarose gel purification of PCR product 
The resultant PCR product was purified using agarose gel electrophoresis.  A 
0.8% agarose gel was prepared by melting 0.8g agarose (Eurogentec) into 
100ml 1X TBE (Tris Borate EDTA) buffer, which was diluted from a 10X 
stock (Sigma Aldrich).  The buffer was heated in a microwave for 
approximately 2mins on medium, until the agarose was molten.  Ethidium 
bromide was then added to the agarose solution, to give a final dilution of 
0.5g/ml, before the agarose gel was poured into the gel electrophoresis 
casting and left to set.  Two 16-well gel-combs were inserted into the agarose 
gel at this point.   
 
Once set, the agarose gel was placed in a gel tank, filled with 1X TBE buffer + 
0.5g/ml ethidium bromide.  Approximately 10-20l PCR product was loaded 
per well, after being diluted 5:1 with Blue Juice sample buffer (Invitrogen).  
The gel was also loaded with 5l of a 1:20 diluted 2-log DNA ladder (New 
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England Biolabs, Hitchin, UK), which provided an accurate molecular weight 
scale, to aid with DNA size quantification.  The gel was run at 120V for 
approximately 60mins.  The DNA molecules ran towards the cathode, being 
separated according to their molecular weight.  The mutagen ethidium bromide 
intercalated itself into the double-stranded DNA, allowing it to be visualised 
under ultra-violet (UV) light, either via the Syngene ChemiGenius BioImaging 
system, or a UV lamp. 
 
The DNA was purified from the agarose gel using the QIAquick Gel 
Extraction kit (Qiagen).  Briefly, the DNA fragments of interest were excised 
from the gel using a clean scalpel and weighed.  The gel slices were dissolved 
in 3X volume of Buffer QG, with occasional agitation, before the DNA was 
precipitated using isopropanol.  The DNA samples were applied to QIAquick 
columns and collected onto the filter by centrifugation at 13,000g for 1min.  
The DNA was then washed be adding Buffer PE and centrifuging the samples 
at 13,000g for 1min.  The DNA was eluted into DNase / RNase free distilled 
water and its concentration was determined using the Nanodrop ND-100 
spectrophotometer according to the manufacturer’s instructions.  The DNA 
PCR product was stored at -20ºC until required. 
 
2.9.6 Restriction digestion of DNA 
Prior to the ligation and bacterial transformation, the vector and PCR product 
were digested using sequence-specific restriction enzymes, to produce 
compatible ends within the DNA.  The restriction enzymes targeted specific 
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sequences in the DNA, which are listed in Table 2.9, alongside the 
concentration of enzyme and 10X buffer used.   
Restriction 
enzyme: 
Target 
sequence in 
DNA: 
Concentration 
of enzyme 
used: 
10X Buffer 
required: 
Supplier: 
XhoI 5’-C*TGGAG-3’ 
 
3’-GAGGT_C-5’ 
 
20units/g 
DNA 
Buffer H 
(with BglII) 
Buffer B 
(with HindIII) 
New 
England 
Biolabs 
BglII 5’-A*GATCT-3’ 
 
3’-TCTAG_A-5’ 
 
5units/g DNA Buffer M 
(alone) 
Buffer H 
(with XhoI) 
Roche 
Applied 
Science 
HindIII 5’-A*AGCTT-3’ 
 
3’-TTCGA_A-5’ 
 
4units/g DNA Buffer B 
(with XhoI) 
Roche 
Applied 
Science  
 
ScaI 5’-AGT*ACT-3’ 
 
3’-TCA_TGA-5’ 
 
4units/g DNA Buffer B 
(with HindIII 
and XhoI) 
Roche 
Applied 
Science 
Table 2.9 – Specification of the restriction endonucleases used to digest DNA 
(cleaved at the points * and _). 
 
 
A 10l reaction volume contained 1l 10X buffer, 4-20units restriction 
enzyme and 1g DNA (as determined using the Nanodrop concentrations), 
with the difference made up using DNase / RNase-free distilled water.  The 
DNA was digested overnight, at 37ºC, with the resulting PCR products run out 
on a 0.8% agarose gel, as described above to confirm that the restriction digest 
had been successful. 
 
2.9.7 TA cloning and preparation of DNA plasmids 
To further amplify the stocks of putative gastrin HRE PCR product, the 
freshly-synthesised DNA was cloned into pCRII-TOPO vector (Invitrogen), 
using the TOPO TA cloning kit (Invitrogen).  The linearised pCRII-TOPO 
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vector was supplied with a single 3’ thymidine residue overhang, which 
allowed for the direct insertion of the PCR product into the vector.  The PCR 
product had to be amplified using a non-proofreading Taq polymerase, as the 
resultant DNA would then always end in a single 3’ adenosine residue 
overhang, due to the activity of an endogenous terminal transferase enzyme.  
This allowed for the PCR product to be bound into the pCRII-TOPO vector, 
via the activity of an endogenous topoisomerase enzyme.   
 
2l of the putative gastrin HRE PCR product was mixed with 1l of the pCRII-
TOPO vector and salt solution and incubated for 10mins at room temperature.  
The TOPO vector (containing the PCR product) was then transformed into 
TOP10F’ competent cells (Invitrogen), using the ‘One shot’ chemical 
transformation protocol.  Briefly, 1l of the TOPO cloning reaction was gently 
added to a vial of ‘One shot’ chemically competent Escherichia coli (E. coli), 
which were then incubated on ice for 30mins.  The cells were heat-shocked for 
30secs at 42ºC, before being transferred immediately to ice, which allowed the 
TOPO vector to be taken up into the bacteria.  125l SOC (Super optimum 
broth, with catabolite repression) medium was added to the sample, which was 
then incubated at 37ºC for 1hour, with constant agitation.   
 
Agar plates (containing ampicillin), were prepared using FastMedia LB Amp 
powder (Fermantas, York, UK).  Briefly, the powdered agar was melted into 
200ml distilled water by heating in a microwave for approximately 4mins on 
medium (with occasional agitation), until the agar was molten.  The agar was 
cooled slightly, before being divided between 10-12 sterile Petri dishes and left 
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to set.  50l of the TOPO vector (plus putative gastrin HRE) transformation 
was spread over the agar, before being incubated overnight at 37ºC. 
 
To ensure that the colonies obtained were from a successful transformation, a 
negative control was also prepared, replacing the TOPO cloning reaction DNA 
with water.  If colonies were obtained from this sample, then the colonies 
obtained on the TOPO cloning plate were less likely to contain the putative 
gastrin HRE PCR product. 
 
Twelve bacterial colonies were selected from the agar plate and grown up 
overnight at 37ºC in 5ml NZY medium (86mM sodium chloride, 17mM 
magnesium sulphate, 5g yeast extract, 10g casein hydrosylate) (all Sigma 
Aldrich, except for magnesium sulphate (Fisher Scientific)) containing 
50g/ml ampicillin (Sigma), with constant agitation.   
 
DNA plasmids were prepared using Genelute plasmid miniprep kit (Sigma).  
Briefly, the E. coli bacteria were centrifuged at 13,000g for 2mins at room 
temperature to form a pellet, before being resuspended in the ‘resuspension’ 
buffer (which contained RNase A solution) and lysed using the ‘lysis’ buffer.  
The resulting lysate was ‘cleared’ using the alkali-based neutralisation buffer, 
before the cell waste was collected via centrifuging at 13,000g for 10mins at 
room temperature.  The cleared lysate was then applied into a ‘mini-spin 
column’.  The sample was centrifuged at 13,000g for 1min, to collect the DNA 
sample into the column filter.  The DNA was then washed using the wash 
solution provided (which contained additional ethanol (Sigma Aldrich)), 
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followed by centrifugation at 13,000g for 1min.  The column filter was dried, 
before the DNA was eluted into DNase / RNase-free distilled water.  The DNA 
concentration was determined using the Nanodrop ND-100 spectrophotometer 
according to the manufacturer’s instructions.  Test restriction digests were 
performed as described above to confirm that the TOPO vector contained the 
PCR product insert.  The DNA was stored at -20ºC until required.   
 
2.9.8 Ligation and transformation of the gastrin luciferase 
reporter plasmid 
PGL4-basic luciferase plasmid and TOPO vector (+ putative gastrin HRE PCR 
product) were digested using XhoI and HindIII restriction enzymes, before 
being gel purified, as described above, to produce molecules with compatible 
ends for ligation.  The use of XhoI and HindIII enzymes cleaved the amplified 
gastrin PCR product out of the TOPO vector and also ensured the correct 
orientation of the PCR product when ligated into the PGL4-basic luciferase 
vector. 
 
For the ligation, the vector and PCR insert was added to the reaction in a 1:3 
molar ratio.  The 10l reaction volume contained 1l 10X buffer, ATP and T4 
ligase enzyme (Stratagene, Amsterdam), 100ng PGL4-basic luciferase vector 
and approximately 200ng putative gastrin HRE PCR product insert, with the 
difference made up using DNase / RNase-free distilled water.  The amount of 
insert required for the ligation was determined using the following equation 
(when using 100ng vector): 
 
Insert (ng) = 3 x 100 x Y/X (where X is the size of the vector (in base pairs)  
and Y is the size of the insert (in base pairs)) 
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A second ligation reaction was set up, which lacked the PCR product insert 
and therefore acted as a negative ligation control.  The two ligations were 
incubated overnight at 4ºC, to allow for the compatible ends of the vector and 
PCR product insert to combine. 
 
The ligated gastrin luciferase reporter plasmid was then transformed into XL1-
Blue Supercompetent (E. coli) cells (Stratagene).  The supercompetent cells 
were thawed on ice, before 3.4l β-mercaptoethanol (Stratagene) was gently 
added.  The supercompetent cells were incubated on ice for 10mins, with 
occasional agitation, before being equally divided into five pre-chilled 14ml 
tubes.  Between 0.1-50ng ligated plasmid was added to two samples of the E. 
coli cells, which were then incubated on ice for 30mins.  Two different 
concentrations of ligation reaction were added to the supercompetent cells, in 
an attempt to obtain bacterial colonies.  If there was too much DNA present in 
the sample, it actually inhibited the process of transformation.  Therefore, the 
use of two different concentrations of the ligated DNA would increase the 
chance of obtaining colonies.  To ensure that the colonies obtained actually 
contained the ligated plasmid; three control transformations were also set up: 
• Ligation negative control, which lacked the PCR product insert.  If 
colonies were obtained from this sample, they were probably due to vector 
self-ligation. 
 
• Transformation negative control, which lacked any DNA.  If colonies were 
obtained from this sample, they were probably due to genomic 
contamination. 
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• Transformation positive control, which contained a ligated single-digested 
PGL4-basic plasmid.  If the transformation experiment was successful, 
bacterial colonies would be present. 
 
After the 30mins incubation, the E. coli cells were ‘heat-shocked’ at 42ºC for 
45secs, which allowed the ligated plasmid to be taken up into the bacteria.  The 
duration of the heat shock was critical for maximum efficiency.  The 
supercompetent cells were then incubated on ice for 2mins, before 450l SOC 
medium was added to each sample.  The tubes were incubated at 37ºC for 
1hour, with constant agitation. 
 
Approximately 50l of each transformation sample were spread over 
ampicillin-containing agar plates, which were then incubated overnight at 
37ºC.  Twenty-four bacterial colonies were selected from the resultant positive 
gastrin luciferase reporter plasmid agar plate and were cultured overnight in 
5ml NZY-ampicillin medium, at 37ºC with constant agitation.  The gastrin 
luciferase reporter plasmids were prepared using Genelute plasmid miniprep 
kit (Sigma), as described above. 
 
2.9.9 Sequencing of plasmid 
Selected clones of the gastrin luciferase reporter plasmid and HRE-multimer 
plasmid were sent to the Biopolymer Synthesis and Analysis Unit, in the 
Queen’s Medical Centre, Nottingham for sequencing.  The sequencing reaction 
used the primer ‘RVPrimer3’ (CTAGCAAAATAGGCTGTCCC), which was 
complementary to 4191-4210bp of the PGL4-basic luciferase plasmid.  The 
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sequencing reaction consisted of 2l Big Dye reaction mix, 2l 5X ABI 
sequencing buffer, 1l plasmid clone, 50ng RVPrimer3 and 4l distilled water, 
which was run using the following GC-rich PCR program; 25 cycles of 98ºC 
for 30secs (denaturing stage), 50ºC for 15secs (annealing stage) and 56.5ºC for 
4mins (extension stage).  The resultant samples were then analysed using the 
ABI 310 Genetic Analyser (Applied Biosystems, Warrington, UK).   
 
2.9.10 HRE multimer oligonucleotide annealing and plasmid 
preparation 
Gastrin HRE multimer luciferase reporter plasmids were synthesised using a 
PGL4-basic luciferase reporter vector, which also contained a SV40 (Simian 
virus 40) minimal promoter element.  The DNA sequence upstream of gastrin 
gene transcript was further screened for the presence of the HRE consensus 
sequence (A/G)CGTG as previously described using the SDSC Biology 
WorkBench software.  The putative HRE sequences (plus surrounding 
nucleotides) were used to construct oligonucleotide sequences, which are listed 
in Table 2.10.  The oligonucleotides were synthesised by Sigma-Genosys, and 
were resuspended in RNase-free distilled water to a final concentration of 
50M.  20l of each oligonucleotide pair (i.e. both forward and reverse 
constructs) were annealed together using the following programme; 2mins at 
100ºC, 10mins at 65ºC, followed by 60mins at 55ºC.  The annealed 
oligonucleotides were then allowed to cool naturally within the heating block 
to room temperature (took approximately 3-4hr), before being ligated into 
BglII-digested PGL4-basic luciferase reporter vector as previously described. 
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Oligonucleotide 
construct name: 
Repeated sequence 
(containing putative 
gastrin HREs) 
Full oligonucleotide sequence 
Oligonucleotide 
1 
 
 
Forward: 
AGTGTATAAAGCG
TGTGCACAGAC 
Reverse: 
TCACATATTTCGCA
C ACGTGTCTG 
Forward: 5’ GATCTAGTGTATΑAGCGT 
GTGCACAGACAGTGTATAAAGCGTGTG
CACAGACAGTGTATAAAGCGTGTGCAC
AGACAGTGTATAAAGCGTGTGCACAGA
CA 3’.  
Reverse: 5’ GATCTGTCTGTGCACACG 
CTTTATACACTGTCTGTGCACACGCTTT
ATACACTGTCTGTGCACACGCTTTATAC
ACTGTCTGTGCACACGCTTTATACACTA
3’   
Oligonucleotide 
2 
 
 
Forward: 
TGGCTCACGTCTG 
Reverse: 
ACCGAGTGCAGAC 
Forward: 5’ GATCTTGGCTCACGTCTG   
TGGCTCACGTCTGTGGCTCACGTCTG 
TGGCTCACGTCTGA 3’.  
Reverse: 5’ GATCTCAGACGTGAGCCA 
CAGACGTGAGCCACAGACGTGAGCCA 
CAGACGTGAGCCAA 3’   
Oligonucleotide 
3  
 
 
Forward:   
TTACAGACGTGAG 
Reverse: 
AATGTCTGCACTC 
Forward: 5’ GATCTTTACAGACGTGAG 
TTACAGACGTGAGTTACAGACGTGAG 
TTACAGACGTGAGA 3’ 
Reverse: 5’ GATCTCTCACGTCTGTAA 
CTCACGTCTGTAACTCACGTCTGTAA 
CTCACGTCTGTAAA 3’ 
Oligonucleotide 
4  
 
 
Forward: 
GCGCACACGTGGC 
Reverse: 
CGCGTGTGCACCG 
Forward: 5’ GATCTGCGCACACGTGGC 
GCGCACACGTGGCGCGCACACGTGGC 
GCGCACACGTGGCA 3’ 
Reverse: 5’ GATCTGCCACGTGTGCGC 
GCCACGTGTGCGCGCCACGTGTGCGC 
GCCACGTGTGCGCA 3’ 
Oligonucleotide 
5  
 
 
Forward: 
CCCAGGACGTGAG 
Reverse: 
GGGTCCTGCACTC 
 
Forward: 5’ GATCTCCCAGGACGTGAG 
CCCAGGACGTGAGCCCAGGACGTGAG 
CCCAGGACGTGAGA 3’ 
Reverse: 5’ GATCTCTCACGTCCTGGG 
CTCACGTCCTGGGCTCACGTCCTGGG 
CTCACGTCCTGGGA 3’ 
Table 2.10 – HRE multimer sequences derived from the DNA upstream of the 
gastrin gene transcript, plus the oligonucleotides used to synthesis the 
plasmids. 
 
 
 
2.10 Transfections 
Carcinoma cell lines were plated into 24-well plates at a density of 2 x 105 
cells/well (in 500l of cell growth medium), to achieve an 80-90% confluency 
after 24hr incubation at 37ºC, in a humidified 5% CO2 atmosphere.  The 
following day, the cells were transfected with 250-1000ng DNA luciferase 
reporter plasmids, which are detailed in Table 2.11.   
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Plasmid: Function Plasmid information: 
Gastrin 
luciferase 
reporter 
plasmids (plus 
gastrin HRE 
multimer 
luciferase 
reporter 
plasmids) 
Main test 
plasmids 
pTA GasProm 1-4 contained full gastrin-
HRE PCR product. 
  PGL4-(gastrin)-HRE 1-2 contained 3-4x 
gastrin-HRE sequence 
(AGTGTATAAAGCGTGTGCACAGAC)
PGL4-(gastrin)-HRE 3-8 contained 3-4x 
gastrin-HRE sequence with an SV40 
minimal promoter element 
PGL4-(LDH)-
HRE reporter 
plasmid 
Positive 
control 
plasmid 
PGL4-basic luciferase reporter plasmid, 
with an SV40 minimal promoter element 
and 3x LDH-HRE sequences 
(GCGGACGTGCGGGAACCCAC) 
VEGF-HRE 
luciferase 
reporter plasmid 
Positive 
control 
plasmid 
Luciferase reporter plasmid with VEGF 
promoter insert (-2018bp to +50bp) 
PGL4-basic 
control plasmid 
Negative 
control 
plasmid 
Basic luciferase reporter plasmid, with no 
promoter or enhancer elements 
SV40 promoter 
control plasmid 
Negative 
control 
plasmid 
PGL4-basic luciferase reporter plasmid, 
with an SV40 minimal promoter element 
Table 2.11 – Firefly luciferase reporter plasmids used for transient 
transfections. 
 
 
For each well that was transfected, 2l Lipofectamine 2000 transfection 
reagent (Invitrogen) was mixed with 50l Opti-MEM I medium (Invitrogen), 
before being incubated for 5mins at room temperature.  250-1000ng test or 
control plasmid DNA, plus 100ng β-Galactosidase control reporter plasmid 
were also diluted to 50l in volume, using Opti-MEM I medium.  The 
lipofectamine 2000 reaction mix was added to the DNA and incubated for 
20mins at room temperature.  100l of plasmid DNA/Lipofectamine 2000 
complex was added per well, in a drop-wise fashion, with constant rocking.  
Each condition was transfected in duplicate, and the data was pooled together 
once the samples were analysed. 
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The transfected cells were incubated for 24hr at 37ºC, in a humidified 5% CO2 
atmosphere.  After approximately 6hr incubation, a further 1ml growth media 
was added per well, before the cells were returned to the incubator.  After the 
full 24hr incubation, the DNA reporter plasmid-transfected carcinoma cells 
were exposed to hypoxia, or serum-starved, ready to be treated with exogenous 
amidated gastrin or EGF, as described above. 
 
2.10.1 Plasmids 
The following plasmids and cell line were used, alongside the gastrin-
luciferase reporter plasmids:  
1) A lactate dehydrogenase (LDH) expressing PGL3-luciferase reporter 
plasmid, which was kindly donated by Dr Kaye Williams (University of 
Manchester) (Figure 2.3).   
 
2) A VEGF-HRE luciferase reporter plasmid was kindly donated by Prof 
Alan Knox (University of Nottingham) (Figure 2.4). 
 
3) A HCT116 dual-luciferase cell line was obtained from Prof Ian Stratford 
(University of Manchester).  It contained a stably-transfected HRE-linked 
firefly luciferase gene and an endogenous control renilla luciferase gene.   
 
 
 
 
 
  90 
PGL3 LDH-HRE luciferase reporter vector 
PGL3 basic
vector (4818bp)
Luc+
(luciferase reporter)
Amp resistance
ori
f1 ori
LDH HRE           SV40 minimal
Multimer promoter
 
Figure 2.3 – A plasmid map of the PGL3-LDH HRE luciferase reporter vector, 
detailing key constructs. 
 
 
 
VEGF promoter luciferase reporter vector 
Luciferase reporter
Amp resistance
ori
VEGF-promoter 
insert (2068bp)
pLuc vector
(5443bp)
SV40 minimal 
promoter
 
Figure 2.4 – A plasmid map of the VEGF promoter luciferase reporter vector, 
detailing key constructs. 
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2.10.2 Dual luciferase reporter plasmid and siRNA transfection 
For the dual transfection, the amount of siRNA and DNA reporter plasmid 
transfected were kept at the normal amounts, whereas the volumes of 
transfection reagent and Opti-MEM medium were reduced by half.  
 
GI carcinoma cell lines were plated as before at a density of 8 x 104 cells/well, 
and incubated for 24hr at 37ºC, in a humidified 5% CO2 atmosphere.  The 
following day, the growth medium was removed and replaced with 200l of 
fresh growth medium.  For each well that was transfected, 2l siPORT Amine 
transfection reagent was mixed with 22l Opti-MEM 1 medium and incubated 
for 20mins as before.  Meanwhile, 1l Lipofectamine 2000 transfection 
reagent was mixed with 25l Opti-MEM I medium.  The siPORT Amine / 
Opti-MEM 1 mixture was added to 1l HIF-1α siRNA, whilst the Opti-MEM-
diluted 500ng PGL4-(LDH)-HRE plasmid and 100ng β-Galactosidase control 
were combined with the Lipofectamine 2000 reagent, before both were 
incubated for a further 20mins at room temperature. 
 
25l of the siRNA/siPORT Amine complex was added per well in a drop-wise 
fashion with constant rocking, alongside 50l of the plasmid 
DNA/Lipofectamine 2000 complex.  Each condition was transfected in 
duplicate, and the data was pooled together once the samples were analysed. 
 
The transfected cells were incubated for 24hr at 37ºC, in a humidified 5% CO2 
atmosphere.  After approximately 6hr incubation, a further 1ml growth media 
was added per well, before the cells were returned to the incubator.  After the 
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full 24hr incubation, the dual siRNA/DNA plasmid-transfected carcinoma cells 
were then exposed to hypoxia, as described above. 
 
To confirm that the down-regulation of the luciferase-reporter activity was 
down to the target-specific siRNA transfected, the carcinoma cell lines were 
also transfected with: 
• Non-targeting siRNA control (Eurogentec), plus the luciferase reporter 
plasmid. 
 
• Mock control, which contained both transfection reagents, but only the 
luciferase reporter plasmid, and no siRNA. 
 
• Untreated control, which only had been transfected with the luciferase 
reporter plasmid. 
 
2.11 Firefly luciferase reporter assay 
Cells transfected with DNA luciferase reporter plasmids were harvested using 
Promega’s passive lysis buffer.  Briefly, the cell growth medium was aspirated 
and the cells washed once in PBS (Oxoid).  The cells were then lysed in 100l 
1X passive lysis buffer (diluted from a 5X stock), before being incubated at 
room temperature for 20mins with constant agitation.  The resultant lysates 
could be analysed immediately or stored at -20ºC until required. 
 
Single Firefly luciferase activity was determined using the Luciferase Reporter 
Assay System (Promega).  5l of each cell lysate was mixed with 25l 
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luciferase assay reagent in a black 96-well plate, before the luminescence was 
analysed for 1sec/well, using a BMG labtech FLUOstar Optima luminometer.  
Each sample was analysed in triplicate.  The luminescence from the luciferase 
assay reagent alone was also determined for each run, to ensure that the 
luminescence produced from the cell lysates was due to specific firefly 
luciferase expression.   
 
For each sample, the firefly luciferase activity was expressed relative to the 
equivalent β-Galactosidase control, to ensure the data obtained was a true 
representation of the results, rather than just being due to differences in cell 
densities. 
 
2.11.1 β-Galactosidase activity assay 
The control β-Galactosidase activity from the same samples was measured 
using the Galacto-Light Plus system (Applied Biosystems).  Briefly, enough 
Galacton-plus Substrate for the immediate assay was diluted with the Reaction 
Buffer Diluent, to form the Reaction Buffer.  5l of each cell lysate was mixed 
with 17.5l reaction buffer, before being incubated for 1hr at room 
temperature.  Each sample was analysed in triplicate.  Immediately prior to 
reading the luminescence, 25l Accelerator II buffer was added per well, 
which were then read for 1sec/well. 
 
2.12 Dual luciferase reporter assay 
The HCT116 dual-luciferase cells were plated at a density of 2 x 105 cells/well 
and were incubated at 37ºC, in a humidified 5% CO2 atmosphere for 24hr.  
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They were then transfected with gastrin siRNA or equivalent scrambled 
control, before being harvested using the passive lysis buffer, as previously 
described. 
 
The luciferase activity was determined using the Stop and Glo Luciferase assay 
System (Promega).  To determine the firefly luciferase activity, 5l of each 
cell lysate was mixed with 25l luciferase assay reagent (II) in a black 96-well 
plate, before the luminescence was analysed for 1sec/well, using a BMG 
labtech FLUOstar Optima luminometer.   
 
To determine the corresponding endogenous renilla luciferase activity, a 1X 
solution of the ‘Stop and Glo’ reagent was prepared by diluting the 50X Stop 
and Glo substrate with the Stop and Glo buffer.  25l of the Stop and Glo 
reagent was added to each well of the plate, immediately after the firefly 
luciferase was read, before the renilla luminescence was analysed for 
1sec/well. 
 
Each sample was analysed in triplicate, with the firefly luciferase activity 
being expressed relative to the equivalent renilla luciferase control. 
 
2.13 Statistical analysis 
The significance of differences in mRNA expression, when investigated as a 
time course was calculated using a one-way ANOVA (Analysis of variance), 
with Bonferroni multiple comparison tests.  The significance of differences in 
mRNA expression, when analysing individual data samples was measured 
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using a student’s t-test.  Data correlation was analysed using a linear regression 
test.  The differences were considered significant if p<0.05. 
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Chapter Three 
VALIDATION OF 
TARGET 
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3.1 Background 
Under hypoxic conditions, the enzymes responsible for the hydroxylation of 
HIF-1α are inhibited and therefore the degradation of HIF-1α is prevented.  
The non-hydroxylated HIF-1α is free to translocate to the nucleus and dimerise 
with the constitutively expressed HIF-1β subunit, forming the complete 
transcription factor, HIF-1.  This then binds to conserved HREs within 
promoter regions of target genes, resulting in the transcription of genes that 
promote cell growth, angiogenesis and metabolism, including erythropoietin, 
VEGF and GLUT1.  The expression of HIF-1-induced target genes enables the 
cell to adapt to and endure the stress exerted on it by hypoxia. 
 
The aim of this chapter was to confirm that the HIF-1 transcription factor was 
up-regulated under hypoxic conditions in GI carcinoma cell lines, both in 
expression and function.  Firstly, the expression of the HIF-1α protein was 
investigated, using both Western blotting and immunofluorescent techniques to 
confirm that it was translocated to the nucleus under hypoxic conditions.  Then 
the expression of the key HIF-1 target gene, VEGF was further investigated, to 
determine whether this HIF-1 transcription factor was functionally active. 
 
3.2 Nuclear expression of HIF-1α protein after chemical 
induction – The accumulation of protein under hypoxic 
conditions 
To investigate the response of GI carcinoma cell lines after treatment with 
chemical agents that mimic hypoxia, and to optimise both the induction time 
and antibody concentration required, HIF-1α protein was induced in cell lines 
using either 150M CoCl2 (an iron antagonist) or 200M DFO (an iron 
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chelator).  Both compounds inhibit the activity of the prolyl hydroxylase 
enzymes, therefore preventing the degradation of the HIF-1α protein under 
normal physiological oxygen tension (See Materials and Methods section 2.2).  
 
The nuclear expression of HIF-1α protein in GI carcinoma cell-lines, under 
both ‘normal’ physiological oxygen concentrations of 20.9% (normoxia) and 
chemically-induced hypoxic conditions was investigated using Western 
blotting (See Materials and Methods section 2.5). 
 
Expression of HIF-1α had been previously investigated in the HCT116 
carcinoma cells by other groups, who found that it was highly inducible under 
hypoxic conditions, but not under normoxia (Krishnamachary et al, 2003).  
The expression of HIF-1α has not been previously investigated in either the 
MGLVA1 or PAN1 carcinoma cell lines. 
 
The nuclear expression of HIF-1α protein under hypoxic conditions was found 
to be increased in the HCT116, MGLVA1 and PAN1 carcinoma cell lines, 
after treatment with either DFO or CoCl2 at all time points investigated.  The 
results for DFO treatment are shown in Figures 3.1, 3.2 and 3.3 (for HCT116, 
MGLVA1 and PAN1 cell lines respectively).  The results for CoCl2 treatment 
are shown in Figures 3.4, 3.5 and 3.6 (for HCT116, MGLVA1 and PAN1 cell 
lines respectively).  DFO treatment induced maximal nuclear accumulation of 
HIF-1α protein after 16hr incubation in all three cell lines tested.  It induced a 
12-fold increase of nuclear expression of HIF-1α protein in the HCT116 cells 
at this time point, and a 50-fold increase in both the MGLVA1 and PAN1 
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cells, with the protein expression reducing after this time point.  CoCl2 
treatment induced a rapid increase in nuclear expression of HIF-1α protein in 
both the HCT116 and MGLVA1 cell lines, with an approximate 18-fold and 2-
fold increase seen in the nuclear expression of HIF-1α protein after treatment 
with the hypoxic mimetic respectively.  The PAN1 cells followed a similar 
pattern to that seen after DFO treatment, with nuclear expression of HIF-1α 
protein under hypoxic conditions peaking after 6-16hr treatment, producing a 
19-fold increase (p=0.0294) in the nuclear expression of HIF-1α protein after 
CoCl2 treatment.   
HIF-1α nuclear protein expression in HCT116 carcinoma cell lines. 
Time point:             2hr                           6hr       16hr                       24hr
Conditions:   Norm        DFO        Norm        DFO            Norm       DFO        Norm       DFO
HIF-1α
β-actin
Bromo-
deoxyuridine
 
Figure 3.1 – HIF-1α nuclear protein expression in HCT116 carcinoma cells, 
after treatment with DFO, relative to β-actin control (Norm = Untreated).  n=2 
(data representative of replicate experiments). 
 
 
HIF-1α nuclear protein expression in MGLVA1 carcinoma cell lines. 
Time point:           2hr                          6hr          16hr                          24hr
Conditions:  Norm      DFO        Norm       DFO                Norm       DFO         Norm        DFO
HIF-1α
β-actin
 
Figure 3.2 – HIF-1α nuclear protein expression in MGLVA1 carcinoma cells, 
after treatment with DFO, relative to β-actin control (Norm = Untreated).  n=2 
(data representative of replicate experiments). 
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HIF-1α nuclear protein expression in PAN1 carcinoma cell lines. 
Time point:              2hr                           6hr      16hr                        24hr
Conditions:    Norm        DFO        Norm       DFO            Norm       DFO         Norm      DFO
HIF-1α
β-actin
Bromo-
deoxyuridine
 
Figure 3.3 – HIF-1α nuclear protein expression in PAN1 carcinoma cells, after 
treatment with DFO, relative to β-actin control (Norm = Untreated).  n=2 (data 
representative of replicate experiments). 
 
 
HIF-1α nuclear protein expression in HCT116 carcinoma cell lines. 
Time point:              2hr                           6hr      16hr                        24hr
Conditions:    Norm       CoCl2 Norm       CoCl2 Norm      CoCl2 Norm      CoCl2
HIF-1α
β-actin
Bromo-
deoxyuridine
 
Figure 3.4 – HIF-1α nuclear protein expression in HCT116 carcinoma cells, 
after treatment with CoCl2, relative to β-actin control (Norm = Untreated).  n=2 
(data representative of replicate experiments).  
 
 
HIF-1α nuclear protein expression in MGLVA1 carcinoma cell lines. 
Time point:            2hr                          6hr         16hr                         24hr
Conditions:   Norm      CoCl2 Norm      CoCl2 Norm       CoCl2 Norm       CoCl2
HIF-1α
β-actin
Bromo-
deoxyuridine
 
Figure 3.5 – HIF-1α nuclear protein expression in MGLVA1 carcinoma cells, 
after treatment with CoCl2, relative to β-actin control (Norm = Untreated).  n=2 
(data representative of replicate experiments). 
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HIF-1α nuclear protein expression in PAN1 carcinoma cell lines. 
Time point:             2hr                          6hr        16hr                         24hr
Conditions:   Norm       CoCl2 Norm       CoCl2 Norm      CoCl2 Norm      CoCl2
HIF-1α
β-actin
Bromo-
deoxyuridine
 
Figure 3.6 – HIF-1α nuclear protein expression in PAN1 carcinoma cells, after 
treatment with CoCl2, relative to β-actin control (Norm = Untreated).  n=2 
(data representative of replicate experiments). 
 
 
Within both HCT116 and PAN1 cells after treatment with either DFO or 
CoCl2, nuclear expression of HIF-1α protein under normoxic conditions was 
negligible at all time points investigated (Figures 3.1, 3.3, 3.4 and 3.6).  In 
MGLVA1 cells, nuclear expression of HIF-1α protein under normoxic 
conditions was consistently detected at low levels throughout the experiment 
(Figures 3.2 and 3.5), which differed from the other cell lines tested.  This 
could be due to MGLVA1 expressing an oncogenic mutation, such as a 
constitutively active Akt protein, or an inactive pVHL, which would allow for 
the endogenous expression of the HIF-1α protein, even under normoxic 
conditions. 
 
The level of protein expression (both HIF-1α and Actin) varied depending on 
the GI carcinoma cell line investigated.  For example, the MGLVA1 cells 
produced very intense protein bands (Figures 3.2 and 3.5), whereas the 
HCT116 cells produced lower levels of protein expression (Figures 3.1 and 
3.4).  The differences were endogenous to the cell lines, as the cell lysates were 
normalised to the same protein concentration prior to loading into the wells.  
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This suggested that the MGLVA1 cells expressed higher levels of HIF-1α and 
β-actin protein, compared to the HCT116 and PAN1 cell lines.   
 
The nuclear expression of HIF-1α protein under hypoxic conditions was shown 
to be specific, as no bands were produced at the equivalent weight of HIF-1α 
protein (120kb) when the samples were probed with a non-specific mouse 
bromodeoxyuridine antibody (Figures 3.1, 3.3, 3.4, 3.5 and 3.6).  
 
The expression of HIF-1α protein was also investigated within the 
corresponding cytoplasmic lysates of the carcinoma cell lines.  As the 
expression was shown to be negligible under both normoxic and hypoxic 
conditions in each cell line tested (data not shown); no further experiments 
were carried out using the cytoplasmic lysates. 
 
The expression of the HIF-2α protein was also investigated under both 
normoxic and hypoxic conditions, after treatment of the GI carcinoma cell 
lines with either CoCl2 or DFO.  No HIF-2α protein was detected at any time 
point tested in any cell line (data not shown).  This was to be expected, as the 
HIF-2 transcription factor is normally only expressed in specific tissues, such 
as endothelial cells, the kidneys and the lungs, whereas the expression of HIF-
1 is ubiquitous.  Therefore, no further work investigating the expression of 
HIF-2α was undertaken in this project. 
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3.3 Nuclear expression of HIF-1β protein after chemical 
induction – The accumulation of protein under hypoxic 
conditions 
The corresponding nuclear protein expression of the constitutively expressed 
HIF-1β subunit was also investigated using Western blotting.  In all cell lines 
tested, the nuclear expression of the HIF-1β protein under normoxic conditions 
was relatively low, but constitutively expressed (Figures 3.7 and 3.8). 
HIF-1β nuclear protein expression in HCT116 carcinoma cell lines. 
Time point:            2hr                            6hr       16hr                       24hr
Conditions:  Norm       CoCl2 Norm       CoCl2 Norm      CoCl2 Norm      CoCl2
HIF-1β
β-actin
 
Figure 3.7 – HIF-1β nuclear protein expression in HCT116 carcinoma cells, 
after treatment with CoCl2, relative to β-actin control (Norm = Untreated).  n=1 
 
 
HIF-1β nuclear protein expression in MGLVA1 carcinoma cell lines. 
Time point:             2hr                         6hr         16hr                         24hr
Conditions:   Norm       CoCl2 Norm      CoCl2 Norm       CoCl2 Norm       CoCl2
β-actin
HIF-1β
MGLVA1 cells  Figure 3.8 – HIF-1β nuclear protein expression in MGLVA1 carcinoma cells, 
after treatment with CoCl2, relative to β-actin control (Norm = Untreated).  n=1 
 
 
On induction of hypoxic conditions by CoCl2, there was a consistent increase 
in the nuclear expression of HIF-1β protein throughout the time course in all 
cell lines tested.  In the HCT116 and MGLVA1 cell lines, the expression of 
nuclear HIF-1β protein increased by a consistent 2-4 fold and 2-5 fold 
respectively under hypoxic conditions (Figures 3.7 and 3.8).  Induction of 
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hypoxic conditions by DFO produced a 1-4 fold increase in the expression of 
nuclear HIF-1β protein at the later time points only (data not shown), which 
may suggest that CoCl2 is more efficient at inducing hypoxia (via chemical 
induction).  In these initial experiments, HIF-1β expression was undetectable 
in PAN1 cells.   
 
These results suggest that the HIF-1β protein was stabilised in the nucleus once 
hypoxia had been established, ready to initiate target gene transcription.  As 
the HIF-1β protein is constitutively expressed within the majority of carcinoma 
cell lines, the increased hypoxic expression of HIF-1β may suggest that HIF-
1α and HIF-1β proteins dimerise within the cytoplasm, translocating to the 
nucleus as the fully formed transcription factor, rather than dimerising within 
the nucleus itself.   
 
3.4 Nuclear expression of HIF-1α protein under 
hypoxic conditions – The accumulation of protein 
under hypoxic conditions 
After the initial studies were performed using chemical treatments to induce 
hypoxia, the Invivo2 400 hypoxic workstation became available for use.  This 
maintains atmospheric hypoxia, as the cells are incubated in 1% oxygen 
environment.  This generates ‘true’ hypoxia within cells, instead of inhibiting 
the enzymes responsible for the degradation of the HIF-1α protein.  Slight 
modifications to the Western lysate preparation assay were required to ensure 
that the HIF-1α protein was not broken down during its brief, but inevitable 
exposure to normoxia (See Materials and Methods section 2.2). 
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The nuclear expression of HIF-1α protein in GI carcinoma cell-lines, under 
both ‘normal’ physiological oxygen concentrations of 20.9% (normoxia) and 
atmospheric hypoxic conditions was investigated using Western blotting.  
These experiments continued to use a similar time-frame of hypoxic induction 
and antibody concentration (1g/ml) as performed in the chemical induction 
experiments.   
 
Within the HCT116, MGLVA1 and PAN1 carcinoma cell lines, the nuclear 
expression of HIF-1α protein was highly inducible under hypoxic conditions 
(Figures 3.9, 3.10 and 3.11 respectively).  Maximal nuclear accumulation of 
HIF-1α protein was reached after 8-12hr hypoxic incubation, in the three cell 
lines tested, with up to a 15-fold increase in nuclear protein expression seen in 
the HCT116 and PAN1 cell lines at this time point, and a 10-fold increase in 
the MGLVA1 cell line.  The maximal nuclear expression of the HIF-1α protein 
induced at 1% oxygen concentration occurred at an earlier time point than 
when induced via chemical treatment.  Under normoxic conditions, nuclear 
expression of HIF-1α protein was negligible at all time points investigated in 
the HCT116 and PAN1 cell lines, but consistently expressed at low levels in 
the MGLVA1 cell line (Figure 3.10).  This could be due to the MGLVA1 
carcinoma cells expressing a carcinogenic mutation, such as a constitutively 
active Akt or an inactive pVHL, which could induce the expression of HIF-1α 
even under normoxic conditions. 
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HIF-1α nuclear protein expression in HCT116 carcinoma cell lines. 
Time point:     0hr               1hr                     4hr   8hr                     12hr                  16hr 
Condition: Control   Norm     Hyp      Norm     Hyp     Norm  Hyp      Norm     Hyp     Norm       Hyp 
HIF-1α
β-actin
 
Figure 3.9 – HIF-1α nuclear protein expression in HCT116 carcinoma cells, 
after incubation under normoxic or hypoxic conditions, relative to β-actin 
control.  n=2 (data representative of replicate experiments). 
 
 
HIF-1α nuclear protein expression in MGLVA1 carcinoma cell lines. 
Time point:     0hr               1hr                     4hr   8hr                   12hr                   16hr 
Condition: Control    Norm     Hyp     Norm     Hyp      Norm Hyp     Norm    Hyp      Norm      Hyp 
HIF-1α
β-actin
 
Figure 3.10 – HIF-1α nuclear protein expression in MGLVA1 carcinoma cells, 
after incubation under normoxic or hypoxic conditions, relative to β-actin 
control.  n=2 (data representative of replicate experiments). 
 
 
HIF-1α nuclear protein expression in PAN1 carcinoma cell lines. 
Time point:     0hr              1hr                      4hr   8hr                     12hr                  16hr 
Condition: Control  Norm     Hyp       Norm     Hyp     Norm  Hyp      Norm     Hyp     Norm       Hyp 
HIF-1α
β-actin
 
Figure 3.11 – HIF-1α nuclear protein expression in PAN1 carcinoma cells, 
after incubation under normoxic or hypoxic conditions, relative to β-actin 
control.  n=4 (data representative of replicate experiments). 
 
 
The expression of HIF-1α protein was also investigated within the 
corresponding cytoplasmic lysates.  As seen in chemically induced hypoxia, its 
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expression was shown to be negligible under both normoxic and hypoxic 
conditions in each cell line tested (data not shown). 
 
3.5 Nuclear expression of HIF-1α protein under 
hypoxic conditions – The accumulation of protein 
under hypoxic conditions using cell immuno-
fluorescence 
To verify the cellular location of the HIF-1α protein under hypoxic conditions, 
HCT116, MGLVA1 and PAN1 cells were incubated at 1% oxygen 
concentration, before the expression of HIF-1α was determined via 
immunofluorescence staining (See Materials and Methods section 2.6).  Under 
hypoxic conditions, the HIF-1α protein was highly expressed within the cell 
nucleus, but not within the nucleoli in each cell line tested (Figures 3.12, 3.13 
and 3.14 for HCT116, MGLVA1 and PAN1 cell lines respectively).  No 
distinguishable HIF-1α protein was identified within the nucleus under 
normoxic conditions within the HCT116 and PAN1 carcinoma cell lines (data 
not shown).  This therefore corroborates the data seen within the Western 
blots, confirming that incubation under hypoxic conditions induces the 
expression and translocation of the HIF-1α protein to the nucleus.  The 
MGLVA1 cells however did express the HIF-1α protein under normoxic 
conditions and the protein appeared to surround the nucleus, without actually 
entering it (Figure 3.15).  The negative control image however also showed a 
level of non-specific staining, of a similar pattern, but at a lower intensity.  
This data corroborates that seen within the MGLVA1 Western blot, where 
HIF-1α protein was expressed under normoxic conditions, at low 
concentrations. 
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HIF-1α nuclear protein localisation in HCT116 carcinoma cell line. 
HIF-1α
protein
expression
Bromo-
deoxyuridine
protein
expression
Hoechst 
nuclear 
counterstain
Hoechst 
nuclear 
counterstain
 
 
Figure 3.12 – HIF-1α protein expression in HCT116 carcinoma cells, after 
incubation under hypoxic conditions, compared to non-specific mouse 
bromodeoxyuridine control.  Nuclear HIF-1α expression was confirmed by 
counterstaining cells with Hoescht nuclear stain.  n=3 (data representative of 
replicate experiments).   
 
 
HIF-1α nuclear protein localisation in MGLVA1 carcinoma cell line. 
HIF-1α
protein
expression
Bromo-
deoxyuridine
protein
expression
Hoechst 
nuclear 
counterstain
Hoechst 
nuclear 
counterstain
 
 
Figure 3.13 – HIF-1α protein expression in MGLVA1 carcinoma cells, after 
incubation under hypoxic conditions, compared to non-specific mouse 
bromodeoxyuridine control.  Nuclear HIF-1α expression was confirmed by 
counterstaining cells with Hoescht nuclear stain.  n=2 (data representative of 
replicate experiments).   
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HIF-1α nuclear protein localisation in PAN1 carcinoma cell line. 
HIF-1α
protein
expression
Bromo-
deoxyuridine
protein
expression
Hoechst 
nuclear 
counterstain
Hoechst 
nuclear 
counterstain
 
 
Figure 3.14 – HIF-1α protein expression in PAN1 carcinoma cells, after 
incubation under hypoxic conditions, compared to non-specific mouse 
bromodeoxyuridine control.  Nuclear HIF-1α expression was confirmed by 
counterstaining cells with Hoescht nuclear stain.  n=2 (data representative of 
replicate experiments).   
 
 
 
 
HIF-1α nuclear protein localisation in MGLVA1 carcinoma cell line. 
HIF-1α
protein
expression
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deoxyuridine
protein
expression
HIF-1α nuclear protein localisation in MGLVA1 carcinoma cell line.
Hoechst 
nuclear 
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Hoechst 
nuclear 
counterstain
 
 
Figure 3.15 – HIF-1α protein expression in MGLVA1 carcinoma cells, after 
incubation under normoxic conditions, compared to non-specific mouse 
bromodeoxyuridine control.  Nuclear HIF-1α expression was confirmed by 
counterstaining cells with Hoescht nuclear stain.  n=1 
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3.6 HIF-1α gene expression after chemical induction – 
down-regulation of the HIF-1α gene expression under 
hypoxic conditions 
The induction of hypoxia, either via incubation in 1% oxygen or after chemical 
treatment, induced nuclear expression of HIF-1α protein, at all time points 
tested, reaching maximal expression between 8-16hr, depending on the cell 
line and the hypoxic induction method used. 
 
The corresponding gene expression of HIF-1α under both normoxic and 
hypoxic conditions was also investigated, using quantitative real-time RT-PCR 
(See Materials and Methods section 2.7).  Initially, the gene expression of HIF-
1α was determined after chemically-inducing hypoxia using 150M CoCl2 or 
200M DFO in MGLVA1 and PAN1 carcinoma cell lines (Figures 3.16). 
 
Chemical induction of hypoxia by DFO caused a significant decrease in the 
gene expression of HIF-1α in both carcinoma cell lines investigated (Figure 
3.16).  After 6hr hypoxic induction, treatment with DFO decreased the gene 
expression of HIF-1α by 85% and 40% for MGLVA1 and PAN1 cells 
respectively (p<0.0001 for both cell lines).  After 16hr chemical treatment, 
DFO again induced a significant decrease in gene expression of HIF-1α by 
70% and 50% in MGLVA1 and PAN1 cells respectively (Figure 3.16, 
p<0.0001 for both cell lines).   
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HIF-1α gene expression after chemical-induction of hypoxia 
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Figure 3.16 – HIF-1α gene expression in MGLVA1 carcinoma cells (top 
graph) and PAN1 carcinoma cells (middle graph), after treatment with either 
CoCl2 or DFO, relative to the HPRT control (*p=0.0281 / ***p<0.0001 
(analysed using a student’s t-test), + 95% confidence interval).  HPRT 
expression in PAN1 and MGLVA1 cells (bottom graphs), after treatment with 
either CoCl2 or DFO.  (PAN1 and MGLVA1 cells, n=2 (data representative of 
replicate experiments)). 
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Mimetic induction of hypoxia by CoCl2 had no obvious effect on the gene 
expression of HIF-1α in PAN1 cells, but significantly decreased gene 
expression in MGLVA1 cells by 25% after 6hr incubation (p<0.0001).  After 
16hr hypoxic induction, CoCl2 had no effect on the gene expression of HIF-1α 
in the MGLVA1 cells, and induced an increase in the gene expression of HIF-
1α in the PAN1 cells (p=0.0281) (Figure 3.16).   
 
The differences seen in HIF-1α gene expression in the MGLVA1 and PAN1 
carcinoma cell lines, after treatment with either CoCl2 or DFO were not due to 
changes in the HPRT control gene expression.  Figure 3.16 shows the mean 
HPRT expression under each condition, at both the 6hr and 16hr time points.  
There was no significant difference in HPRT expression after treatment with 
the hypoxia mimetics, when compared to the normoxic control, suggesting that 
the decrease in HIF-1α gene expression is induced by DFO treatment. 
 
3.7 HIF-1α gene expression after hypoxic induction – 
down-regulation of the HIF-1α expression under 
hypoxic conditions 
After the initial studies were performed using chemical treatments to induce 
hypoxia, the assay was performed in 1% oxygen and the expression of the 
HIF-1α gene was investigated in HCT116, MGLVA1 and PAN1 carcinoma 
cell lines, at a number of different time points, under both normoxic and 
hypoxic conditions, using quantitative real-time RT-PCR.   
 
In HCT116, MGLVA1 and PAN1 cell lines, incubation under hypoxic 
conditions induced a significant decrease in the HIF-1α gene expression over 
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the first 2-8hr of the experiment (Figures 3.17, p<0.0001).  The expression of 
the HIF-1α gene then levelled off over the remaining part of the time course, 
resulting in it being between 50-80% (cell line-dependent) lower than the 
equivalent normoxic control expression.  Under normoxic conditions, there 
was a slight increase in the expression of the HIF-1α gene (5-40%, cell line-
dependent) over the time points investigated (Figures 3.17). 
 
The expression of the HIF-1α gene under hypoxic conditions displayed the 
opposite behaviour to the equivalent HIF-1α protein expression, when the RT-
PCR data was compared with its corresponding Western blotting data.  As the 
HIF-1α protein levels increased over the first 1-8hr, the equivalent HIF-1α 
gene expression decreased, before levelling off over the rest of the experiment.  
The expression of the HIF-1α protein however, started to decrease once it had 
reached its maximal expression after 8-12hr hypoxic incubation.  Despite the 
noticeable differences between the HIF-1α nuclear protein and gene expression 
under hypoxic conditions, statistical correlation analysis proved inconclusive, 
possibly due to the limited number of HIF-1α gene expression data points 
available for analysis. 
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HIF-1α gene expression after hypoxic incubation. 
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Figure 3.17 – HIF-1α gene expression in HCT116 carcinoma cells (top graph), 
MGLVA1 carcinoma cells (middle graph) and PAN1 carcinoma cells (bottom 
graph), after incubation under normoxic or hypoxic conditions, relative to the 
HPRT control (p<0.0001 (analysed using a one-way ANOVA), individual data 
points; ***p<0.0001, + 95% confidence interval).  (HCT116 and MGLVA1 
cells, n=2 (data representative of replicate experiments), PAN1 cells n=4 (data 
representative of replicate experiments)). 
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3.8 VEGF gene expression after hypoxic induction - 
Up-regulation of the VEGF gene expression 
To determine whether the nuclear HIF-1α protein induced during hypoxia was 
transcriptionally active, the gene expression of VEGF, a known target gene of 
HIF-1-regulated transcription was investigated in the HCT116, MGLVA1 and 
PAN1 carcinoma cell lines, under both normoxic and hypoxic conditions, 
using quantitative real-time RT-PCR. 
 
VEGF gene expression was shown to significantly increase after 6-8hr hypoxic 
incubation, continuing to increase throughout the rest of the time course in 
HCT116, MGLVA1 and PAN1 cell lines (Figures 3.18).  The VEGF gene 
expression under hypoxic conditions increased by 4 to 5-fold (cell line-
dependent, p<0.0001), compared to the equivalent normoxic gene expression, 
which remained virtually consistent throughout the experiment, only slightly 
increasing after 16hr incubation (Figures 3.18).   
 
The increase seen in the VEGF gene expression under hypoxic conditions 
correlated (p=0.0324, PAN1 cells) with the increase in HIF-1α nuclear protein 
expression.  These results suggested that the HIF-1α protein that was up-
regulated under hypoxic conditions was forming a functional transcription 
factor and initiating the transcription of target genes. 
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VEGF gene expression after hypoxic incubation. 
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Figure 3.18 – VEGF gene expression in HCT116 carcinoma cells (top graph), 
MGLVA1 carcinoma cells (middle graph) and PAN1 carcinoma cells (bottom 
graph), after incubation under normoxic or hypoxic conditions, relative to the 
HPRT control (p<0.0001 (analysed using a one-way ANOVA), individual data 
points; ***p<0.0001, + 95% confidence interval).  (HCT116 and MGLVA1 
cells, n=2 (data representative of replicate experiments), PAN1 cells n=4 (data 
representative of replicate experiments)). 
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3.9 Chapter Summary and Conclusions 
The translocation of the HIF-1α protein to the nucleus under hypoxic 
conditions is required for the activation of the HIF-1 transcription factor, 
alongside dimerisation with the HIF-1β subunit.  Specific nuclear expression 
of the HIF-1α protein was highly inducible under hypoxic conditions in the 
three carcinoma cell lines investigated (HCT116, MGLVA1 and PAN1 cells), 
when compared to the normoxic equivalent.  HIF-1α protein was inducible 
either via treatment with CoCl2 or DFO, or under atmospheric hypoxic 
conditions (i.e. 1% oxygen).  The generation of hypoxia inhibits the activity of 
the prolyl hydroxylase enzymes, which are oxygen, iron and 2-oxoglutarate-
dependent enzymes, responsible for targeting the HIF-1α subunit for 
degradation (Bruick and McKnight, 2001).  The iron chelator CoCl2 and iron 
antagonist DFO inhibit the availability of iron to the prolyl hydroxylase, 
therefore inducing a hypoxic state, similar to that induced by reduced oxygen 
tension (Wang et al, 1995).   
 
The pattern and expression levels of nuclear HIF-1α protein, after either 
incubation under atmospheric hypoxic conditions or chemical induction with 
CoCl2 or DFO, were very similar in the three carcinoma cell lines investigated; 
the expression mainly varied in the timescale of induction.  The prolyl 
hydroxylase enzymes are active under normoxic conditions, resulting in the 
rapid degradation of the HIF-1α protein.  Also, restoring normoxia from 
previously hypoxic conditions produces a HIF-1α protein with a half-life of 
less than five minutes (Wang et al, 1995)…When inhibiting the prolyl 
hydroxylases however, using iron chelators or antagonists, the resultant effects 
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will last as long as it takes for the cell to metabolise the compound and 
therefore stabilising the expression of HIF-1α protein even under normoxic 
conditions.  The concentration of CoCl2 used to induce HIF-1α expression was 
quite high (150M) and seemed to be cytotoxic to the MGLVA1 cells after 16-
24hr incubation, as it reduced the β-actin expression of the cells, despite the 
levels of HIF-1α protein increasing.  Wang and Semenza (1995) showed that 
HIF-1α protein expression was inducible after treatment with only 25M 
CoCl2.  Therefore, if the hypoxia chamber had not become available during 
this project, the concentration of CoCl2 used to induce HIF-1α expression 
would have been reduced for subsequent experiments, and additional loading 
controls would be used, such as tubulin, to identify if the cytotoxic effect of 
CoCl2 may have been β-actin-specific.   
 
Other GI carcinoma cell lines where HIF-1α was shown to be inducible after 4-
24 incubation under hypoxic conditions include the colorectal carcinoma cells 
Colo201, DLD-1 and HCT116 (Krishnamachary et al, 2003; Kuwai et al, 
2003), the gastric carcinoma cell line TMK-1 (Stoelzing et al, 2004) and the 
pancreatic carcinoma cells Capan1 and PANC1 (Büchler et al, 2003) at the 
single time points investigated.  The hypoxic induction of HIF-1α protein in 
the HCT116, MGLVA1 and PAN1 carcinoma cell lines follow a similar 
pattern to that originally described in Hep3B cells (Wang et al, 1995), where 
the nuclear HIF-1α protein expression was rapidly inducible under hypoxic 
conditions, before increasing to a maximal expression after 4-8hr incubation.   
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Nuclear translocation of the HIF-1α protein under hypoxic conditions was 
confirmed in the HCT116, MGLVA1 and PAN1 carcinoma cell lines using 
HIF-1α cell immunofluorescent staining.  The HIF-1α protein produced a 
distinctive pattern of accumulation within the nucleus, which excluded the 
nucleolus; a structure that is involved in ribosome synthesis and mitosis 
regulation (reviewed in Boisvert et al, 2000), rather than gene transcription.  
The pattern of HIF-1α accumulation in the three cell lines investigated was 
identical to that produced in HepG2 cells after exposure to 5 hours hypoxia, as 
shown by Mottet et al (2003). 
 
Under normoxic conditions, there was only negligible expression of the HIF-
1α protein in the HCT116 and PAN1 carcinoma cell lines, which was likely to 
be due to the hydroxylation, ubiquitination and degradation of HIF-1α that 
normally occurs under physiological oxygen concentrations.  In the MGLVA1 
cells however, there was a consistently low level of active HIF-1α protein 
expressed under normoxic conditions.  This could be due to mutations that 
may have occurred in growth factor signalling pathways, which would allow 
for the stabilisation of the HIF-1α protein under normoxic conditions, in a cell-
specific manner.  For example, the downstream targets of PI3-kinase/Akt 
signalling pathway mTOR and FRAP have been linked to the stabilisation of 
HIF-1α protein under normoxic conditions (Hudson et al, 2002; Laughner et 
al, 2001; Treins et al, 2002), as has the loss of PTEN inhibitory signalling 
(Zundel et al, 2000).  Further investigations are now required to determine the 
exact nature of the mutations within the signalling pathways of the MGLVA1 
cells, using target-specific inhibitors such as rapamycin (for mTOR and 
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FRAP).  As gastrin also signals via the PI3-kinase/Akt pathway (Harris et al, 
2004), the role of gastrin in MGLVA1 cell signalling and HIF-1α expression 
could also be investigated.    
 
The nuclear expression of the HIF-1β protein was also increased under 
hypoxic condition (via treatment with CoCl2) in both the HCT116 and 
MGLVA1 carcinoma cell lines, compared to the normoxic expression.  Unlike 
the HIF-1α protein however, the HIF-1β subunit was consistently detectable 
under normoxic conditions.  This result confirms that of Wang et al (1995), 
which suggested that the nuclear HIF-1β protein expression was increased 
under hypoxic conditions, in parallel with the nuclear HIF-1α protein 
expression.  These results suggested that the HIF-1β protein also is 
translocated to the nucleus under hypoxic conditions, or becomes stabilised 
within the nucleus through binding to the HIF-1α subunit.   
 
HIF-1α gene is generally considered to be constitutively expressed throughout 
the majority of mammalian cell and tissue types.  It has been shown to be 
expressed in ‘normal’ tissue, such as the lung, heart, liver, spleen, kidney and 
brain as well as the corresponding tumour tissue (Wiesener et al, 2001).  Its 
expression has been shown to be unaffected by the presence of hypoxia, in 
both colorectal (HCT116 cells) and gastric carcinoma cell lines (SGC7901 
cells) (Kuwai et al, 2003; Liu et al, 2008).  However, in the HCT116, 
MGLVA1 and PAN1 carcinoma cell lines investigated in this study, the HIF-
1α gene expression was shown to decrease under hypoxic conditions (either 
induced by atmospheric incubation or chemical treatment), when compared to 
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the normoxic expression of the HIF-1α gene.  The decrease in HIF-1α gene 
expression was not due to increased cell death, as the HPRT control levels 
were unaffected by hypoxic incubation.   
 
A similar observation was made in an early study into HIF-1α gene expression, 
which was conducted by Wang et al (1995).  This study suggested that under 
hypoxic conditions, the HIF-1α mRNA declined in expression from 2hr 
onwards, reaching minimal expression levels after 8hr hypoxic incubation.  
The HIF-1α gene then recovered its expression over the rest of the time course.  
The decrease in HIF-1α mRNA expression was suggested to be due to the 
presence of eight RNA instability elements (5’ – UUAUUUAWW – 3’) in the 
3’ untranslated region of the HIF-1α gene (Wang et al, 1995).  RNA instability 
elements are often found in transiently-expressed mRNA sequences and are 
often possessed by oncogenes, resulting in the destabilisation of their 
expression (Shaw and Kamen, 1986).  As the expression of the HIF-1α gene 
under hypoxic conditions recovered over time in the Hep3B cells used by 
Wang et al (1995), it would be reasonable to consider whether the same event 
would have occurred in the HCT116, MGLVA1 and PAN1 carcinoma cell 
lines, if incubated under hypoxic conditions for a longer time point. 
 
To determine whether the HIF-1α protein induced under hypoxic conditions 
was transcriptionally functional, the expression of VEGF, a known target gene 
of HIF-1 was investigated in a panel of GI carcinoma cell lines.  VEGF gene 
expression was significantly increased under hypoxic conditions, suggesting 
that HIF-1 was functionally active.  The VEGF gene expression up-regulation 
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occurred slightly downstream of the HIF-1α protein induction, which could 
suggest that time was required to synthesise the HIF-1α protein, before it 
translocated to the nucleus, ready to up-regulate target gene transcription.  
Similar results were observed in further GI carcinoma cell lines, including 
colorectal carcinoma cells, CaCo2, HT29 and DLD-1 (Mizukami et al, 2004) 
and pancreatic carcinoma cells, MIA PaCa-2 (Büchler et al, 2003), where 
VEGF gene expression was up-regulated by up to 10-fold after a 12-24hr 
incubation. 
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Chapter Four 
REGULATION OF 
HYPOXIA-
INDUCIBLE FACTOR-
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4.1 Background 
Gastrin has been shown to play a role in tumourigenesis, influencing cancer 
proliferation and metastasis, as well as possessing both pro-angiogenic and 
anti-apoptotic capabilities, which would further aid tumour progression.  By 
binding to its CCK-2 receptor, gastrin is able to initiate cellular signalling 
pathways that can up-regulate the actions of transcription factors, such as c-fos.  
This leads to the production of growth factors, such as HB-EGF and 
amphiregulin, which are able to signal via the EGF receptor, enhancing any 
proliferative effect.   
 
The resultant cellular effects induced by activation of the HIF-1 transcription 
factor are similar to those induced by gastrin, especially the process of 
angiogenesis; therefore the aim of this chapter was to determine whether 
gastrin signals through HIF-1α when initiating its pro-carcinogenic effects.  
Firstly, the effect of exogenous gastrin on HIF-1α expression was determined, 
before the expression of the pro-angiogenic target gene VEGF was 
investigated after gastrin treatment.  Finally, the effect of endogenous gastrin 
inhibition on HIF-1α was examined. 
 
4.2 Effects of exogenous gastrin treatment on HIF-1α 
expression and transcriptional activity 
 
4.2.1 Nuclear expression of HIF-1α protein after treatment with 
exogenous amidated gastrin 
HIF-1α nuclear protein expression was investigated after the treatment of 
carcinoma cell lines with 1nM, 10nM and 100nM exogenous amidated gastrin 
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or 10nM peptide control, under both normoxic and hypoxic conditions (1% 
oxygen) via Western blotting. 
 
Initial experiments in PAN1 carcinoma cells revealed that treatment with 
exogenous gastrin increased the expression of HIF-1α under both normoxic 
and hypoxic conditions (Figure 4.1). 
HIF-1α nuclear protein expression in PAN1 carcinoma cell lines. 
HIF-1α
β-actin
Condition:                4hr normoxic                     24hr normoxic                               4hr hypoxic
Gastrin conc:  Control   1nM    10nM  100nM    Control   1nM    10nM  100nM Control   1nM    10nM  100nM
 
Figure 4.1 – HIF-1α nuclear protein expression in PAN1 carcinoma cells, after 
treatment with exogenous amidated gastrin under normoxic and hypoxic 
conditions, relative to β-actin control.  n=3 (data representative of replicate 
experiments).   
 
 
Under normoxic conditions, exogenous gastrin had little effect on HIF-1α 
expression after only 4hr treatment.  After 24hr normoxic incubation however, 
there was a noticeable increase in nuclear HIF-1α after 1nM and 10nM 
amidated gastrin treatment.  Treatment with the peptide control failed to induce 
nuclear HIF-1α protein expression to the levels seen after whole molecule 
amidated gastrin treatment, under normoxic conditions.  Under hypoxic 
conditions, treatment with exogenous gastrin only slightly augmented the 
expression of HIF-1α protein that already existed, due to the reduced oxygen 
concentrations.   
 
The expression of HIF-1α nuclear protein after treatment with increasing 
concentrations of exogenous amidated gastrin was also investigated in other 
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carcinoma cell lines of different GI origins, to determine whether the effects 
seen in the PAN1 cells were replicated in other cell lines.  Treatment of colonic 
HCT116 and gastric MGLVA1 carcinoma cell lines with increasing 
concentrations of exogenous gastrin failed to induce expression of HIF-1α 
protein under both normoxic and hypoxic conditions (data not shown).  Both 
the HCT116 and MGLVA1 cells are known to not to endogenously express the 
CCK-2 receptor (Colucci et al, 2008; McWilliams et al, 1998), so were not 
expected to respond to exogenous gastrin treatment, despite expressing high 
levels of endogenous gastrin gene (Grabowska et al, 2008).  The CCK-2 
receptor status of the PAN1 cells is currently unknown.   
 
As exogenous gastrin treatment had only induced an effect in the PAN1 
carcinoma cell line and not cells from different GI origins, the effect of 
amidated gastrin on the expression of nuclear HIF-1α protein was then 
investigated in further pancreatic carcinoma cell lines, as PAN1 was pancreatic 
in origin.   
 
Treatment of BxPC3 and PANC1 carcinoma cells with increasing 
concentrations of exogenous amidated gastrin under normoxic conditions had 
negligible effect on the expression of nuclear HIF-1α at any concentration 
tested, in either cell line (data not shown).  Under hypoxic conditions, the 
exogenous gastrin treatment failed to significantly induce the existing 
expression of the nuclear HIF-1α protein in the BxPC3 and PANC1 cell lines 
(Figure 4.2), above that already induced by hypoxia itself.  The slight decrease 
seen in the HIF-1α protein expression after 4hr hypoxia was probably due to 
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non-specific affects of the treatment with exogenous gastrin, or the scrambled 
control peptide.  
HIF-1α nuclear protein expression in BxPC3 and PANC1 carcinoma cell 
lines. 
BxPC3 cells 
HIF-1α
β-actin
Condition:                 4hr hypoxic                    8hr hypoxic            
Gastrin conc:    Untr.     Scr.     1nM    10nM       Untr.    Scr.    1nM    10nM
 
 
PANC1 cells 
HIF-1α
β-actin
Condition:                  4hr hypoxic                   8hr hypoxic
Gastrin conc:     Untr.     Scr.     1nM   10nM       Untr.     Scr.      1nM    10nM
 
 
Figure 4.2 – HIF-1α nuclear protein expression in BxPC3 and PANC1 
carcinoma cells, after treatment with exogenous amidated gastrin under 
hypoxic conditions, relative to β-actin control.  n=2 (for both cell lines) (data 
representative of replicate experiments).   
 
 
 
4.2.2 HIF-1α target gene expression after normoxic treatment 
with exogenous amidated gastrin 
Whilst the treatment of PAN1 cells with exogenous amidated gastrin had no 
significant affect on nuclear HIF-1α protein expression under hypoxic 
conditions, treatment with both 1nM and 10nM amidated gastrin induced the 
expression of HIF-1α under normoxic conditions.  To further investigate 
whether exogenous gastrin treatment had any affect on HIF-1α in normoxia, 
emphasis was changed from HIF-1α expression to HIF-1α activity.  The 
transcription factor HIF-1 is responsible for up-regulating the expression of a 
number of target genes under hypoxic conditions.  Therefore, the effect of 1nM 
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and 10nM exogenous gastrin treatment on the expression of the HIF-1 target 
gene, VEGF was investigated under normoxic conditions.   
 
After both 24hr and 48hr treatment of PAN1 carcinoma cells with increasing 
concentrations of exogenous amidated gastrin under normoxic conditions, the 
expression of the VEGF gene increased by 20-105%, when compared to the 
VEGF expression obtained after 10nM scrambled control treatment (Figure 
4.3, p<0.02).  These data suggested that exogenous gastrin may up-regulate 
HIF-1 transcriptional activity under normoxic conditions. 
 
4.2.3 Cell reporter luciferase expression after normoxic 
treatment with exogenous amidated gastrin 
Under normoxic conditions, HIF-1 may be responsible for up-regulating 
VEGF gene expression, as its protein expression can be stabilised by several 
oncogenic signalling pathways that override the usual normoxic HIF-1α 
degradation system.  Other growth-factor regulated signalling pathways 
however, are known to play a role in regulating VEGF gene expression in a 
HIF-1-independent manner. 
 
Therefore, to determine whether the increase in VEGF gene expression 
induced by exogenous amidated gastrin treatment was HIF-1-dependent, cells 
were transfected with a range of luciferase-reporter plasmids that contained the 
HRE sequence, which the HIF-1 transcription factor binds to within the 
promoter region of the target genes, to initiate their transcription. 
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VEGF gene expression in PAN1 carcinoma cell lines. 
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Figure 4.3 – VEGF gene expression in PAN1 carcinoma cells, after 24hr (top 
graph) and 48hr (bottom graph) treatment with exogenous amidated gastrin 
under normoxic conditions, relative to the HPRT control (*p=0.0106 / 
***p<0.003  (analysed using students t-test), + 95% confidence interval).  n=3 
(for 24hr time point) N=2 (for 48hr time point) (data representative of replicate 
experiments).   
 
 
To determine whether treatment with exogenous amidated gastrin allowed 
HIF-1 to initiate transcription, two different luciferase models were used, as 
described below: 
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1) VEGF-HRE luciferase reporter plasmid, which contains the DNA promoter 
sequence from upstream of the VEGF coding region (-2018bp to +50bp), 
attached to a firefly-luciferase reporter construct.  After test transfections of 
the VEGF-HRE luciferase reporter plasmid, there was a significant 2-3 
fold increase in luciferase expression, under hypoxic conditions, compared 
to that obtained in the equivalent normoxic control (Figure 4.4, p<0.02) 
(See Materials and Methods section 2.11).   
Firefly luciferase expression after transfection with VEGF-HRE luciferase 
reporter plasmid. 
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Figure 4.4 – Firefly luciferase expression in PAN1 carcinoma cells under both 
normoxic and hypoxic conditions, after transfection with VEGF-HRE 
luciferase reporter plasmid (*p<0.02 (analysed using student’s t-test), + S.D).  
Each bar represents combined data from duplicate transfections (n=1).  
 
 
 
2) PGL4-(LDH)-HRE luciferase reporter plasmid, which contains multiple 
copies of the HRE sequence expressed in the promoter of the LDH gene, a 
known target gene of HIF-1.  The PGL4-(LDH)-HRE reporter plasmid was 
derived from a LDH-expressing PGL3-luciferase reporter plasmid, which 
was kindly donated by Dr Kaye Williams (University of Manchester).  The 
LDH-HRE construct and a SV40 minimal promoter were originally 
excised from a PGL3 luciferase reporter plasmid and ligated into the 
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PGL4-basic luciferase reporter plasmid (Promega), to help eliminate 
background luminescence.  Test transfections of the PGL4-(LDH)-HRE 
luciferase reporter plasmid induced a significant 8.5 fold increase in 
luciferase expression under hypoxic conditions, compared to that obtained 
under normoxic conditions (Figure 4.5, p<0.0001).   
Firefly luciferase expression in PAN1 cells transfected with PGL4-(LDH)-
HRE luciferase reporter plasmid 
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Figure 4.5 – Firefly luciferase expression in PAN1 carcinoma cells under both 
normoxic and hypoxic conditions, after transfection with PGL4-(LDH)-HRE 
luciferase reporter plasmid (**p<0.0001 (analysed using a student’s t-test), + 
S.D).  Each bar represents combined data from duplicate transfections.  n=10 
(data representative of replicate experiments).   
 
 
 
VEGF-HRE luciferase reporter plasmid 
Treatment of PAN1 cells with increasing concentrations of exogenous 
amidated gastrin for both 24hr and 48hr under normoxic conditions, after being 
transiently transfected with the VEGF-HRE luciferase reporter plasmid also 
had no significant effect on the expression of the firefly luciferase gene (Figure 
4.6) at any concentration tested, when compared to the expression obtained 
after treatment with the scrambled control.  Similar results were obtained in 
replicate experiments, whether the cells were only treated once with exogenous 
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gastrin, or repeatedly dosed with fresh gastrin every 12hr.  Similar results were 
also obtained after 72hr exogenous gastrin treatment (data not shown). 
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Figure 4.6 – Firefly luciferase expression in PAN1 carcinoma cells, after 
transfection with VEGF-HRE luciferase reporter plasmid, prior to 24hr 
treatment (top graph) or 48hr treatment (bottom graph) with exogenous 
amidated gastrin that was dosed every 12hr, under normoxic conditions (non-
significant (analysed using a student’s t-test), + S.D).  Each bar represents 
combined data from duplicate transfections. .  n=2 (for both time points) (data 
representative of replicate experiments).   
 
 
 
PGL4-(LDH)-HRE luciferase reporter plasmid 
Treatment of PAN1 cells with exogenous amidated gastrin for 24hr under 
normoxic conditions, after transfection with the PGL4-(LDH)-HRE luciferase 
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reporter plasmid had no significant effect on the firefly luciferase expression, 
at any concentration, when compared to the luciferase expression induced via 
treatment with the equivalent scrambled control (Figures 4.7).  Similar results 
were also replicated at all time points investigated (i.e. 48hr and 72hr, data not 
shown). 
Firefly luciferase expression after transfection with PGL4-(LDH)-HRE 
luciferase reporter plasmid. 
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Figure 4.7 – Firefly luciferase expression in PAN1 carcinoma cells, after 
transfection with PGL4-(LDH)-HRE luciferase reporter plasmid, prior to 24hr 
treatment with exogenous amidated gastrin that was dosed every 12hr, under 
normoxic conditions (non-significant (analysed using a student’s t-test), + 
S.D).  Each bar represents combined data from duplicate transfections.  n=3 
(data representative of replicate experiments).   
 
 
 
The use of the two HRE-reporter systems (i.e. the VEGF-HRE and PGL4-
(LDH)-HRE luciferase reporter plasmids) suggested that the increase in VEGF 
gene expression induced after exogenous gastrin treatment was probably not 
HIF-1-dependent or mediated through the VEGF promoter.  As a result, 
investigations into the affect of exogenous amidated gastrin treatment on HIF-
1α expression and activity were discontinued. 
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4.3 Effects of endogenous gastrin activity on HIF-1α 
expression and transcriptional activity 
 
4.3.1 Effect of gastrin siRNA transfection on HIF-1α gene 
expression 
In an attempt to determine whether endogenous gastrin plays a role in the 
regulation of HIF-1α expression and/or function, carcinoma cell lines were 
transfected with a gastrin-specific siRNA to knock down any endogenous 
gastrin expression (See Materials and Methods section 2.8). 
 
PAN1 carcinoma cells were transfected with either 20nM gastrin-specific 
siRNA or 20nM scrambled control siRNA (i.e. consists of identical nucleotides 
to those found in the gastrin-specific siRNA, but whose order had been 
scrambled), under both normoxic and hypoxic conditions. 
 
Under normoxic conditions, transfection of gastrin-specific siRNA resulted in 
a 75-95% down-regulation in the expression of the gastrin gene, compared to 
the scrambled control (Figure 4.8, p<0.0001).  Similar results were also seen 
under hypoxic conditions, where gastrin-specific siRNA transfection resulted 
in 75-85% down-regulation in gastrin gene expression (Figure 4.8, p<0.0001).  
The gastrin siRNA inhibits the production of endogenous gastrin, which would 
usually be secreted into the surrounding environment, where it could act in an 
autocrine fashion, up-regulating gastrin signalling via the CCK-2 receptor.  It 
is currently unknown whether the PAN1 carcinoma cell line expresses the 
CCK-2 receptor. 
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Gastrin gene expression after gastrin siRNA transfection.  
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Figure 4.8 – Gastrin gene expression in PAN1 carcinoma cells, after 
transfection with gastrin siRNA or scrambled control siRNA, under normoxic 
(top graph) and hypoxic (bottom graph) conditions, relative to the HPRT 
control (***p<0.0001 (analysed using student’s t-test), + 95% confidence 
interval).  Each bar represents combined data from duplicate transfections.  
n=5 (for normoxic induction) / n=2 (for hypoxic induction) (data representative 
of replicate experiments).   
 
 
 
Exogenous gastrin was shown to up-regulate the expression of HIF-1α protein 
in the PAN1 carcinoma cell line.  Therefore to determine whether endogenous 
gastrin played a role in the regulation of HIF-1α under normoxic conditions, 
target-specific gastrin siRNA was used to determine the effect on HIF-1α gene 
expression.  Transfection of PAN1 carcinoma cells with gastrin-specific 
siRNA resulted in an approximate 30% decrease in HIF-1α gene expression 
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under normoxic conditions (Figure 4.9, p<0.0001), when compared to the HIF-
1α expression achieved after transfection with the scrambled control siRNA.  
Under hypoxic conditions however, transfection with gastrin siRNA had no 
significant effect on the level HIF-1α gene expression (data not shown).  This 
data suggests that endogenous gastrin is partially responsible for the regulation 
of HIF-1α gene expression under normoxic conditions, possibly acting via its 
CCK-2 receptor located on the cell surface.   
HIF-1α gene expression after gastrin siRNA transfection under normoxic 
conditions. 
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Figure 4.9 – HIF-1α gene expression in PAN1 carcinoma cells after 
transfection with gastrin siRNA or scrambled control siRNA, under normoxic 
conditions, relative to the HPRT control (***p<0.0001 (analysed using 
student’s t-test), + 95% confidence interval).  Each bar represents combined 
data from duplicate transfections.  n=2 (data representative of replicate 
experiments).   
 
 
 
The down-regulation of HIF-1α gene expression may lead to a reduction in 
HIF-1α protein expression and as a result reduce the overall level of 
downstream HIF-1 transcriptional activity.  To determine whether the 
inhibition of HIF-1α gene expression has an effect on the level of HIF-1 
transcriptional activation, HCT116 dual luciferase carcinoma cells (that had 
been stably transfected with an HRE-luciferase construct) were transiently 
  137 
transfected with 20nM gastrin siRNA or its scrambled control under both 
normoxic and hypoxic conditions.  
 
HCT116 dual luciferase cells contain a stably-expressed HRE-luciferase 
(firefly) reporter, alongside an endogenous renilla-luciferase control.  Pilot 
study data revealed that there was a significant six-fold increase in luciferase 
expression, under hypoxic conditions, compared to the normoxic equivalent 
(Figure 4.10, p<0.01) (See Materials and Methods section 2.12). 
Firefly luciferase expression in HCT116 dual-luciferase reporter cells. 
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Figure 4.10 – Firefly luciferase expression in HCT116 dual-luciferase reporter 
carcinoma cells under both normoxic and hypoxic conditions (**p<0.01 
(analysed using a student’s t-test), + S.D (Standard deviation)).  Each bar 
represents combined data from duplicate transfections (n=1).  
 
 
Transfection of the HCT116 dual luciferase cells with gastrin siRNA had no 
significant effect on the level of firefly luciferase expression under either 
normoxic or hypoxic conditions (Figure 4.11), when compared to luciferase 
expression obtained after scrambled control siRNA transfection.  This data 
suggested that even if gastrin played a role in regulating the expression of HIF-
1α gene and protein, it does not affect the transcriptional activity of the 
transcription factor (i.e. it does not act through an HRE sequence). 
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Firefly luciferase expression after gastrin siRNA transfection under both 
normoxic and hypoxic conditions. 
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Figure 4.11 – Firefly luciferase expression in HCT116 dual luciferase 
carcinoma cells, after transfection with gastrin siRNA or scrambled control 
siRNA, under both normoxic and hypoxic conditions (non-significant 
(analysed using a student’s t-test), + S.D).  Each bar represents combined data 
from duplicate transfections (n=1).  
 
 
 
4.4 Chapter Summary and Conclusions 
Treatment with exogenous amidated gastrin only induced an increase in 
nuclear HIF-1α protein expression in the PAN1 carcinoma cell line, despite 
several other carcinoma cell lines being investigated, including those from 
both similar and different tissues of origin.  The increase of the HIF-1α protein 
under normoxic conditions within the PAN1 cell line was often low and 
therefore quite difficult to visualise and interpret.  This may be explained by 
the suggestion that only a subset of the PAN1 cells were responsive to 
exogenous gastrin treatment.  In a study by Chao et al, (2006) the presence of 
the CCK-2 receptor splice variant CCK2i4 increased the normoxic basal 
expression of HIF-1α protein in HEK-293 cells, compared to those transfected 
with wild-type CCK-2 receptors.  The CCK2i4-expressing cells were shown to 
be more responsive to the proliferative effects of gastrin, using a xenograft 
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model.  The authors did not however, investigate whether exogenous gastrin 
treatment using either the stably CCK-2i4-transfected cell line or xenograft 
mouse model further enhanced the HIF-1α protein expression.  A subset of the 
PAN1 carcinoma cells used in the nuclear HIF-1α protein expression studies 
could have expressed the CCK2i4 receptor, making them more responsive to 
exogenous gastrin treatment.  To determine whether the increase in HIF-1α 
protein expression seen in PAN1 cells was due to the affects of gastrin 
treatment, the cells should be pre-treated with a CCK-2 receptor or CCK2i4 
receptor-specific antagonist, prior to HIF-1α expression being investigated.   
 
Exogenous gastrin treatment of the pancreatic carcinoma cell lines (i.e. PAN1, 
BxPC3 and PANC1) under hypoxic conditions failed to significantly augment 
the already high levels of nuclear HIF-1α protein that had been induced by the 
presence of low oxygen tension.  Any real effect that the exogenous amidated 
gastrin treatment had on the HIF-1α protein expression was probably masked 
by the high levels of HIF-1α and therefore is only considered as trivial when 
inducing the final downstream activities of the HIF-1 transcription factor. 
 
Investigations into the effect of exogenous amidated gastrin treatment on HIF-
1α were transferred from HIF-1α protein expression studies to HIF-1α protein 
activity assays (i.e. RT-PCR and luciferase reporter assays), in a final attempt 
to elucidate whether gastrin played a role in regulating the HIF-1 transcription 
factor.  The previously partially-responsive PAN1 carcinoma cell line was 
transfected with one of two different HRE-luciferase reporter plasmids, the 
activity of which were dependent on the up-regulation of HIF-1 transcriptional 
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activity.  The HRE-transfected cells were then treated with increasing 
concentrations of exogenous amidated gastrin,  This failed to significantly 
induce the luciferase expression in cells transfected with either the VEGF-HRE 
plasmid or PGL4-(LDH)-HRE plasmids at any time point or concentration 
investigated.  Therefore, it was concluded that exogenous amidated gastrin 
treatment had no affect on the activity of the HIF-1 transcription factor and that 
this part of the hypothesis should not be continued any further and instead 
replaced with investigations into the role of hypoxia on gastrin mRNA 
expression.   
 
Conversely, treatment with exogenous amidated gastrin significantly increased 
the VEGF gene expression after both 24hr and 48hr incubation.  VEGF is a 
known target gene of the HIF-1 transcription factor and has been previously 
shown to be increased under hypoxic conditions (see Figure 3.17).  However, 
despite the lack of involvement of HIF-1α in gastrin signalling, as shown using 
both Western blotting and luciferase reporter assays, the VEGF gene 
expression was still inducible under normoxic conditions.  This increase in 
expression may be explained by growth factor signalling pathways, induced by 
molecules such as EGF and IGF-1, which are also known to be active under 
normoxia (reviewed in Mikhopadhyay and Datta, 2004).  Gastrin known to up-
regulate the expression of growth factors, such as amphiregulin and HB-EGF, 
which act at the EGF receptor (Tsutsui et al, 1997), and therefore may up-
regulate the normoxic VEGF gene expression in a HIF-1-independent fashion.  
To be completely certain that HIF-1α is not involved in the up-regulation of 
VEGF gene expression by gastrin, the carcinoma cells should be transfected 
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with a HIF-1α-specific siRNA prior to exogenous gastrin treatment, to remove 
any endogenous HIF-1α activity that may up-regulate the expression of the 
VEGF gene. 
 
Transfection of PAN1 cells with gastrin specific siRNA induced a high level of 
endogenous gastrin gene knock-down under both normoxic and hypoxic 
conditions.  The levels of gene knock-down obtained matched those previously 
described in a study by Grabowska et al (2007), which used the same siRNA 
constructs.  In this study, the loss of the gastrin gene led to a reduction of 
gastrin-regulated events, such as decreased cell growth and increased 
apoptosis.  The large level of gastrin gene knock-down may suggest that 
endogenous gastrin plays a role in cell proliferation and survival.  Endogenous 
gastrin would be secreted into the surrounding environment, where it would act 
in an autocrine manner, up-regulating gastrin-specific signalling pathways via 
the CCK-2 receptor.  Treatment with exogenous gastrin may further enhance 
the endogenous actions of gastrin, which may result in up-regulating HIF-1α 
expression, as seen in the PAN1 carcinoma cell line.  To determine whether 
endogenous gastrin plays a role in cell signalling, carcinoma cell lines could be 
treated with a CCK-2 receptor antagonist, alongside being transfected with 
gastrin siRNA.   
 
Transfection of gastrin siRNA also induced a partial decrease in HIF-1α gene 
expression, suggesting that gastrin plays a partial role in the regulation of HIF-
1α at the gene expression level under normoxic conditions only.  Generally, the 
level of HIF-1α gene remains constant in carcinoma cells, even under hypoxic 
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conditions (Kuwai et al, 2003; Liu et al, 2008) and it is the induction of the 
HIF-1α protein which is responsible for the activation of the HIF-1 
transcription factor.  If gastrin is however partially responsible for the 
regulation of the HIF-1α gene expression, it may suggest that the HIF-1 
transcription factor is partly responsible in transmitting the downstream affects 
of gastrin signalling, such as increased angiogenesis and cell survival.  The 
transfection of a HRE-expressing cell line with the gastrin siRNA had 
negligible effect on the transcriptional activity of HIF-1, which suggests that 
any affect that gastrin has on the HIF-1 transcription factor is not regulated 
through a HRE sequence.  This data further supports the idea that 
investigations into the role of gastrin on HIF-1α activity should be 
discontinued in favour of investigating the role of hypoxia on gastrin 
expression. 
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Chapter Five 
REGULATION OF 
GASTRIN 
EXPRESSION BY 
HYPOXIA 
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5.1 Background 
Gastrin has been shown to play a role in cancer cell proliferation, as well as 
possessing pro-angiogenic and anti-apoptotic capabilities.  The induction of 
HIF-1 activation also has been linked to increased tumour growth, 
angiogenesis and loss of apoptosis; therefore the aim of this chapter was to 
determine whether gastrin was a target gene of the HIF-1 transcription factor.  
Firstly, it was established whether gastrin expression was regulated by 
hypoxia, and then more specifically, whether it was regulated by HIF-1α itself. 
 
5.2 Gastrin gene expression after hypoxic induction - 
Up-regulation of gastrin gene expression 
Gastrin gene expression was investigated after exposure of GI carcinoma cell 
lines to hypoxia (1% oxygen), using quantitative real-time RT-PCR.  Gastrin 
gene expression was shown to significantly increase after 16hr hypoxic 
incubation in the HCT116, MGLVA1 and PAN1 carcinoma cell lines (Figure 
5.1, p<0.0001).  The gastrin gene expression under hypoxic conditions 
increased by 17-50 fold (cell line-dependent, p<0.0001), compared to the 
corresponding normoxic gene expression, which remained at a consistently 
low level throughout, in these cell lines.  In the MGLVA1 cells, the gastrin 
gene expression was always higher under hypoxic conditions, when compared 
to the equivalent normoxic controls at each time point tested (between 1-12hr) 
(Figure 5.1).   
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Gastrin gene expression after hypoxic incubation. 
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Figure 5.1 – Gastrin gene expression in HCT116 carcinoma cells (top graph), 
MGLVA1 carcinoma cells (middle graph) and PAN1 carcinoma cells (bottom 
graph), after incubation under normoxic or hypoxic conditions, relative to the 
HPRT control (p<0.0001 (analysed using a one-way ANOVA), individual data 
points; *p<0.05 / **p<0.001 / ***p<0.0001, + 95% confidence interval). 
n=2 (HCT116 cells) / n=3 (MGLVA1 cells) / n=8 (PAN1 cells) (data 
representative of replicate experiments). 
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The large induction of gastrin gene expression occurred only after 16hr 
hypoxic incubation in the GI carcinoma cell lines and not at any earlier time 
points, with the exception of PAN1 cells, in which, after 12hr hypoxic 
incubation, there was a consistent two-fold increase in gastrin gene expression, 
compared to the normoxic equivalent (data not shown, p<0.002). 
 
5.3 Gastrin gene expression after hypoxic induction - 
Expression of the gastrin gene in other GI carcinoma 
cell lines 
In the previous section, incubation under hypoxic conditions induced the up-
regulation of gastrin gene within the HCT116, MGLVA1 and PAN1 
carcinoma cell lines (see Figure 5.1).  These three cell lines were originally 
derived from different locations within the GI tract.  To determine whether the 
increase of gastrin gene induced under hypoxic conditions was reproducible 
throughout the entire digestive system, the expression of gastrin gene was 
investigated in a panel of GI carcinoma cells, whose origins ranged from 
oesophageal, gastric, pancreatic and colonic in nature.  Whilst the majority of 
the GI carcinoma cell lines did show an increase in gastrin gene expression 
under hypoxic conditions, other different expression patterns were also 
identified.   
 
5.3.1 Up-regulation of gastrin gene expression under hypoxic 
conditions 
In the majority of additional GI carcinoma cell lines investigated, gastrin gene 
expression was significantly increased by 3-4-fold (cell line-dependent) under 
hypoxic conditions, compared to the equivalent normoxic control, as well as 
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the 0hr control samples (i.e. the initial gastrin gene expression prior to hypoxic 
induction).  The cell lines studied included AGS cells, a gastric cell line 
(Figure 5.2, p<0.0001), BxPC3 cells, a pancreatic cell line (Figure 5.2, 
p<0.0004), OE19 and OE33 cells, which were both oesophageal cell lines 
(Figures 5.2, p<0.0004).  
 
With the majority of the cell lines tested, the gastrin gene expression after 16hr 
incubation under normoxic conditions slightly decreased, when compared to 
the 0hr control.  This proved to be significant in the BxPC3 and OE19 cells 
(see Figures 5.2 p<0.0004).  The other cell lines, such as the OE33, the gastrin 
gene expression increased slightly after 16hr normoxic incubation, compared 
to the 0hr control,  (see Figure 5.2, p<0.0001).  These observations may 
actually reflect the level of cell confluency within the cell culture well, as 
opposed to a genuine result.  Increased cell number may have induced gastrin 
expression, due to the increased ‘stresses’ of their environment.  However, the 
slight increase in the normoxic gastrin expression in the OE33 carcinoma cells 
after 16hr incubation may also be due to endogenous gastrin activity, up-
regulating its expression by signalling via its CCK-2 receptor in an autocrine 
manner.   
 
5.3.2 Reduction of basal gastrin gene expression 
In the majority of GI carcinoma cell lines investigated, gastrin gene expression 
was significantly increased under hypoxic conditions, however, the gastric 
carcinoma cell line ST16 consistently showed a different pattern of gastrin 
gene expression, when compared to other GI carcinoma cells (Figure 5.3).   
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Gastrin gene expression after 16hr hypoxic incubation. 
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Figure 5.2 – Gastrin gene expression in AGS carcinoma cells (top graph), 
BxPC3 carcinoma cells (middle graph), OE19 carcinoma cells (middle graph) 
and OE33 carcinoma cells (bottom graph), after 16hr incubation under 
normoxic or hypoxic conditions, relative to the HPRT control (**p=0013/ 
***p<0.0004 (analysed using a student’s t-test), + 95% confidence interval). 
n=2 (BxPC3) / n=1 (AGS/OE19/OE33) (data representative of replicate 
experiments). 
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Gastrin gene expression significantly decreased under both normoxic and 
hypoxic conditions, when compared to the basal gastrin expression (i.e. 0hr 
control) (Figure 5.3, p<0.0001 (normoxic cells) p<0.02 (hypoxic cells)).  The 
ST16 cell line showed the highest level of endogenous gastrin gene expression 
of any of the carcinoma cell lines tested.  Investigations into the gastrin gene 
expression after the 16hr hypoxic incubation, resulted in an 11-fold increase in 
expression, when compared to the equivalent normoxic control (Figure 5.3, 
p<0.0001).  This may be due to the affects of endogenous gastrin signalling 
within the ST16 carcinoma cells.  At the 0hr time point, there could be a high 
level of endogenous gastrin signalling, which in turn up-regulates the 
transcription of the gastrin gene via acting at the CCK-2 receptor.  After the 
16hr normoxic incubation however, a negative-feedback mechanism may have 
been induced, to prevent over-expression of the gastrin gene.  
Gastrin gene expression after 16hr hypoxic incubation. 
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Figure 5.3 – Gastrin gene expression in ST16 carcinoma cells, after 16hr 
incubation under normoxic or hypoxic conditions, relative to the HPRT control 
(*p=0.0182/ ***p<0.0001 (analysed using a student’s t-test), + 95% 
confidence interval).  n=3 (data representative of replicate experiments). 
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5.3.3 Up-regulation of gastrin gene expression under normoxic 
conditions 
In the majority of cell lines investigated, there was a significant increase in the 
gastrin gene expression under hypoxic conditions, compared to the equivalent 
normoxic control and the normoxic expression of the gastrin gene remained at 
a consistently low level throughout the experiments.   
 
In the colonic C170HM2 and oesophageal OE21 carcinoma cell lines however, 
16hr incubation under both normoxic and hypoxic conditions induced a 
significant increase in gastrin gene expression (Figure 5.4, p<0.0001), with the 
gastrin gene expression under normoxic conditions being approximately two-
fold higher than that seen under hypoxic incubation.  This also could be due to 
the effects of endogenous gastrin on both the C170HM2 and OE21 carcinoma 
cell lines.  Production of high levels of endogenous gastrin over the time 
course could induce the expression of the gastrin gene, in a CCK-2 receptor-
dependent manner, increasing the relatively low gastrin gene expression at 0hr, 
to the high expression observed after 16hr normoxic incubation.  Under 
hypoxic conditions at the same time point, either a negative-feedback 
mechanism has been induced; preventing the build-up of large amounts of 
gastrin gene, or part of the gastrin transcription-signalling mechanism is 
intolerant to hypoxia, reducing the level of overall gastrin gene expression.   
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Gastrin gene expression after 16hr hypoxic incubation. 
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Figure 5.4 – Gastrin gene expression in C170HM2 carcinoma cells (top graph) 
and OE21 carcinoma cells (bottom graph), after 16hr incubation under 
normoxic or hypoxic conditions, relative to the HPRT control (***p<0.0001 
(analysed using a student’s t-test), + 95% confidence interval).  n=2 
(C170HM2 cells) / n=1 (OE21 cells) (data representative of replicate 
experiments). 
 
Under hypoxic conditions, gastrin gene expression increased by 2.7- and 2.9-
fold in C170HM2 and OE21 cell lines respectively (Figure 5.4, p<0.0001), 
however, the increase in gastrin gene expression under normoxic conditions 
was approximately 5-fold in both cell lines (Figures 5.4, p<0.0001).  
Therefore, the effect of hypoxia on gastrin gene expression can be considered 
cell line dependent-effect.   
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5.4 Gastrin protein expression after hypoxic induction - 
Up-regulation of gastrin expression 
As gastrin gene expression was shown to increase under hypoxic conditions in 
a number of GI carcinoma cell lines, the effect of hypoxia (i.e. 1% oxygen) on 
gastrin protein expression was also investigated, using both Western blotting 
and cell immunofluorescence.   
 
The detection of the gastrin protein by Western blotting was unsuccessful.  The 
gastrin-specific antibody, which targeted the C-terminus of the gastrin protein 
failed to detect any protein expression at the correct molecular weight 
(~8.8kDa), but generated a high level of non-specific protein binding, which 
was identical to that produced in the negative control Western blots (data not 
shown).  However, pilot study data from cell immunofluorescence experiments 
suggested that gastrin protein expression was specifically increased under 
hypoxic conditions, in the HCT116 and PAN1 carcinoma cells (Figures 5.5 
and 5.6 respectively), compared to the negative control.  The gastrin protein 
expression also appeared to be nuclear in nature.  Under normoxic conditions, 
gastrin protein was detectable, but only at low levels (Figure 5.7, HCT116 
cells only) when compared to the hypoxic equivalents.  These data indicate that 
the gastrin protein was also up-regulated under hypoxic conditions, although 
further repeats are required before the data can be considered as significant.  
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Figure 5.5 – Gastrin protein expression in HCT116 carcinoma cells, after 
incubation under hypoxic conditions, compared to universal rabbit negative 
control (n=1). 
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Figure 5.6 – Gastrin protein expression in PAN1 carcinoma cells, after 
incubation under hypoxic conditions, compared to universal rabbit negative 
control (n=1).   
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Figure 5.7 – Gastrin protein expression in HCT116 carcinoma cells, after 
incubation under normoxic conditions, compared to universal rabbit negative 
control (n=1). 
 
 
 
5.5 Effect of HIF-1α siRNA transfection on HIF-1α 
gene expression and protein function 
To determine whether the HIF-1 transcription factor was involved in the up-
regulation of the gastrin gene under hypoxic conditions, target-specific siRNA 
was used to knock-down HIF-1 gene expression, and as a result, its 
transcriptional activity.   
 
5.5.1 Optimisation of transfection – HIF-1α gene expression 
The initial aim was to use HIF-1α and ARNT (HIF-1β) siRNAs in combination 
to knock-down total HIF-1 expression and the resultant protein activity, 
however, pilot experiments using the HIF-1β siRNA failed to induce any 
significant knock-down of the HIF-1β gene (data not shown).  As HIF-1β is 
known to dimerise with several proteins, and therefore will not specifically 
inhibit the activity of the HIF-1 transcription factor, all subsequent siRNA-
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inhibition experiments concentrated on the knock-down of the HIF-1α subunit, 
rather than HIF-1β, to down-regulate HIF-1 expression and its resulting 
functional activity.   
 
Pilot HIF-1α siRNA transfection experiments used the PAN1 carcinoma cell 
lines.  The cells were originally transfected with 20nM HIF-1α under both 
normoxic and hypoxic conditions.  Transfection with HIF-1α siRNA knocked 
down the HIF-1α gene expression by over 80% under normoxic conditions and 
55-60% under hypoxic conditions (Figure 5.8. p<0.0001), when compared to 
the HIF-1α expression in non-targeting control siRNA-transfected cells.  In the 
majority of transfection experiments, transfection with the non-targeting 
control siRNA increased the basal gene expression by approximately 15-35%, 
under both normoxic and hypoxic conditions, when compared the data 
obtained from untreated cells (data not shown).  This increase in gene 
expression was probably a non-specific effect caused by the transfection 
reagent, as similar levels of HIF-1α gene expression were obtained from cells 
treated with the transfection reagent alone, when compared to the results 
obtained from cells treated with non-targeting control siRNA (data not shown).  
Any knock-down of the HIF-1α gene after HIF-1α siRNA transfection was 
therefore considered a genuine affect.   
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HIF-1α gene expression after HIF-1α siRNA transfection. 
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Figure 5.8 – HIF-1α gene expression in PAN1 carcinoma cells under normoxic 
conditions (top graph) and hypoxic conditions (bottom graph), after 
transfection with HIF-1α siRNA, or non-targeting (NT) control siRNA 
(**p=0.0016 / ***p<0.0001 (analysed using student’s t-test), + 95% 
confidence interval).  Each bar represents combined data from duplicate 
transfections (n=1).   
 
 
 
In an attempt to increase the knock-down efficiency of the HIF-1α gene under 
hypoxic conditions, the concentration of siRNA transfected was doubled from 
a 20nM to 40nM per well.  20nM HIF-1α siRNA induced a 46% decrease in 
HIF-1α gene expression under hypoxic conditions, compared to the HIF-1α 
expression from the non-targeting control siRNA transfection, whereas 40nM 
increased the HIF-1α gene knock down to 65% (Figure 5.9, p<0.0001).  
However, the increase in HIF-1α gene knock-down could be explained by an 
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increase in HIF-1α gene expression in non-targeting control siRNA-treated 
cells rather than a decrease in overall HIF-1α gene expression after transfection 
with the target-specific siRNA.  As a result, subsequent transfections were 
performed using 20nM siRNA concentration of the siRNA. 
HIF-1α gene expression after HIF-1α siRNA transfection under hypoxic 
conditions. 
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Figure 5.9 – HIF-1α gene expression in PAN1 carcinoma cells under hypoxic 
conditions, after transfection with either 20nM or 40nM HIF-1α siRNA or 
non-targeting (NT) control siRNA (***p<0.0001 (analysed using student’s t-
test), + 95% confidence interval).  Each bar represents combined data from 
duplicate transfections.  n=2 (data representative of replicate experiments). 
 
 
5.5.2 Effect of HIF-1α siRNA transfection on HIF-1α gene 
expression and protein function in a panel of GI carcinoma cell 
lines 
To confirm that the HIF-1α siRNA specifically down-regulates HIF-1α gene 
expression throughout the GI tract, rather than just being a cell type-dependent 
event, the affect of HIF-1α siRNA on gene expression was investigated in a 
panel of GI carcinoma cell lines.  HCT116, MGLVA1 and PAN1 carcinoma 
cells were transfected with 20nM HIF-1α siRNA or non-targeting control 
siRNA, before being incubated under normoxic or hypoxic conditions.   
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In all three cell lines investigated, transfection with HIF-1α siRNA resulted in 
down-regulation of HIF-1α gene expression under normoxic (70-90%) and 
hypoxic (60-80%) conditions (Figures 5.10 and 5.11, cell line-dependent, all 
p<0.0001), when compared to the HIF-1α expression obtained from non-
targeting control siRNA transfection.  These results were similar to those 
obtained in the pilot siRNA transfection studies (see Figure 5.8), suggesting 
that the HIF-1α siRNA affects HIF-1α gene expression throughout the entire 
GI tract.  Despite the differences seen in the level of down-regulation of HIF-
1α gene expression under both normoxic and hypoxic conditions, the final 
level of HIF-1α gene expression obtained was approximately equal (e.g. 0.1 for 
HCT116 cells, 0.6-0.8 for MGLVA1 cells and 0.1 for PAN1 cells) (see Figures 
5.10 and 5.11). 
 
Again, transfection with the non-targeting control (random) siRNA increased 
the base line HIF-1α gene expression by approximately 20-35%, under both 
normoxic and hypoxic conditions, when compared to data obtained from 
untreated cells (data not shown).  Similar results were also obtained from cells 
treated with the transfection reagent alone, and therefore the increase can be 
considered a non-specific affect induced by the reagent. 
 
Transfection with either the HIF-1α or non-targeting control siRNA also 
slightly decreased the expression of the control gene HPRT, under both 
normoxic and hypoxic conditions, when comparing the data obtained from 
untreated cells (data not shown).  However, the decrease in HPRT expression 
was consistent throughout all transfected cells.   
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HIF-1α gene expression after HIF-1α siRNA transfection under normoxic 
conditions. 
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Figure 5.10 – HIF-1α gene expression in HCT116 carcinoma cells (top graph) 
MGLVA1 carcinoma cells (middle graph) and PAN1 carcinoma cells (bottom 
graph) under normoxic conditions, after transfection with HIF-1α siRNA or 
non-targeting (NT) control siRNA (***p<0.0001 (analysed using student’s t-
test), + 95% confidence interval).  Each bar represents combined data from 
duplicate transfections.  n=2 (for each cell line) (data representative of 
replicate experiments).  Transfection-reagent induced HIF-1α gene expression 
was approximately equal to that induced by the non-targeting control siRNA. 
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HIF-1α gene expression after HIF-1α siRNA transfection under hypoxic 
conditions. 
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Figure 5.11 – HIF-1α gene expression in HCT116 carcinoma cells (top graph), 
MGLVA1 carcinoma cells (middle graph) and PAN1 carcinoma cells (bottom 
graph) under hypoxic conditions, after transfection with HIF-1α siRNA or non-
targeting (NT) control siRNA (***p<0.0001 (analysed using student’s t-test), 
+ 95% confidence interval).  Each bar represents combined data from duplicate 
transfections.  n=2 (for each cell line) (data representative of replicate 
experiments).  Transfection-reagent induced HIF-1α gene expression was 
approximately equal to that induced by the non-targeting control siRNA. 
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To confirm that using the HIF-1α-specific siRNA to down-regulate HIF-1α 
expression also led to the inhibition of HIF-1 transcriptional activity, cells 
were dual-transfected with the HIF-1α siRNA and a HIF-1 reporter plasmid 
PGL4-(LDH)-HRE, which contained the HRE sequence expressed in the 
promoter of the LDH gene, a known target gene of the HIF-1 transcription 
factor (See Materials and Methods section 2.12).   
 
HIF-1α siRNA transfection produced a significant 95% down-regulation of 
HIF-1 transcriptional activity under hypoxic conditions, in all three cell lines, 
(Figure 5.12, p=0.0244 (HCT116 cells), p=0.0008 (MGLVA1 cells) and 
p=0.0014 (PAN1 cells)), when compared to the firefly luciferase expression 
obtained from non-targeting control siRNA transfection. 
 
Despite the low expression levels of the HIF-1α protein under normoxic 
conditions, transfection with both HIF-1α siRNA and PGL4-(LDH)-HRE 
luciferase reporter plasmid also significantly down-regulated HIF-1 
transcriptional activity in the HCT116 and MGLVA1 carcinoma cell lines, by 
80% and 95% respectively, under normoxic conditions (Figure 5.13, p=0.0097 
(HCT116 cells) and p=0.0232 (MGLVA1 cells)), when compared to the firefly 
luciferase expression obtained after non-targeting control siRNA transfection.   
The HIF-1α siRNA transfection had no significant effect on normoxic PAN1 
HIF-1 transcriptional activity, when compared to that obtained in the non-
targeting control siRNA transfected cells (Figure 5.13).  Although, to confirm 
whether these observations were genuine, the data needs to be correlated to the 
protein concentration of the luciferase samples.   
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Firefly luciferase expression after HIF-1α siRNA transfection under 
hypoxic conditions. 
*
HCT116 cells
NT control siRNA HIF-1α siRNA
0
2
4
6
8
10
12
14
16
18
20
22
24
siRNA transfected
Fi
re
fly
 
lu
ci
fe
ra
se
 
ex
pr
es
si
o
n
re
la
tiv
e 
to
ββ ββ-
G
al
ac
to
si
da
se
 
co
n
tr
o
l
 
 
***
MGLVA1 cells
NT control siRNA HIF-1α siRNA
0
10
20
30
40
50
60
70
80
90
100
siRNA transfected
Fi
re
fly
 
lu
ci
fe
ra
se
 
ex
pr
es
si
o
n
re
la
tiv
e 
to
ββ ββ-
G
al
ac
to
si
da
se
 
co
n
tr
o
l
 
 
**
PAN1 cells
NT control siRNA HIF-1α siRNA
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
3000
siRNA transfected
Fi
re
fly
 
lu
ci
fe
ra
se
 
ex
pr
es
si
o
n
re
la
tiv
e 
to
ββ ββ-
G
al
ac
to
si
da
se
 
co
n
tr
o
l
 
 
Figure 5.12 – Firefly luciferase expression in HCT116 carcinoma cells (top 
graph), MGLVA1 carcinoma cells (middle graph) and PAN1 carcinoma cells 
(bottom graph) under hypoxic conditions, after dual-transfection with PGL4-
(LDH)-HRE reporter plasmid and HIF-1α siRNA or non-targeting (NT) 
control siRNA (*p=0.0244 / **p=0.0014 / ***p=0.0008 (analysed using 
student’s t-test), + S.D).  Each bar represents combined data from duplicate 
transfections.  n=1 (for HCT116 / MGLVA1 cells) n=2 (PAN1 cells) (data 
representative of replicate experiments).  Transfection reagent induced HIF-1α 
gene expression was approximately equal to that induced by the non-targeting 
control siRNA. 
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Firefly luciferase expression after HIF-1α siRNA transfection under 
normoxic conditions. 
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Figure 5.13 – Firefly luciferase expression in HCT116 carcinoma cells (top 
graph), MGLVA1 carcinoma cells (middle graph) and PAN1 carcinoma cells 
(bottom graph) under normoxic conditions, after dual-transfection with PGL4-
(LDH)-HRE reporter plasmid and HIF-1α siRNA or non-targeting (NT) 
control siRNA (*p=0.0232 / **p=0.0097 (analysed using student’s t-test), + 
S.D).  Each bar represents combined data from duplicate transfections.  n=1 
(for HCT116 / MGLVA1 cells) n=2 (PAN1 cells) (data representative of 
replicate experiments).  Transfection reagent-induced HIF-1α gene expression 
was approximately equal to that induced by the non-targeting control siRNA. 
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The raw Firefly luciferase expression data of HCT116 and MGLVA1 cells was 
10-fold higher than that seen in the PAN1 cells (data not shown), suggesting a 
higher level of HIF-1 transcriptional activity within these cell lines.  This 
correlated with the nuclear Western blots of these cell lines, which showed a 
greater intensity of HIF-1α expression in the HCT116 and MGLVA1 cells, 
compared to the PAN1 cells.  These results could suggest that the HCT116 and 
MGLVA1 carcinoma cell lines express a level of growth factor signalling, 
which induces HIF-1 transcriptional activity under normoxic conditions, 
whereas the PAN1 carcinoma cell line lacked this signalling. 
 
5.6 Effect of HIF-1α siRNA transfection on gastrin gene 
expression 
To determine whether the HIF-1 transcription factor was involved in the up-
regulation of the gastrin gene under hypoxic conditions, HIF-1α siRNA was 
used to specifically knock-down HIF-1α gene expression, and its resultant 
transcriptional activation.  As shown above, test transfections using HIF-1α 
siRNA were shown to significantly down-regulate both HIF-1α gene 
expression and the resultant protein activity of the HIF-1 transcription factor.  
Gastrin gene expression was investigated in a panel of GI carcinoma cell lines, 
after transfection with either 20nM HIF-1α siRNA or non-targeting control 
siRNA, before being incubated under hypoxic conditions. 
 
In the HCT116 and PAN1 carcinoma cell lines, transfection with HIF-1α 
siRNA under hypoxic conditions resulted in a 45% and 65% decrease in 
gastrin gene expression respectively (Figure 5.14, p<0.0001), when compared 
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to the gastrin gene expression obtained after non-targeting control siRNA 
transfection.   
 
The expression of the gastrin gene in the presence of HIF-1α siRNA under 
hypoxic conditions was reduced to the level of gastrin expression normally 
seen under normoxic conditions at the same time point in the HCT116 and 
PAN1 carcinoma cells (after transfection with the non-targeting control siRNA 
(data not shown)).  As previously seen in the HIF-1α gene expression studies, 
transfection with the non-targeting control siRNA increased the base line 
gastrin gene expression, when comparing the data obtained from untreated 
cells, which was probably caused by the transfection reagent (data not shown). 
 
Inhibition of gastrin gene expression after HIF-1α siRNA transfection was not 
replicated in the MGLVA1 carcinoma cells, as transfection with HIF-1α 
siRNA induced a 30% increase in the hypoxic gastrin gene expression, when 
compared to the expression obtained in the non-targeting control siRNA-
treated cells (Figure 5.15, p=0.0002).  These results suggest that HIF-1α plays 
a role in regulating gastrin gene expression under hypoxic conditions, but in a 
cell-dependent manner. 
 
 
 
 
 
 
  166 
Gastrin gene expression after HIF-1α siRNA transfection under hypoxic 
conditions. 
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Figure 5.14 – Gastrin gene expression in HCT116 carcinoma cells (top graph) 
and PAN1 carcinoma cells (bottom graph) under hypoxic conditions, after 
transfection with HIF-1α siRNA or non-targeting (NT) control siRNA 
(***p<0.0001 (analysed using student’s t-test), + 95% confidence interval).  
Each bar represents combined data from duplicate transfections.  n=2 (for both 
cell lines) (data representative of replicate experiments).   
 
Gastrin gene expression after HIF-1α siRNA transfection under hypoxic 
conditions. 
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Figure 5.15 – Gastrin gene expression in MGLVA1 carcinoma cells under 
hypoxic conditions, after transfection with HIF-1α siRNA, non-targeting (NT) 
control siRNA, or untreated control  (***p=0.0002 (analysed using student’s t-
test), + 95% confidence interval).  Each bar represents combined data from 
duplicate transfections.  n=2 (data representative of replicate experiments).   
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5.7 Chapter Summary and Conclusions 
Specific expression of the gastrin gene was up-regulated under hypoxic 
conditions in a number of GI carcinoma cell lines, derived from different 
origins throughout the GI tract.  These included colorectal carcinoma cells 
(HCT116 cells), gastric carcinoma cell lines (MGLVA1 and ST16 cells), 
oesophageal carcinoma cells (OE19, OE21 and OE33) and pancreatic 
carcinoma cells (BxPC3 and PAN1).  The up-regulation of gastrin expression 
under hypoxic conditions may help cells endure the harsh conditions found in 
hypoxia, by up-regulating gastrin-dependent pro-survival mechanisms, such as 
increased cell proliferation (Colucci et al, 2005; Smith et al, 2005), 
angiogenesis (Clarke et al, 2006; LeFranc et al, 2004) and invasion 
(Wroblewski et al, 2002).  Gastrin expression may also lead to the down-
regulation of anti-survival mechanisms, such as apoptosis (Hartwich et al, 
2000).     
 
The up-regulation of gastrin expression under hypoxic conditions was further 
confirmed by gastrin cell immunofluorescent staining, which appeared to be 
nuclear in nature.   
 
The up-regulation of the gastrin gene under hypoxic conditions consistently 
occurred downstream of hypoxic VEGF gene induction.  Generally, target 
genes of HIF-1 are noticeably up-regulated within the first 4-8hr of hypoxic 
incubation, although this figure can vary.  A study by Semenza et al (1994) 
investigated the role of hypoxia on the expression of a number of glycolytic 
enzymes.  They showed that some enzymes (e.g. aldolase A) were inducible 
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within 1hr hypoxic incubation, whereas the induction of other enzymes took 
much longer, such as phosphoglycerate kinase, which took over 8hr before the 
enzyme was detectable.  Therefore, the next step was to determine whether the 
gastrin gene was a target gene of HIF-1 or whether its induction was due to a 
secondary indirect mechanism.  Therefore, the effect of HIF-1 inhibition on 
gastrin expression was investigated using target-specific siRNA. 
 
Transient transfection of HIF-1α siRNA proved to be very successful at down-
regulation the expression of the HIF-1α gene, and as a result, the 
transcriptional activity of the HIF-1 transcription factor, under both normoxic 
and hypoxic conditions, in all carcinoma cell lines investigated.  The original 
plan was to co-transfect both HIF-1α and HIF-1β siRNA into the carcinoma 
cell lines, to fully inhibit the activity of HIF-1.  However, the HIF-1β-specific 
siRNA had failed to induce a significant affect on the expression of the HIF-1β 
gene.  Targeting the HIF-1β gene would not have provided specific inhibition 
for the HIF-1 transcription factor, as HIF-1β or ARNT is a common subunit of 
multiple bHLH-PAS proteins, such as the aryl hydrocarbon receptor (Wang et 
al, 1995) and therefore the siRNA would have targeted more than one gene for 
knockdown.  This would have meant that any downstream events as a result of 
HIF-1β knockdown could not be completely associated to the HIF-1 
transcription factor. 
 
The up-regulation of the gastrin gene expression was partially inhibited by a 
HIF-1α-specific siRNA in a cell line-dependent manner.  This suggested that 
the gastrin gene up-regulation under hypoxic conditions was partially mediated 
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via HIF-1 and as a result, its promoter may include a ‘hypoxia-response 
element’ (HRE).   
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Chapter Six 
CONSTRUCTION AND 
EVALUATION OF A 
LUCIFERASE 
REPORTER PLASMID 
CONTAINING A 
PUTATIVE GASTRIN 
HRE SEQUENCE 
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6.1 Background 
The transcription factor HIF-1 is responsible for the up-regulation of several 
key target genes under hypoxic conditions.  These genes have roles in cell 
growth and survival, cell proliferation, angiogenesis and metabolism, and 
include examples such as VEGF, GLUT1 and the glycolytic enzymes.  HIF-1 
is often up-regulated in cancers, which leads to the increased expression of its 
target genes, driving progression through the carcinoma sequence.  A key 
feature of the HIF-1 target genes is the expression of a HRE upstream of their 
transcription start site.  This element is required for HIF-1 to bind and up-
regulate transcription, and is encoded by five key bases (A/G)CGTG.   
 
In the previous chapter, hypoxia was shown to significantly up-regulate the 
expression of the gastrin gene in a panel of GI carcinoma cell lines.  The 
gastrin gene was also shown to be partially responsive to HIF-1α siRNA 
transfection, suggesting that gastrin is partially mediated via HIF-1.  As a 
result its promoter may contain a HRE sequence.  Both gastrin and HIF-1α 
have been independently shown to possess similar cell proliferative, 
angiogenic and anti-apoptotic properties; therefore the aim of this chapter was 
to determine whether gastrin was a target gene of the HIF-1 transcription 
factor.  Firstly, the DNA upstream of the gastrin gene transcription start site 
was screened for the presence of a HRE sequence.  As this proved successful, 
the putative gastrin HRE sequence was cloned into a luciferase reporter vector 
to determine whether it was directed regulated by HIF-1. 
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6.2 Identification of a putative hypoxia-response 
element upstream of the gastrin gene transcript 
To determine whether up-regulation of gastrin gene expression under hypoxic 
conditions was due to the activity of the HIF-1 transcription factor itself, or a 
secondary effect of a HIF-1 target gene activity, the DNA upstream of the 
gastrin gene transcript was examined for the presence of a hypoxia-response 
element (See Materials and Methods section 2.9). 
 
Approximately 4000bp of the DNA sequence upstream of the gastrin 
transcription start site was downloaded from the Ensembl genome browser 
(www.ensembl.org, Ensembl file number ENSG00000184502).  Homology 
between the 4000bp DNA sequence (from upstream of the gastrin transcript) 
and the VEGF HRE sequence (from -985bp to -939bp within the VEGF 
promoter (Forsythe et al, 1996)) was investigated using the ClustalW multiple 
alignment program within the SDSC Biology WorkBench software.  The 
resulting alignment between the two sequences is shown in Figure 6.1.  The 
DNA sequence -2985bp and -2933bp upstream of the gastrin transcription start 
site shared approximately 66% homology with the VEGF HRE sequence.  
 
The DNA upstream of the gastrin gene transcript also contained a five base 
pair HRE consensus sequence GCGTG within this region of homology 
(Wenger et al, 2005, Figure 6.1, red box).  The presence of this putative HRE 
sequence upstream of the gastrin transcript may explain the induction of 
gastrin gene under hypoxic conditions and the ability of HIF-1α siRNA to 
inhibit gastrin gene expression.   
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Potential HRE sequence upstream of the gastrin transcription start site. 
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Figure 6.1 – The location and sequence of the putative hypoxia response 
element within the DNA upstream of the gastrin gene. 
 
 
 
To determine whether this putative HRE sequence was responsive to hypoxia, 
and more specifically the HIF-1 transcription factor, luciferase reporter 
plasmids containing the DNA sequence upstream of the gastrin gene transcript, 
including the putative gastrin HRE sequence (AGTGTATAAAGCGTGTGCA 
CAGAC) were generated. 
 
The DNA sequence from upstream of the gastrin transcription start site, exon 
one of the gastrin gene transcript and part of intron one (i.e. from -3500 base 
pairs to +77 base pairs) was screened for the presence of restriction enzyme 
digest sites, using the TACG program from the SDSC Biology WorkBench 
software.  The restriction sites present within this DNA were then compared to 
those found in the multiple cloning region of the PGL4-basic luciferase 
reporter vector (Figure 6.2), which was the vector used in the preparation of 
the gastrin luciferase reporter plasmids.   
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The PGL4-basic luciferase reporter vector (Promega) was a 4242bp vector that 
contained a synthetic firefly luciferase gene, but lacked any additional 
promoter or enhancer elements (Figure 6.2). 
PGL4-basic luciferase reporter vector 
 
 
 
Figure 6.2 – A plasmid map of the PGL4-basic luciferase reporter vector (from 
Promega), detailing key constructs and restriction enzyme digest sites. 
 
 
 
The results of the TACG screening program revealed an endogenous XhoI 
restriction digest site (CTCGAG) 246-252bp upstream of the putative gastrin 
HRE sequence (Figure 6.3).  The DNA sequence however did not contain any 
further digest sites from the multiple cloning region of the PGL4-basic 
luciferase reporter vector (i.e. for the enzymes EcoRV, BglII, BglI/SfiI and 
HindIII (see Figure 6.2)).  Therefore, to ensure that the DNA upstream of the 
gastrin gene transcript was inserted into the plasmid in the correct orientation, 
an extra restriction enzyme site was added to the end of the reverse primer. 
 
To allow for the DNA upstream of the gastrin gene transcript to be amplified 
using PCR, forward and reverse primers were designed using the Primer3 
program from the SDSC Biology WorkBench software.  The forward primer 
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(sequence 5’-ATCAGTTCCTGGTACACGGC-3’) and reverse primer 
(sequence GGTTTTCTCACCTGCAGAGC-3’) (Figure 6.3) were located at 
-3362bp to -3342bp and +25bp to +42bp of the DNA sequence respectively, 
producing a final promoter fragment of 3320bp.  A BglII restriction enzyme 
site (AGATCT) was added to the end of the reverse primer (new sequence 5’-
CCTCCTCCTTCTAGAGGTTTTCTCACCTGCAGAGC-3’, incorporating 
the BglII restriction digest site), to ensure that the DNA was inserted into the 
plasmid in the correct orientation. 
 
6.3 Preparation of gastrin luciferase reporter plasmid 
for use in luciferase reporter assays 
 
6.3.1 Optimisation of restriction enzymes 
To determine the optimum concentration of restriction enzyme required, 1g 
of PGL4-basic plasmid was digested overnight with 5-10units/g BglII or 
XhoI.  The BglII restriction enzyme successfully digested the entire PGL4-
basic vector added (Figure 6.4A), therefore for all subsequent digestions, the 
BglII restriction enzyme was used at this concentration.  The XhoI restriction 
enzyme failed to digest the entire vector at this concentration (Figure 6.4A).  
Therefore, the concentration of XhoI restriction enzyme was increased to 
20units/g DNA, which was shown to be successful at completely digesting 
the PGL4-basic plasmid (Figure 6.4B). 
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Locations of the XhoI restriction enzyme digest site and the primer 
annealing sites. 
Forward primer
Putative Gastrin
HRE sequenceVEGF HRE sequence
Gastrin promoter sequence
Gastrin promoter sequence
XhoI restriction digest site
 
     
------------------------------------------------------------
TGAGGGCTTTATAAGGCAGGCCTGGAGCATCAAGCAGAGCAGAGACCTGAGAGGCACCAG
------------------------------------------------------------
------------------------------------------------------------
GCCCAGCCGTGGCACCACACACCTCCCAGCTCTGCAGGTGAGAAAACCCAGGAGGAGAGG
----------------------------CGAGACGTCCACTCTTTTGG------------
---------------------------
GGAGAGGCTAGGAAGTGGGTTGACAGG
---------------------------
Gastrin promoter sequence
Reverse primer
 
 
Figure 6.3 – The DNA sequence -3460bp to -2560bp (top) and -70bp to +77bp 
(bottom) upstream of the gastrin gene transcript, highlighting the locations of 
the putative gastrin HRE sequence, the endogenous XhoI restriction enzyme 
site and annealing site of the forward and reverse primers. 
 
Restriction digest of PGL4-basic plasmid with BglII and XhoI. 
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Figure 6.4 – A.  Restriction digest of PGL4-basic plasmid with 5units/g BglII 
or 10units/g XhoI.  B. Restriction digest of PGL4-basic plasmid with 
20units/g XhoI.   
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6.3.2 Optimisation of PCR protocol 
All PCR experiments performed during the preparation of the gastrin luciferase 
reporter plasmid used DNA extracted from HCT116 carcinoma cells, as gastrin 
mRNA was inducible under hypoxic conditions and was responsive to HIF-1α 
siRNA transfection in these cells. 
 
The first few attempts at amplifying the DNA upstream of the gastrin gene 
transcript used standard PCR protocols; 40 cycles of 95ºC for 1min, 60ºC for 
1min and 72ºC for 3mins.  These were however unsuccessful at amplifying the 
DNA for use in the gastrin luciferase reporter plasmid, despite the DNA 
successfully producing bands when amplified using other PCR protocols and 
primers (data not shown).   
 
Reducing the annealing temperature of the standard PCR protocol (e.g. to 50ºC 
or 55ºC) had no effect on the success rate of the PCR in amplifying the DNA 
upstream of the gastrin gene transcript. 
 
Therefore, it was decided to use a PCR protocol specifically designed to 
amplify long DNA fragments (i.e. up to 10kb in length).  This protocol 
consisted of 35 cycles of 94ºC for 30 seconds, 55ºC for 1min and 68ºC for 
3.5mins (for the first 10 cycles), plus an additional 10 seconds per cycle for the 
remaining 25 cycles.  The initial PCR protocol for long DNA fragments also 
failed (data not shown), however, the addition of Q-solution to the reaction 
resulted in the DNA fragment being successfully amplified, producing a single 
DNA band approximately 3.3kb in size (Figure 6.5).  Q-solution helps to 
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increase the success-rate of DNA amplification of sequences that are GC-rich 
in nature or have a high level of secondary structure, both of which are 
common features found in promoter regions of DNA.  Q-solution changes the 
melting behaviour of the DNA, allowing the Taq enzyme to make contact with 
DNA that has profound secondary structures. 
Confirmation of successful amplification of the DNA upstream of the 
gastrin gene transcript. 
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Figure 6.5 – Successful amplification of the DNA upstream of the gastrin gene 
transcript using DNA from HCT116 cells.  PCR protocol consisted of 94ºC for 
15mins, then 35 cycles of 94ºC for 30 seconds, 55ºC for 1min and 68ºC for 
3.5mins (for the first 10 cycles), plus an additional 10 seconds per cycle for the 
remaining 25 cycles. 
 
 
 
6.3.3 Issues with promoter fragment concentration 
The next stage of the gastrin luciferase reporter plasmid construction required 
the preparation of large batches of XhoI and BglII restriction enzyme-digested 
PGL4-basic vector and HCT116 promoter fragment ready for ligation.  This 
required a minimum of 100ng vector and approximately 220ng promoter 
fragment to set up.  Therefore, approximately 5g of both the vector and DNA 
fragment prepared via PCR were purified via gel extraction, using the 
QIAquick gel extraction kit (Qiagen).  These were then digested with the XhoI 
and BglII restriction enzymes (see Materials and Methods section 2.9.6), gel 
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purifying in between each digestion, due to the close proximity of the 
restriction digest sites.  The images in Figure 6.6 show a batch of promoter 
fragment undergoing gel purification, prior to restriction digest by XhoI and 
BglII respectively.  After each gel purification step, it was noted that a 
considerable amount of promoter fragment had been lost (Figure 6.6).  Whilst 
the PGL4-basic vector was clearly visible (4.2kb in size), following the 
restriction digest and gel purification, the promoter fragment, which was 
expected to be 3.3kb in size, was undetectable alongside the vector.   
 
Several repeats of DNA amplification and restriction digestion were performed 
in an attempt to prepare enough XhoI and BglII-digested promoter fragment 
for use in ligation.  Altering the purification process from gel extraction to 
ethanol precipitation, increasing the number of cycles of the PCR program or 
increasing the initial concentration of DNA in the PCR reaction all failed to 
have a significant effect on increasing the yield of promoter fragment obtained. 
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Loss of promoter fragment after gel purification. 
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Figure 6.6 – Loss of HCT116 promoter fragment after gel purification and 
overnight restriction digestion with either XhoI or BglII. 
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6.3.4 Generation of gastrin luciferase reporter plasmid 
In order to increase the yield of promoter fragment, for ligation into the PGL4-
basic luciferase reporter vector, the whole PCR product was successfully 
subcloned into a TA cloning vector, pCRII-TOPO (Figure 6.7, Invitrogen), 
before being transformed into E. coli.   
PCRII TOPO TA cloning vector. 
 
                   
Figure 6.7 – A plasmid map of the pCRII-TOPO TA vector (from Invitrogen), 
detailing key constructs and restriction digest sites. 
 
 
 
Ampicillin-resistant individual transformants (pTA Gasprom (i.e. contains the 
DNA upstream of the gastrin transcript)) were picked, grown up and plasmid 
DNA extracted using the Genelute plasmid miniprep kit.  Linearisation of the 
pTA Gasprom transformants with the restriction enzyme HindIII confirmed the 
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insertion of the entire promoter fragment (3320bp in size) in the TA cloning 
vector, forming a plasmid of 7320bp in size (data not shown).  The promoter 
fragment could have been inserted in one of two orientations; clockwise or 
anticlockwise (Figure 6.8).   
Possible plasmid maps of the pTA Gasprom transformants 
 
1/4000 Hind III (277)
Endogenous XhoI site (43)
PCR product insert (3320bp)
XhoI (377)
BglII (1326)
ScaI (2480)
(BglII (3320))
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PCR product insert (3320bp)
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ScaI (2480)
(BglII (3320))
                   
Figure 6.8 – Plasmid maps of the pTA Gasprom transformants.  The promoter 
fragment could have been inserted in a clockwise (top) or anti-clockwise 
fashion (bottom). 
 
 
Digestion of four of the clones with BglII to determine insert orientation was 
found to only linearise the plasmid, suggesting the BglII site with in the primer 
had been lost during PCR or cloning. 
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The pTA Gasprom transformants were therefore digested with both XhoI and 
HindIII, alongside the PGL4-basic vector to ensure the correct orientation of 
the promoter fragment within the luciferase reporter plasmid.  The addition of 
the restriction enzyme ScaI further cleaved the TA cloning vector, allowing for 
easy identification of the promoter fragment.  The triple digestion of the pTA 
Gasprom with XhoI, HindIII and ScaI produced three bands of approximately 
3.4kb, 2.1kb and 1.5kb in size (data not shown).   
 
The 3.4kb band contained the gastrin gene transcript required for the luciferase 
reporter plasmid and was ligated into the PGL4-basic vector, prior to being 
transformed into supercompetent TOPO10F’ E. coli bacteria (See Materials 
and Methods section 2.9.7). 
 
This methodology resulted in the successful ligation of the 3.4kb promoter 
fragment into the PGL4 basic luciferase-reporter plasmid.  Figure 6.9 shows a 
test restriction digest using the XhoI and HindIII enzymes, of four clones of 
the gastrin luciferase reporter plasmid, chosen at random.  All four plasmids 
contained the PGL4-basic vector (4.2kb in size) and the inserted DNA, derived 
from upstream of the gastrin transcription start site (3.4kb in size).  A 
simplified map of the gastrin luciferase reporter plasmid is also shown in 
Figure 6.9. 
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Confirmation of a successful plasmid via the restriction digest of plasmid 
with XhoI and HindIII. 
Ladder    PGL4 basic    Clone 1     Clone 2      Clone 3     Clone 4MW
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Figure 6.9 – The plasmid map and restriction digest of gastrin luciferase 
reporter plasmids using restriction enzymes XhoI and HindIII, confirming the 
expression of the 3.4kb promoter fragment within the PGL4-basic plasmid. 
 
 
 
6.3.5 Sequencing of the gastrin luciferase reporter plasmid 
Gastrin luciferase reporter plasmid clones 1, 2 and 4 were sent away for 
sequencing at the Biopolymer Synthesis and Analysis Unit, in the Queen’s 
Medical Centre, Nottingham.  The sequencing used the RVPrimer3 
(CTAGCAAAATAGGCTGTCCC), which anneals to the PGL4-basic plasmid 
at 4191-4210, approximately 60 base pairs upstream of the XhoI restriction 
digest site (i.e. the start of the DNA sequence from upstream of the gastrin 
gene transcript).  There was a high level of homology seen between the DNA 
sequence from upstream of the gastrin gene transcript (line 4 of sequence) and 
clones 1, 2 and 4 (Lines 1, 2 and 3 respectively) (Figure 6.10).   
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The green boxes represent conserved residues within the sequence, whereas 
blue residues suggest identical residues and red residues suggest bases that are 
similar in shape, but not identical.  The putative gastrin HRE sequence is 
highlighted by the clear black box in the centre of the sequence and is 
completely conserved throughout all four sequences.  The shaded box at the 
top of the figure represents the location of the forward primer and highlights an 
area where the sequences are similar, but not identical. 
 
6.4 Initial test transfections of gastrin luciferase 
reporter plasmids 
From the batch of plasmids that were suggested to contain the DNA upstream 
of the gastrin gene transcript, four were chosen for further investigation, 
including the three clones that were sequenced.  The four clones of the gastrin 
luciferase reporter plasmid were transfected into HCT116 cells at a 
concentration of 500ng/well, alongside the PGL4-(LDH)-HRE multimer 
luciferase reporter as a positive control and PGL4- basic as a negative control.   
 
After 16hr hypoxic incubation, there was a significant 20-30% increase in the 
firefly luciferase expression in the HCT116 cells transfected with the four 
plasmid clones (Figure 6.11, p<0.03), when compared to the equivalent 
normoxic luciferase expression.  However, transfection with the PGL4-(LDH)-
HRE positive control plasmid induced an 800% increase in luciferase 
expression under hypoxic conditions (Figure 6.11, p<0.03), which was 
approximately 9-fold higher than that obtained after transfection with the 
gastrin luciferase reporter plasmids. 
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Initial sequencing of the gastrin luciferase reporter plasmids 
 
Figure 6.10 –Initial sequencing of gastrin luciferase reporter plasmids clones 1, 
2 and 4 (lines 1, 2 and 3 respectively), in comparison with the DNA sequence 
of the DNA upstream of the gastrin gene transcript (line 4).  Green represents 
conserved residues, blue represents identical residues and red represents 
similar residues (in shape).   
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Firefly luciferase expression after transfection with gastrin luciferase 
reporter plasmids. 
*
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Figure 6.11 – Firefly luciferase expression in HCT116 carcinoma cells under 
both normoxic and hypoxic conditions (16hr incubation), after transfection 
with 500ng/well gastrin luciferase reporter plasmid (GasProm) 1-4, PGL4-
(LDH)-HRE or PGL4-basic control plasmid (*p<0.03 / **p<0.004 (analysed 
via student’s t-test), + S.D).  Each bar represents combined data from duplicate 
transfections.  n=3 (data representative of replicate experiments). 
 
 
 
In an attempt to optimise the hypoxic luciferase expression, HCT116 cells 
were transfected with increasing concentrations of gastrin luciferase reporter 
plasmid clone 4 (250ng/well, 500ng/well and 1000ng/well), alongside PGL4-
(LDH)-HRE and PGL4-basic plasmids, before being exposed to hypoxia for 
increasing lengths of time.   
 
Incubation under hypoxic conditions induced a significant 20-35% increase in 
the firefly luciferase expression within the HCT116 cells transfected with 
500ng/well gastrin luciferase reporter plasmid (16hr and 24hr incubation) or 
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100ng/well (24hr incubation time point only), when compared to the 
equivalent normoxic luciferase expression (Figure 6.12, p<0.05).  
 
Transfection with the PGL4-(LDH)-HRE positive control plasmid however, 
induced a 200-700% (time point-dependent) increase in luciferase expression 
under hypoxic conditions (Figure 6.12, p<0.05), which was up to 24-fold 
higher than that obtained after transfection with the gastrin luciferase reporter 
plasmid. 
Firefly luciferase expression after transfection with gastrin luciferase 
reporter plasmid. 
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Figure 6.12 – Firefly luciferase expression in HCT116 carcinoma cells under 
both normoxic and hypoxic conditions, after transfection with increasing 
concentrations of gastrin luciferase reporter plasmid (GasProm4), PGL4-
(LDH)-HRE or PGL4-basic control plasmid (*p<0.05 / **p<0.007 (analysed 
via student’s t-test), + S.D).  Each bar represents combined data from duplicate 
transfections.  n=1. 
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Further attempts at optimising the gastrin luciferase reporter plasmid 
transfection in an effort to increase the luciferase expression under hypoxic 
conditions included altering: 
1) The carcinoma cell line transfected (e.g. changed from HCT116 to PAN1 
carcinoma cells). 
 
2) The media conditions (e.g. changed from FBS-containing media to serum-
free media). 
 
3) The endogenous control transfected (e.g. changed from β-Galactosidase to 
Renilla luciferase). 
 
The introduction of any or all of these alterations to the transfection protocol 
failed to significantly improve the induction of luciferase expression under 
hypoxic conditions (data not shown).  Therefore, all subsequent transfections 
using the gastrin luciferase reporter plasmid were performed using 500ng/well, 
with a 16hr hypoxic incubation. 
 
6.5 Responsiveness of gastrin luciferase reporter 
plasmid transfection to exogenous EGF treatment 
The sequencing of the gastrin luciferase reporter plasmids suggested that they 
contained the DNA sequence upstream of the gastrin gene transcript, however, 
to confirm the responsiveness of the gastrin promoter, HCT116 cells were 
transfected with the gastrin luciferase reporter plasmid (clone 4), prior to 
exogenous treatment with 10g/ml EGF.  The gastrin promoter is known to 
express an EGF-response element, upstream of the gastrin transcription start 
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site (Merchant et al, 1995).  Therefore, treatment with EGF was expected to 
increase the activity of the gastrin luciferase reporter plasmid. 
 
Exogenous treatment of EGF for 24hr resulted in an increase in luciferase 
expression by 30% under normoxic condition (Figure 6.13, p=0.0182) and 
68% under hypoxic conditions (Figure 6.13, p=0.0141), when compared to the 
untreated PGL4-basic control.  This data suggested that the gastrin luciferase 
reporter plasmids are partially responsive to EGF and therefore may contain 
the EGF-response element expressed in the gastrin promoter sequence. 
Firefly luciferase expression after transfection with gastrin luciferase 
reporter plasmid. 
HCT116 cells
0
2
4
6
8
10
12
14
16
18
20
Untr.           EGF            Untr.           EGF
    PGL4-basic                     GasProm
                 Normoxic incubation
Plasmids transfected
Fi
re
fly
 
lu
ci
fe
ra
se
 
ex
pr
es
si
o
n
 
re
la
tiv
e 
to
ββ ββ-
ga
la
ct
o
si
da
se
 
an
d 
PG
L4
-
ba
si
c
pl
as
m
id
*
HCT116 cells
0
2
4
6
8
10
12
14
16
18
20
Untr.           EGF            Untr.           EGF
    PGL4-basic                     GasProm
                  Hypoxic incubation
Plasmids transfected
Fi
re
fly
 
lu
ci
fe
ra
se
 
ex
pr
es
si
o
n
 
re
la
tiv
e 
to
ββ ββ-
ga
la
ct
o
si
da
se
 
an
d 
PG
L4
-
ba
si
c
pl
as
m
id
*
 
 
Figure 6.13 – Firefly luciferase expression in HCT116 carcinoma cells under 
normoxic (left) and hypoxic conditions (right), after transfection with 
500ng/well gastrin luciferase reporter plasmid (GasProm), or PGL4-basic 
control plasmid, prior to endogenous EGF treatment (16hr incubation) 
(*p<0.02 (analysed via a student’s t-test) + S.D).  Each bar represents 
combined data from duplicate transfections.  n=3 (for normoxic incubation) / 
n=2 (for hypoxic incubation) (data representative of replicate experiments).   
 
 
 
6.6 Preparation and test transfections of Gastrin-HRE 
multimer reporter plasmid 
In an attempt to further enhance the luciferase expression induced under 
hypoxic conditions after transfection with the gastrin luciferase reporter 
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plasmid, 3-4 copies of the putative gastrin HRE sequence (5’-
AGTGTATAAAGCGTGTGCACAGAC-3’, see Figure 6.1 for further 
information) were cloned into PGL4-(LDH)-HRE reporter plasmid, which 
expressed a luciferase gene and a SV40 minimal promoter.  Essentially, the 
LDH HRE-multimer sequence was cleaved from the plasmid via BglII 
restriction digest, prior to the oligonucleotide expressing 3-4 copies of the 
putative gastrin HRE sequence being ligated in its place.  The PGL4-(gastrin)-
HRE plasmid were sequenced prior to use, to confirm that they expressed the 
putative gastrin HRE sequence (Figure 6.14). 
 PGL4-(gastrin)-HRE 1 sequence (contains 3x putative Gastrin HRE sequence) 
 
TTCTTTCCTTATCCAGAAAATTTTCTCTGGCCTAACTGGCCGGTACCTGAGCTCGCTAGCCTC 
 
GAGATCTAGTGTATAAAGCGTGTGCACAGACAGTGTATAAAGCGTGTGCACAGACAGTGTATA 
 BglII 
AAGCGTGTGCACAGACAGATCTGCGATCTGCATCTCAATTAGTCAGCAACCATAGTCCCGCCC 
       BglII 
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATCGCTGA 
SV40 minimal promoter 
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAG 
 
TGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTGGCAATCCGGTACTGTTGGTA 
      HindIII 
 
 
PGL4-(gastrin)-HRE 2 sequence (contains 4x putative Gastrin HRE sequence) 
 
TGCCCCTTTCGATAGAAAATTTTCTCTGGCCAACTGGCCGGTACCTGAGCTCGCTAGCCTCGA 
 
GATCTAGTGTATAAAGCGTGTGCACAGACAGTGTATAAAGCGTGTGCACAGACAGTGTATAAA 
BglII 
GCGTGTGCACAGACAGTGTATAAAGCGTGTGCACAGACAGATCTGCGATCTGCATCTCAATTA 
        BglII 
GTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGC 
SV40 promoter sequence 
CCATTCTCCGCCCCATCGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC 
 
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCT 
           HindIII 
TGGCAATCCGGTACTGTTGGTAAAGCCACCATGGAAGATGCCAAAAACATTAAGAAGGGCCCA 
 
Figure 6.14 – initial sequencing of the PGL4-(gastrin)-HRE luciferase reporter 
plasmids 1 and 2, highlighting the expression of the putative gastrin HRE 
sequence.  
  192 
Two clones of the PGL4-(gastrin)-HRE luciferase reporter plasmid were 
transfected into HCT116 cells, alongside the PGL4-(LDH)-HRE multimer 
luciferase reporter as a positive control and SV40 negative control plasmid as a 
negative control.   
 
After 16hr hypoxic incubation there was a 20-30% decrease in the luciferase 
expression of cells transfected with the PGL4-(gastrin)-HRE plasmids, 
compared to the equivalent normoxic control expression (Figure 6.15, 
p=0.0006).  Transfection with the PGL4-(LDH)-HRE positive control induced 
an approximate 2-fold increase under hypoxic conditions (Figure 6.15, 
p=0.0117).  This data suggested that the putative HRE sequence located 
upstream of the gastrin gene transcript was not responsible for the up-
regulation of the gastrin gene expression under hypoxic conditions. 
Firefly luciferase expression after transfection with gastrin-(HRE) 
reporter plasmid. 
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Figure 6.15 – Firefly luciferase expression in HCT116 carcinoma cells under 
both normoxic and hypoxic conditions (16hr incubation), after transfection 
with 500ng/well PGL4-(gastrin)-HRE luciferase reporter plasmids, PGL4-
(LDH)-HRE or SV40 negative control plasmid (*p=0.0117 / ***p=0.0006 
(analysed via student’s t-test), + S.D).  Each bar represents combined data 
from duplicate transfections.  n=2 (data representative of replicate 
experiments).   
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6.7 Preparation and test transfection of further HRE 
multimer reporter plasmids derived from the DNA 
upstream of the gastrin gene 
Incubation of a number of carcinoma cell lines investigated under hypoxic 
conditions induced a significant increase in gastrin gene expression.  It has 
been suggested above that this increase was dependent on the activity of HIF-
1α; however it was not dependent on the presence of the HRE sequence 
approximately 3000bp upstream of the gastrin transcription start site.  Further 
screening of the DNA upstream of the gastrin gene was undertaken, using the 
Ensembl software to compare the DNA with the known HRE consensus 
sequence.  This revealed four additional possible HRE sequences that could be 
responsible for the up-regulation of gastrin gene expression under hypoxic 
conditions (Table 6.1).   
 
To determine whether any of the above sequences possessed a functional HRE 
sequence, multiple copies of the motifs were cloned into a PGL4 luciferase 
reporter plasmid, which expressed both a luciferase element and a SV40 
minimal promoter.  The six successful clones of the PGL-4-(gastrin)-HRE 
luciferase reporter plasmids (described in Table 6.1) were transfected into 
HCT116 cells, alongside the PGL4-(LDH)-HRE multimer luciferase reporter 
as a positive control and the SV40 negative control plasmid. 
 
After 16hr hypoxic incubation, there was a 40-180% increase in the expression 
of the luciferase gene in all plasmid clones tested (Figure 6.16, p<0.02), when 
compared to the normoxic luciferase expression.   
 
  194 
Oligonucleotide 
construct name: 
Repeated sequence 
(containing gastrin 
HRE) 
Full oligonucleotide sequence 
Oligonucleotide 
2  
 
(PGL4-(Gastrin)-
HRE 3) 
Forward: 
TGGCTCACGTCTG 
Reverse: 
ACCGAGTGCAGAC 
Forward: 5’ GATCTTGGCTCACGTCTG   
TGGCTCACGTCTGTGGCTCACGTCTG 
TGGCTCACGTCTGA 3’.  
Reverse: 5’ GATCTCAGACGTGAGCCA 
CAGACGTGAGCCACAGACGTGAGCCA 
CAGACGTGAGCCAA 3’   
Oligonucleotide 
3  
 
(PGL4-(Gastrin)-
HRE 4 and 5) 
Forward:   
TTACAGACGTGAG 
Reverse: 
AATGTCTGCACTC 
Forward: 5’ GATCTTTACAGACGTGAG 
TTACAGACGTGAGTTACAGACGTGAG 
TTACAGACGTGAGA 3’ 
Reverse: 5’ GATCTCTCACGTCTGTAA 
CTCACGTCTGTAACTCACGTCTGTAA 
CTCACGTCTGTAAA 3’ 
Oligonucleotide 
4  
 
(PGL4-(Gastrin)-
HRE 6 and 7) 
Forward: 
GCGCACACGTGGC 
Reverse: 
CGCGTGTGCACCG 
Forward: 5’ GATCTGCGCACACGTGGC 
GCGCACACGTGGCGCGCACACGTGGC 
GCGCACACGTGGCA 3’ 
Reverse: 5’ GATCTGCCACGTGTGCGC 
GCCACGTGTGCGCGCCACGTGTGCGC 
GCCACGTGTGCGCA 3’ 
Oligonucleotide 
5  
 
(PGL4-(Gastrin)-
HRE 8) 
Forward: 
CCCAGGACGTGAG 
Reverse: 
GGGTCCTGCACTC 
 
Forward: 5’ GATCTCCCAGGACGTGAG 
CCCAGGACGTGAGCCCAGGACGTGAG 
CCCAGGACGTGAGA 3’ 
Reverse: 5’ GATCTCTCACGTCCTGGG 
CTCACGTCCTGGGCTCACGTCCTGGG 
CTCACGTCCTGGGA 3’ 
Table 6.1 – Additional HRE sequences derived from the DNA upstream of the 
gastrin gene transcript, plus the oligonucleotides used to synthesise the 
plasmids. 
 
 
Only half the increases however, induced under hypoxic conditions proved to 
be significant, and the majority of the luciferase expression induced by the 
PGL4-(gastrin)-HRE luciferase reporter plasmids were lower than that caused 
by the SV40 negative control plasmid (Figure 6.16).  
 
This data suggested that the PGL4-(gastrin)-HRE reporter plasmids (and 
therefore the putative gastrin hypoxia-response elements) were only partially 
responsive to HIF-1α regulation.  The data produced was inconclusive whether 
these new putative HRE sequences were responsible for the increase seen in 
the gastrin gene expression under hypoxic conditions.  Further investigation is 
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required to determine whether one of these putative HRE sequences is 
responsible for the up-regulation of gastrin gene under hypoxic conditions. 
Firefly luciferase expression after transfection with HRE multimer 
reporter plasmids. 
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Figure 6.16 – Firefly luciferase expression in HCT116 carcinoma cells under 
both normoxic and hypoxic conditions (16hr incubation), after transfection 
with 500ng/well PGL4-(gastrin)-HRE luciferase reporter plasmids, PGL4-
(LDH)-HRE or SV40 negative control plasmid (*p<0.02 / **p<0.01 / 
***p<0.0009 (analysed via student’s t-test), + S.D).  Each bar represents 
combined data from duplicate transfections (n=1). 
 
 
6.8 Chapter Summary and Conclusions 
Screening of the DNA upstream of the gastrin gene transcript resulted in a 
putative gastrin HRE sequence being identified -2985bp to -2933bp upstream 
of the transcription start site.  Within this sequence was a HRE-consensus 
sequence GCGTG (Wenger et al, 2005) required for the binding of the HIF-1 
transcription factor into the major groove of target genes (Semenza et al, 1994; 
Wang and Semenza, 1995). 
 
The DNA upstream of the gastrin gene transcript that contained the putative 
gastrin HRE sequence was successfully cloned into the PGL4-basic plasmid.  
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Exogenous treatment with epidermal growth factor induced a small increase in 
luciferase production under both normoxic and hypoxic conditions, suggesting 
that the putative gastrin-promoter (pTA Gasprom) plasmid contained the DNA 
upstream of the gastrin gene transcript.  The gastrin promoter is known to 
contain an EGF-response element -54bp to -68bp upstream of the gastrin 
transcription start site (Merchant et al, 1991).  The location of the EGF-
response element in the PCR product was very close to the reverse primer site.  
At this location, it would be more likely to develop mutations within the 
sequence during the PCR process, which may account for some of the lower 
than expected responses to hypoxic conditions, although sequencing the 
current EGF-response element would confirm this.  Future experiments would 
aim to amplify and clone the EGF response element with a longer region 
between the HRE and the primer site to determine if that affects the level of 
induction observed. 
 
The pTA Gasprom plasmid only induced a small, but significant increase in 
luciferase expression under hypoxic conditions, suggesting the presence of an 
HRE sequence upstream of the gastrin coding region.  Under the same 
conditions, the positive control plasmid induced a 9-fold greater response to 
hypoxia, when compared to that induced by the pTA Gasprom plasmids, 
although the positive control plasmid contained four HRE sequences versus the 
single putative gastrin HRE sequence and therefore was expected to produce a 
slightly larger response to hypoxia.   
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Comparison of the pTA Gasprom plasmid luciferase induction with an 
idealised PGL4-(LDH)-HRE luciferase reporter plasmid may also not have 
been appropriate.  The PGL4-(LDH)-HRE consists of an optimised HRE 20bp 
multimer, whereas the pTA Gasprom plasmid consists of an endogenous 
promoter fragment.  Therefore, repeating the transfections, using another 
endogenous promoter fragment, such as the VEGF-promoter plasmid, as a 
positive control may confirm the HRE sequence upstream of the gastrin coding 
region as a true hypoxia response element.   
 
The isolation of the putative gastrin HRE sequence into PGL4-(gastrin)-HRE 
multimer luciferase reporter plasmids confirmed that the hypoxic induction of 
gastrin gene was not regulated by the HIF-1 transcription factor at this site.  
The addition of an Sp-1 binding site to the gastrin HRE sequence may also 
enhance the hypoxic induction of the gastrin gene, to produce a positive 
response.  Welford et al (2006) have shown in mutational analysis experiments 
that an Sp-1 site adjacent to the HRE sequence caused an increase in HIF-1 
transcriptional activity in a mouse embryonic fibroblast model, which were 
transfected with putative HRE constructs. 
 
Further possible HRE sequences derived from the DNA sequence upstream of 
the gastrin gene transcript have now been discovered and are currently under 
investigation as to whether they are responsible for the up- regulation of the 
gastrin gene under hypoxic conditions.  Screening these sequences for the 
presence of a Sp-1 binding site may aid in the selection of possible constructs 
for transfection. 
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Recently an alternative transcript has been discovered for the gastrin gene, 
which originates within intron one of the gastrin transcript (Grabowska et al, 
2008).  Screening of the DNA upstream of the new transcript has revealed the 
presence of the HRE consensus sequence, ACGTG, which will also be cloned 
into a luciferase reporter plasmid.   
 
Therefore, it is currently inconclusive as to whether the gastrin gene is a true 
target of the HIF-1 transcription factor, or whether its expression is increased 
by a secondary indirect mechanism.    
 
 
  199 
 
 
 
 
Chapter Seven 
DISCUSSION 
 
 
 
 
 
 
 
 
 
  200 
7.1 Study aims and objectives 
The aim of this study was to investigate the relationship between the digestive 
hormone gastrin and hypoxia within GI carcinoma cells.  The main finding 
from this study was that gastrin mRNA was significantly up-regulated under 
hypoxic conditions.  This result led to the generation of a further objective, to 
investigate whether gastrin was a downstream transcriptional target of the HIF-
1 transcription factor. 
 
7.2 Gastrin and hypoxia – a putative link in GI cancers 
Gastrin is a known pro-survival factor in the development of GI cancers, with 
roles in cell proliferation / tumour growth (Colucci et al, 2005; Haigh et al, 
2003; Smith et al, 2004; Tsutsui et al, 1997), angiogenesis (Clarke et al, 2006; 
LeFranc et al, 2004), and invasion (Clarke et al, 2006; Wroblewski et al, 2002; 
Yu et al, 2006) and has also been linked with reduced apoptosis (Hartwich et 
al, 2001; Mao et al, 2008).  The presence of increased serum gastrin 
concentrations (hypergastrinemia) is common occurrence in patients with GI 
cancers (Bombski et al, 2003; D’Agostino et al, 1995; Hartwich et al, 2001; 
Konturek et al, 2000; Mihas et al, 1995; Seitz et al, 1991; Thorburn et al, 
1998), which would aid increased tumour growth and survival (Chu et al, 
1995; McGregor et al, 1982; Watson and Smith, 2001).  As the tumour 
expands, aided by the pro-survival actions of gastrin, the existing vasculature 
is unable to supply the entire tumour with its oxygen and nutrient requirements 
(reviewed in Vaupel et al, 1989), which would lead to the generation of areas 
of hypoxia.  The presence of tumour hypoxia is known to increase resistance to 
both radiotherapy (Brizel et al, 1997; Nordsmark et al, 1996) and 
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chemotherapy (Hussein et al, 2006; Sermeus et al, 2008; Teicher et al, 1981; 
Teicher et al, 1990) in cancer patients.   
 
The main finding of this study was that gastrin gene expression was up-
regulated under hypoxic conditions.  The increased presence of gastrin within 
hypoxic regions of tumours may aid cell survival, which may further stabilise 
the treatment resistance to both chemotherapy and radiotherapy.  Under 
hypoxic conditions, the expression of the HIF-1α protein is stabilised (Wang 
and Semenza, 1993; Wang and Semenza, 1995; Wang et al, 1995), leading to 
the up-regulation of target gene transcription in solid tumours, which aids 
tumour growth and angiogenesis (Maxwell et al, 1997).  The downstream 
signalling effects of both HIF-1 and gastrin show a level of redundancy, 
leading to the suggestion that gastrin may be a downstream transcriptional 
target of the HIF-1 transcription factor. 
 
7.3 Alternate isoforms of hypoxia-inducible factors 
The main focus of this study was the nuclear expression and function of the 
HIF-1α protein.  There are however, three known isoforms of the hypoxia-
inducible factor-alpha subunits; HIF-1α, HIF-2α and HIF-3α.   
 
HIF-3α isoform is the least understood of the three proteins.  It is believed that 
HIF-3α is responsible for the antagonism of HRE-dependent gene expression 
(reviewed in Ratcliffe, 2007), acting via different DNA binding elements, not 
found within either HIF-1α or HIF-2α (Maynard et al, 2007).  HIF-3α reduces 
the ability of the other isoforms to bind to the HRE sequences and therefore 
  202 
reduces their transcriptional activity (Maynard et al, 2007).  Its expression is 
often down-regulated in cancers (Maynard et al, 2007) and therefore was not 
investigated in this study.   
 
The HIF-2α isoform does play a role in target gene transcription via also 
forming a dimer with the HIF-1β subunit, and subsequently binding to the 
HRE sequences within promoter regions of target genes under hypoxic 
conditions (Tian et al, 1997), alongside the HIF-1 transcription factor, as 
highlighted in gastric, ovarian and glioblastoma cell lines (Koizume et al, 
2008).  Whilst the expression of the HIF-1α subunit is ubiquitous amongst 
mammalian cells, the HIF-2α subunit is limited to vascular endothelial cells, 
the kidney, heart, lung, astrocytes and the epithelium of the small intestine 
(reviewed in Gordan and Simon, 2007).  HIF-2α protein is not the dominant 
isoform expressed throughout the GI tract.  For example, in a study 
investigating the expression of HIF-alpha isoforms in oesophageal carcinomas, 
over 50% of the tumour samples showed strong expression of the HIF-1α 
protein, whereas only 13% of samples had HIF-2α staining (Koukourakis et al, 
2001).  In initial investigations via Western blotting into the expression of 
HIF-1α protein in the panel of GI carcinoma cells, HIF-2α expression was also 
investigated, however, as no HIF-2α protein was detectable (data not shown), 
no further work in this area was undertaken.   
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7.4 Effects of hypoxia on gastrin gene expression 
The key finding of the study was that the expression of gastrin mRNA was 
significantly increased by 2.5-20 fold after 16hr hypoxic incubation in the 
majority of GI carcinoma cell lines investigated.  Within the panel of GI 
carcinoma cells, the HIF-1α nuclear protein was shown to be expressed (at low 
levels) after only 1hr hypoxic incubation.  The HIF-1 transcription factor was 
shown to be functionally active soon after, by inducing a significant increase in 
VEGF expression within 6-8hr hypoxic incubation.  The increase in gastrin 
mRNA expression however, was delayed compared to that of the VEGF 
expression, only being induced after 16hr hypoxic incubation.  This could 
suggest that the hypoxic induction of gastrin is induced by a downstream target 
of the HIF-1 transcription factor, such as VEGF or even another, currently 
unidentified transcription factor, rather than HIF-1 itself.  The transcription 
factors Sp-1, c-fos and NF-κB are known to be responsible for the up-
regulation of gastrin gene (Marks et al; 1996; Merchant et al, 1995; Ogasa et 
al, 2003).  Further investigation is required to determine whether either is 
regulated by the HIF-1 transcription factor.   
 
Investigations were designed to interrogate whether the increase seen in the 
gastrin mRNA expression was regulated via the HIF-1 transcription factor, as a 
result of a HIF-1-target gene activity, or a HIF-1-independent mechanism.  The 
induction of HIF-1 target gene expression under hypoxic conditions is 
generally variable and is not necessarily dependent on the distance of the HRE 
sequence from the target gene transcript (Wenger et al, 2005).  For example, 
the expression of the glycolytic enzyme aldolase A was inducible after only 
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1hr under hypoxic conditions, whereas the expression of phosphoglycerate 
kinase 1 was only induced after 8hr hypoxic incubation (Semenza et al, 1994).  
The locations of their HRE sequences however, were both approximately 
200bp upstream of the gene transcript (Wenger et al, 2005). 
 
In an attempt to determine whether the increase in gastrin mRNA expression 
under hypoxic conditions was dependent on HIF-1 functional activity, three GI 
carcinoma cell lines were transfected with HIF-1α siRNA, before the 
expression of gastrin mRNA was investigated.  Importantly, the HIF-1α 
siRNA had been shown to down-regulate both HIF-1α gene expression and 
resultant transcriptional activity by approximately 70-95% under both 
normoxic and hypoxic conditions.  The affect of HIF-1α siRNA on HIF-1α 
protein expression was also investigated; however, the siRNA transfection 
produced a high level of cytotoxicity within the cells, resulting in a very low 
yield of protein being obtained.  Therefore, the transcriptional activity of the 
HIF-1 transcription factor was investigated instead.  Gastrin mRNA expression 
was down-regulated by 45-65% after transfection of HIF-1α siRNA, in the 
HCT116 and PAN1 cells only.  The HIF-1α siRNA had no effect on gastrin 
mRNA of the gastric MGLVA1 cells, and in fact induced a small, but 
significant increase in the hypoxic gastrin mRNA expression.  This suggested 
that the HIF-1 transcription factor only played a partial role in hypoxic gastrin 
gene induction, in a cell line-dependent manner. 
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7.5 Role of HIF in mediating the up-regulation of the 
gastrin gene 
The original putative gastrin HRE sequence was located -2985bp to -2933bp 
upstream of the gastrin gene transcript, and shared a high level of homology 
with the VEGF HRE sequence, located approximately -985 to -939 upstream 
of the VEGF transcription start site (Forsythe et al, 1996).  Whilst the putative 
gastrin HRE sequence appeared a large distance away from the transcription 
start site of the gene, other known functional HRE sequences at a similar 
distance from the start codon have been described.  For example, the HRE 
sequences of connective tissue growth factor and endothelial nitric oxide 
synthase are located over 3000bp and 5000bp respectively upstream of the 
transcription start site (Wenger et al, 2005). 
 
Using the gastrin promoter construct, a small, but significant increase in firefly 
luciferase expression was induced after 16hr hypoxic incubation, suggesting 
that the HIF-1 transcription factor was partially responsible for the induction of 
gastrin gene expression under hypoxic conditions.  The luciferase expression 
induced using the gastrin promoter construct however, was still approximately 
nine-fold less than the positive control LDH-HRE construct tested.   
 
In an attempt to enhance the hypoxic firefly luciferase expression, multimer 
putative gastrin HRE constructs were prepared, containing either three or four 
repeats of the gastrin HRE sequence.  These constructs however, failed to 
induce luciferase expression, suggesting that the HRE sequence at -2985bp to 
-2933bp was not responsible for the induction of the gastrin mRNA expression 
under hypoxic conditions.  The previous induction of luciferase was lost when 
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the HRE sequence was extracted from the full promoter.  This could suggest 
that the induction of HIF-1 transcriptional activity needs more than just HIF-1 
binding to a HRE sequence, for example interactions with possible co-factors 
or other transcription factors, such as Sp-1. 
 
Further putative gastrin multimer HRE constructs were then prepared from 
alternate HRE sequences located upstream of the gastrin gene transcript.  All 
six clones tested induced a small increase in hypoxic firefly luciferase 
expression, however, not all were significant, and none induced the 10-fold 
increase as seen in the positive control LDH positive control HRE construct.  
This again suggested that these alternative gastrin HRE sequences were not 
responsible for the induction of the gastrin mRNA expression under hypoxic 
conditions or were unable to act in isolation. 
 
In a review of 108 genes proposed to be regulated by HIF-1 under hypoxic 
conditions, Wenger et al (2005) proposed the sequence of the ‘optimum’ 
hypoxia-response element, taken from the promoter elements of the HIF-1 
target gene sequences.  Figure 7.1 summarises the central region of the 
proposed HRE sequence, consisting of eight nucleotides.  The core CGTG 
residues were conserved in all HRE sequences investigated, whereas there was 
a slight degree of flexibility either side of this consensus region.  From Figure 
7.1, the size of the residues in positions -2, -1, +5 and +6 indicates the 
probability of appearing in the consensus HRE sequence. 
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(C/G/T/A)(G/A)CGTG(C/G/T/A)(C/G/T/A)
Position   -2         -1     +1 +2 +3 +4       +5               +6
 
 
Figure 7.1 – The optimum hypoxia-response element, adapted from Wenger et 
al, 2005.   
 
 
 
Table 7.1 lists the putative gastrin HRE sequences and their level of homology 
with the ‘optimum’ HRE sequence, as described in Figure 7.1.  The original 
putative gastrin HRE sequence shares 63% homology with the ideal construct.  
The other four alternative HRE sequence all shared 88% homology with the 
‘optimum’ HRE sequence.  All five putative gastrin HRE sequences contained 
the central ‘CGTG’ motif.  In theory, all five constructs should have induced a 
hypoxic response and yet none induced a strong luciferase induction.  This 
response may however be considered as a positive effect, if it was compared to 
a more relevant positive control, such as the VEGF promoter plasmid.  This 
plasmid contains the DNA upstream of the VEGF gene, and is therefore more 
comparable to the gastrin promoter plasmid, rather than the idealised PGL4-
(LDH)-HRE reporter plasmid.  Also, the addition of a Sp-1 site adjacent to the 
putative gastrin HRE sites may also up-regulate HIF-1 transcription (Welford 
et al, 2006).   
Plasmid clone Putative HRE 
sequence 
Level of homology with 
optimum HRE 
sequence 
PGL4-(gastrin)-1/2 AGCGTGTG 5/8 (63%) 
PGL4-(gastrin)-3 GACGTGAG 7/8 (88%) 
PGL4-(gastrin)-4/5 GACGTGAG 7/8 (88%) 
PGL4-(gastrin)-6/7 CACGTGGC 7/8 (88%) 
PGL4-(gastrin)-8 GACGTGAG 7/8 (88%) 
Table 7.1 – Putative gastrin HRE sequences in comparison with the ‘optimum’ 
HRE sequence.   
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A recent study by Grabowska et al (2008) has identified an alternative gastrin 
transcript within the PAN1 and other GI cell lines, which differed from that 
listed in the Ensembl database.  The new, alternative transcript of the gastrin 
gene originated within intron one of the gastrin transcript and was probably 
driven by a promoter that is present further upstream within intron one of the 
gastrin gene.  Translation of alternative transcript is increased in conditions of 
‘stress’, which included hypoxia (Grabowska et al, 2008).   
 
Using the Ensembl software, the non-coding gastrin intron 1 sequence was 
scanned for the presence of the core HRE sequence.  A putative gastrin HRE 
sequence (ACGTG) was identified within intron 1 of the gastrin gene, from 
+524bp to +528bp.  The identification of a further putative gastrin HRE 
sequence upstream of the new transcript could provide an explanation for the 
increase in gastrin mRNA expression induced under hypoxic conditions.  
Therefore, an intron 1 gastrin HRE luciferase reporter plasmid is currently 
being constructed and investigated for the induction of firefly luciferase 
expression under hypoxic conditions.  No data is available as of yet.   
 
7.6 Alternative mechanisms for up-regulation of gastrin 
under hypoxia 
If the hypoxic gastrin mRNA expression was only partially regulated via the 
HIF-1 transcription factor, other mechanisms may also be involved in the 
regulation of gastrin expression, either working in combination with HIF-1 or 
are HIF-1-independent. 
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If the HIF-1 transcription factor failed to induce transcriptional activation of 
the gastrin gene, we should consider the possibility that HIF-2 plays a role in 
the regulation of gastrin expression, despite the known lack of HIF-2α 
expression within the GI tract; it could still play an important role within 
emerging tumour cells.  The HIF-1 and HIF-2 transcription factors have been 
shown to regulate both distinct and overlapping groups of genes, in a cell-type-
dependent manner (Koizume et al, 2008; Lau et al, 2007 and reviewed in 
Taylor, 2008), suggesting that they play different roles in tumour progression.  
HIF-1α is mainly responsible for activating genes required for glycolysis (i.e. 
the glycolytic enzymes, such as lactate dehydrogenase and phosphoglycerate 
kinase) and apoptosis (e.g. BNIP3), whereas HIF-2α is solely responsible for 
the expression of key proliferative genes, such as transforming growth factor-α 
and cyclin-D1, and the de-differentiation protein Oct4 (Hu et al, 2007; Lau et 
al, 2007; Raval et al, 2005 and reviewed in Gordan and Simon, 2007).  Both 
HIF-1α and HIF-2α proteins however, are responsible for the activity of pro-
angiogenic genes, (such as VEGF, platelet-derived growth factor and 
Angiopoietin-2) and pro-metastatic and invasion genes (such as CXCR4 (CXC 
chemokine receptor 4), MMP-2 and lysyl oxidase) (Raval et al, 2005 and 
reviewed in Gordan and Simon, 2007).  Generally, tissue that has high HIF-2α 
expression shows lower HIF-1α expression and vice versa (Koizume et al, 
2008; Koukourakis et al, 2001), therefore, the expression of the overlapping 
genes is generally controlled by the dominant HIF-alpha isoform present in the 
cell (Carroll and Ashcroft, 2006; Koizume et al, 2008; Sowter et al, 2003). 
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Both HIF-1α and HIF-2α isoforms bind to the same HRE sequence within the 
promoter region of target genes under hypoxic conditions and share similar 
structural motifs, such as the ODD domain, dimerisation domain, DNA 
binding motifs and conserved regulatory elements (i.e. prolyl and asparagyl 
hydroxylation sites) (Lau et al, 2007; Tian et al, 1997).  Unlike the HIF-1 
transcription factor, which simply has to bind to the HRE sequence within the 
promoters of target genes to initiate transcription, HIF-2 requires the 
involvement of the N-terminal and C-terminal transactivation domains to 
differentially bind to the promoter to initiate any downstream effects (Koizume 
et al, 2008; Lau et al, 2007).  Lau et al (2007) showed that if the C-terminal 
domain of the HIF-1α protein was replaced with the C-terminal domain of 
HIF-2α, the HIF-1 transcription factor gained the ability to regulate HIF-2α-
specific target genes.  Similar results were also induced via the replacement of 
the HIF-1α N-terminal transactivation domain with the HIF-2α equivalent (Hu 
et al, 2007).  Therefore, just expressing the target gene HRE sequence within a 
luciferase construct would not allow for HIF-2 transcriptional activation, as the 
sequence would lack the additional regulatory elements.  Further elements of 
the promoter region would also have to be added to the luciferase reporter 
construct to determine what effect HIF-2α had on target gene transcription.   
 
Gastrin has previously been linked to cell proliferation, angiogenesis and 
invasion in GI carcinoma cells, which are similar properties to those induced 
by HIF-1/ HIF-2 transcription factors.  Therefore it could be suggested that the 
increase hypoxic gastrin gene expression was regulated via HIF-1 and HIF-2, 
acting alone or possibly in cooperation with each other.  The use of HIF-1α 
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siRNA only partially inhibited the induction of gastrin mRNA expression 
under hypoxic conditions, in both PAN1 and HCT116 cell lines.  To 
investigate whether the HIF-2 transcription factor plays a role in the regulation 
of the gastrin gene, the effect of HIF-2α siRNA transfection on gastrin gene 
expression should be determined.  Also, the gastrin promoter luciferase 
reporter construct could be transfected into a HIF-2α-dominant carcinoma cell 
line, such as RCC4, to determine whether the HIF-2 transcription factor could 
further increase the induction of luciferase expression, compared to that 
achieved via HIF-1. 
 
The HIF-1 transcription factor was only partially responsible for the large 
increase seen in hypoxic gastrin gene in a cell-line specific manner.  This may 
imply the need for another transcription factor, acting in synergy with HIF-1 to 
increase target gene expression.  For example, under hypoxic conditions, the 
key tumourigenic protein β-catenin is competitively-inhibited from binding to 
the TCF transcription factor, therefore preventing the up-regulation of β-
catenin/TCF target genes, such as c-myc and cyclin D1 (Kaidi et al, 2007).  
Instead, β-catenin is suggested to form a complex with HIF-1α, which then 
binds to promoter regions of HIF-1 target genes, increasing HIF-1-dependent 
transcription (Kaidi et al, 2007), which may include the gastrin gene.  To 
determine whether the addition of β-catenin further augments the 
transcriptional activity of HIF-1, the induction of luciferase expression after 
transfection with the gastrin promoter construct should be investigated in the 
presence of increasing concentrations of β-catenin. 
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Alternatively, HIF-1α has been shown to interact with the Notch transcription 
factor, specifically at its intracellular domain, which leads to enhanced 
recruitment of HIF-1 to the promoters of target genes, such as GLUT1 and 
lysyl oxidase, and therefore increasing its transcriptional activity (Sahlgren et 
al, 2008 Zheng et al, 2008).  The Notch transcription factor has a role in cell 
development and proliferation, and is especially important in the 
differentiation of stem cells (reviewed in Sahlgren et al, 2008).  Again, to 
determine whether the Notch transcription factor played a role in augmenting 
the hypoxic expression of the gastrin gene, the induction of luciferase 
expression after transfection with the gastrin promoter construct should be 
investigated in the presence of a dominant-negative Notch construct.  Similar 
findings have also been identified with the HIF-2 transcription factor, as HIF-
2α has been shown to act in cooperation with the transcription factor Elk-1, up-
regulating the expression of HIF-2α-specific target genes, such as cited-2 
(CBP/p300-interacting transactivator, with glutamic acid (E) and aspartic acid 
(D)-rich tail-2) and erythropoietin (Hu et al, 2007), both of which may also be 
linked to gastrin gene expression. 
 
If the increase in gastrin gene expression induced under hypoxic conditions 
partially involved HIF-1α or HIF-2α and alternative HIF-independent 
mechanisms, potential mechanisms may involve the transcriptional coactivator 
PGC-1α (peroxisome-proliferator-activated receptor-γ coactivator-1α), which 
alongside HIF-1α, is induced under hypoxic conditions and is responsible for 
the induction of VEGF expression and the resultant angiogenesis in skeletal 
muscle cells (Arany et al, 2008).  PGC-1α was shown to induce angiogenesis 
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in a HIF-1α-independent fashion, via forming a transcriptional complex with 
the orphan nuclear receptor ERR-α (Estrogen receptor-related receptor-alpha), 
that binds to ERR-α binding sites (AAGGTCA) within the promoter of target 
genes, instead of an HRE sequence (Arany et al, 2008).  It is possible that 
PGC-1α may also regulate the pro-angiogenic gastrin gene and therefore, the 
gastrin promoter should be investigated for the presence of ERR-α binding 
sites. 
 
Another possible indirect mechanism behind the hypoxia-induced gastrin 
expression could involve targeted RNA sequestration via miRNA (Micro-
ribonucleic acid)-dependent inhibition of mRNA translation.  miRNA are 
formed when hair-pin RNA molecules are cleaved into 21-23 nucleotide 
molecules (with a 2-3 nucleotide overhang) via Dicer enzymes (reviewed in 
Farazi et al, 2008; Liu et al, 2005), before being incorporated into ‘RISC’ 
(RNA-induced silencing complex), which also recruit Argonaute proteins 
(reviewed in Hutvagner and Simard, 2008; Meister, 2007).  The Argonaute 
proteins, associated with the miRNA-RISC complex binds to the 3’-
untranslated region of the mRNA strand, allowing the Argonaute proteins to 
compete with the eukaryotic translation initiation factor eIF4E for the cap 
binding, therefore preventing ribosomal association and the initiation of 
translation of the mRNA (reviewed in Hutvagner and Simard, 2008; Meister, 
2007).  The Argonaute proteins are also required for untranslated mRNA 
translocation to specific cytoplasmic ‘processing’ (P) bodies, where the mRNA 
can be either stored or degraded (Liu et al, 2005).  The increase in gastrin 
mRNA expression under hypoxic conditions could be due to increased 
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sequestration of untranslated gastrin mRNA within the P bodies.  This theory 
suggests that gastrin is not involved in tumour progression under hypoxic 
conditions, but may suggest that it is needed for recovery from hypoxia. 
 
Alternatively, the expression of the gastrin mRNA may be stabilised under 
hypoxic conditions via binding to ‘RNA binding proteins’ at its 3’-untranslated 
region.  Previous studies using VEGF mRNA revealed that the VEGF 
transcript binds to the double-stranded RNA-binding proteins, such as HuR, 
TIA-1 (T-cell intracellular antigen) and 76/NF90 (Levy et al, 1998; Nabors et 
al, 2001; Suswam et al, 2005; Vumbaca et al, 2008), which led to increased 
hypoxic VEGF mRNA stability and therefore increased VEGF protein 
secretion, in a HIF-1-independent fashion.  The binding protein targets AU-
rich elements at the 3’-untranslated region of the target mRNA transcript 
(Nabors et al, 2001; Suswam et al, 2005).  Repression of RNA binding 
proteins reduced both mRNA stability and ribosomal association, leading to a 
reduction of hypoxic VEGF expression and resultant angiogenesis within 
breast carcinoma orthotopic mouse model (Levy et al, 1998; Vumbaca et al, 
2008).  RNA binding proteins were consistently expressed in tumour models, 
especially in areas adjacent to necrotic regions, where pro-angiogenic factors, 
such as VEGF were expressed (Nabors et al, 2001).  Stabilisation of the gastrin 
transcript, via RNA-binding proteins would increase tumour progression; 
therefore, the 3’-untranslated region of the gastrin mRNA should be screened 
for RNA-binding protein elements. 
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7.7 Effects of gastrin on HIF-1α expression 
Exogenous amidated gastrin treatment of GI carcinoma cells only induced an 
increase in nuclear expression of the HIF-1α protein in the PAN1 carcinoma 
cell line, under normoxic conditions, despite several other carcinoma cell lines 
being investigated, including those from both similar and different tissues of 
origin.  The effect seen in the PAN1 cells was induced with either the 1nM or 
10nM gastrin concentration, however, was extremely weak and often difficult 
to visualise and interpret.   
 
Hypoxic HIF-1α protein expression was also investigated after exogenous 
treatment with amidated gastrin and again there was a slight indication that 
1nM gastrin induced HIF-1α expression in the PAN1 cells, although this was 
not significant.  The data was often difficult to quantify, due to the high levels 
of nuclear HIF-1α protein expression that were naturally induced under 
hypoxic conditions.  Any effect of the gastrin treatment would be masked by 
the strong HIF-1α induction.  Therefore, despite the evidence suggesting that 
normoxic signalling pathways, such as those involving PI3-kinase / Akt, 
MAPK and possibly gastrin signalling can induce nuclear HIF-1α 
accumulation, the actual expression levels achieved are lower than those 
induced via hypoxia (Li et al, 2005).  The increase induced by these pathways 
under hypoxic conditions probably had little cumulative effect on the total 
HIF-1α expression, compared to the amount induced via true hypoxia alone. 
 
Despite the lack of clear evidence of stabilisation of HIF-1α protein as a result 
of gastrin signalling, the resultant mRNA expression of its target gene VEGF 
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was significantly increased after treatment with 1nM or 10nM exogenous 
gastrin, under normoxic conditions.  To determine whether the increase in 
VEGF expression was a HIF-1α-mediated effect, cells transiently-transfected 
with either the VEGF-HRE or PGL4-(LDH)-HRE luciferase reporter plasmids 
were treated with either 1nM or 10nM exogenous gastrin. 
 
The treatment with amidated gastrin had no significant effect on the induction 
of firefly-luciferase expression, when compared to that induced by the 
scrambled control, which suggested that gastrin did not induce HIF-1α 
expression or activity.  This also indicates that the significant increase in 
VEGF mRNA expression induced after exogenous gastrin treatment was not 
dependent on HIF-1α expression, but other growth factor signalling pathways, 
such as NF-κB-signalling pathway (reviewed in Miknopadhyay and Datta, 
2004; Pradeep et al, 2005). 
 
Treatment with amidated gastrin had no significant effect on firefly luciferase 
induction or nuclear HIF-1α protein expression, with the exception of PAN1 
carcinoma cells.  It is not however, only the final amidated products of the 
gastrin gene that induce biological effects; processing intermediates, such as 
progastrin and gly-gastrin have been speculated to have their own independent 
biological roles.  Both progastrin and gly-gastrin have been shown to induce 
proliferation and development of the colonic mucosa (Cobb et al, 2004; 
Hollande et al, 1997; Koh et al, 1999; Koh et al, 2004; Ogunwobi and Beales, 
2006; Siddheshwar et al, 2001; Singh et al, 2003; Wang et al, 1996).  Some 
studies have suggested that colorectal carcinomas express progastrin and gly-
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gastrin over that of amidated gastrin (Hollande et al 1997; Thorburn et al, 
1997).  It is possible that exogenous treatment of GI carcinoma cells with 
either progastrin or gly-gastrin may up-regulate the expression or 
transcriptional activity of the HIF-1 transcription factor, instead of amidated 
gastrin. 
 
The data produced after treatment with exogenous amidated gastrin does not 
agree with a study conducted by Chao et al (2006), which used mice xenograft 
models, generated using HEK-293 cells, transfected with either the wild-type 
CCK-2 receptor or its splice variant CCK2i4, which retains intron 4 that is 
normally excised from the wild-type receptor.  Expression of the splice variant 
CCK2i4 receptor increased xenograft tumour growth as a result of endogenous 
gastrin signalling.  It acted via up-regulation of HIF-1α and its target gene 
VEGF in a Src-dependent fashion, leading to increased tumour microvessel 
density.  Expression of the wild-type CCK-2 receptor however, failed to 
induce similar increases in tumour proliferation and angiogenesis.  This data 
suggests that the increase in HIF-1α protein expression induced in the PAN1 
carcinoma cells under normoxic conditions may have been a genuine result, 
which failed to reach significance as it only involved a sub-set of cells that 
possibly expressed the CCK-2 receptor splice variant.  Over-expressing the 
CCK2i4 receptor in a panel of GI carcinoma cells would help determine 
whether HIF-1α protein expression and transcriptional activity was induced via 
gastrin signalling through this alternative receptor. 
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7.8 Effects of gastrin on HIF-1α expression – possible 
mechanisms of action 
There are two main pathways that gastrin could utilise, to induce HIF-1α 
protein stabilisation; the PI3-kinase / Akt signalling pathway or the NF-κB 
signalling pathway.  Gastrin has been shown to up-regulate the expression of 
activated (i.e. phsophorylated) Akt protein, in a CCK-2 receptor-dependent 
fashion (Harris et al, 2004; Todisco et al, 2001), which enhanced cell survival 
in a pro-angiogenic and anti-apoptotic manner.  The activated Akt protein has 
not been directed linked to the stabilisation of HIF-1α protein.  Instead,  
downstream targets of Akt signalling, such as mTOR and FRAP have been 
suggested to stabilise HIF-1α expression under normoxic conditions, as shown 
using PI3-kinase, FRAP or mTOR target-specific inhibitors (Hudson et al, 
2002; Lang et al, 2007; Laughner et al, 2001; Treins et al, 2002;  Zhong et al, 
2000).  To investigate whether gastrin induced HIF-1α expression via the PI3-
kinase / Akt signalling pathway, the GI carcinoma cells could be pre-treated 
with either Akt pathway inhibitors (e.g. LY294002 (for PI3-kinase) or 
rapamycin (for mTOR/FRAP)) or pathway activators (e.g. dominant-negative 
Akt construct) before the effect on HIF-1α expression was determined, 
following exogenous gastrin treatment.   
 
Gastrin has also been shown to activate NF-κB signalling, via initiating the 
degradation of the inhibitory protein IκB (inhibitor of NF-κB) by its kinase, 
IκB-kinase (IKK), leading to IκB ubiquitination and resultant proteasomal 
degradation, via a CCK-2-receptor-PKC-dependent signalling mechanism 
(Ogasa et al, 2003).  NF-κB is normally sequestered in the cytoplasm via the 
actions of IκB, but is released upon IκB phosphorylation and is then free to 
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translocate to the nucleus, up-regulating target gene expression.  The activation 
of IKK (especially the β-isoform) in macrophages has also been linked to NF-
κB nuclear translocation, which leads to increased levels of HIF-1α protein 
accumulation and increased target gene expression, such as VEGF, COX-2 and 
GLUT1, as well as the usual increase in cytokine and chemokine expression 
(Rius et al, 2008), as it induces the degradation of IκB, therefore up-regulating 
NF-κB activity.  In this study, NF-κB activity was also linked to increased 
HIF-1α mRNA expression under normoxic conditions, as well as increased 
HIF-1α protein expression under hypoxic conditions, as the HIF-1α promoter 
contains a NF-κB response element, located at -197bp to -188bp (Rius et al, 
2008).  NF-κB translocation was shown to occur prior to HIF-1α protein 
accumulation, suggesting that in macrophages, NF-κB may control HIF-1α 
expression under hypoxic conditions (Rius et al, 2008). 
 
If gastrin was responsible for the up-regulation of HIF-1α expression, it would 
induce the expression of several pro-survival characteristics, which would be 
beneficial for solid tumour progression.  Alongside the increase in VEGF, stem 
cell factor and glycolytic enzyme activity (Forsythe et al, 1996; Han et al, 
2008; Semenza et al, 1994), which would aid neovascularisation (in a VEGF-
receptor and EGF-receptor-dependent mechanism) and anaerobic respiration, 
an increase in HIF-1α activity would also aid tumour progression, metastasis 
and invasion.  Therefore, the up-regulation of the HIF-1 transcription factor 
could be the mechanism behind some of pro-malignant effects induced by 
gastrin.   
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In a study investigating the significance of HIF-1α in the progression of gastric 
cancer, HIF-1α protein expression was shown to increase in both density and 
intensity as tumourigenesis progressed from Helicobacter pylori–associated 
gastritis, through intestinal metaplasia and epithelial dysplasia to full gastric 
adenocarcinoma (Griffiths et al, 2007).  The HIF-1α expression was again 
significantly associated with the invading tumour margin and areas of necrosis, 
as seen in previous studies (Mizokami et al, 2006; Zhong et al, 1999), as well 
as macrophages, indicating a role of HIF-1α in an inflammatory response.  In 
another study, HIF-1α protein expression was also significantly correlated with 
the depth of tumour invasion and therefore was considered as a poor patient 
prognostic factor, despite only being expressed in 16% of gastric tumour 
samples tested (Oh et al, 2008).  HIF-1α was responsible for the up-regulation 
of pro-invasion target genes, such as MMP-2, extracellular matrix proteases 
and uPAR (urokinase plasminogen activator receptor), as highlighted in 
HCT116 carcinoma cells (Krishnamachary et al, 2003).  HIF-1α was also 
responsible for up-regulating the expression of pro-metastatic proteins TWIST 
and lysyl oxidase (Erler et al, 2006; Yang et al, 2008), aiding tumour 
metastasis and therefore increasing levels of treatment failure and patient 
mortality.  TWIST is another bHLH transcription factor, which is normally 
required during development for gastrulation and mesoderm-specification, but 
has been implicated in cancer metastasis, being associated with aggressive 
tumour progression and poor patient outcome (reviewed in Peinado and Cano, 
2008).  HIF-1 regulates the expression of both TWIST and lysyl oxidase via 
binding to an HRE sequence within their promoters (Erler et al, 2006; Yang et 
al, 2008).  The induction of lysyl oxidase enhanced epithelial-to-mesenchymal 
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transition, a key process behind tumour cell motility and invasion (Higgins et 
al, 2007; Sahlgren et al, 2008). 
 
A similar metastatic phenotype is also generated as a result of gastrin 
signalling, which is known to play a role in tumour cell invasion and 
extracellular membrane remodelling.  For example, gastrin has been shown to 
up-regulate the expression of molecules responsible for the degradation of the 
extracellular matrix, such as MMP-9 in both cell and patient models 
(Wroblewski et al, 2002).  As a result, gastrin induced the invasion of 
basement membranes in a MMP-9-dependent fashion, acting via a CCK-2 
receptor-PKC-Raf-MEK-dependent signalling pathway (Wroblewski et al, 
2002).  Gastrin also induced the expression of focal adhesion kinase, a key 
molecule in tumour malignancy, in a CCK-2 receptor-dependent manner (Yu 
et al, 2006), which resulted in increased colon cancer invasion and lymph node 
metastasis.  Finally, the presence of hypergastrinemia has been associated with 
liver metastasis in colorectal cancer patients (Kameyama et al, 1993).  The up-
regulation of a metastatic and invasive phenotype, induced by gastrin 
signalling could have been transmitted via the HIF-1 transcription factor, 
which would result in the up-regulation of the expression of MMPs and pro-
metastatic proteins to promote tumour invasion.. 
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7.9 Biological and clinical implications of the up-
regulation of gastrin in GI carcinoma under hypoxic 
conditions 
The induction of the gastrin gene under hypoxic conditions would have 
implications throughout all stages of tumour progression, from its initiation, 
through to development of metastatic phenotype.   
 
The expression of the gastrin gene has been shown to be regulated by the β-
Catenin/TCF-dependent pathway (Koh et al, 2000), which would allow for 
increased gastrin signalling acting via its CCK-2 receptor.  However, in what 
could be described as a positive feedback pathway, gastrin has also been 
shown to up-regulate the expression of the β-catenin gene, which leads to 
increased colorectal tumour growth and survival, by up-regulating β-
catenin/TCF target gene expression (Cao et al, 2006; Pannequin et al, 2007), 
which includes cyclin D1 and c-myc.   
 
Under physiological conditions, HIF-1α protein has been shown to sequester 
Max, the dimerisation partner of c-myc, either directly or via the up-regulation 
of the alternate binding partner MXI-1, therefore preventing c-myc 
transactivation (reviewed in Dang et al, 2008; Corn et al, 2005; Koshiji et al, 
2004).  HIF-1α also directly blocks the activity of c-myc, either by directly 
competing for binding to the promoter (as both HIF-1α and c-myc use the 
consensus sequence, ACGTG) (Koshiji et al, 2004), or via competing with 
TCF for interaction with β-catenin (Kaidi et al, 2007).  Under pathological 
conditions, which may include hypoxia, c-myc can become de-regulated.  This 
deregulation of c-myc has been described in approximately 30% of cancers, 
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including colorectal carcinomas (reviewed in Dang et al, 2008), and even may 
be as a result of gastrin signalling up-regulating the β-catenin signalling 
pathway.   
 
HIF-1α has been suggested to act in co-operation with the deregulated c-myc 
protein, promoting key cellular functions, such as glycolysis and angiogenesis 
via up-regulating hexokinase 2 and VEGF expression respectively (Kim et al, 
2007; Robey et al, 2008).  There is a level of redundancy between the 
transcriptional targets of the c-myc and HIF-1 transcription factors (possibly 
due to the similarity in both their recognition sequences), as they both lead to 
the induction of key metabolic and angiogenic gene expression, which would 
further aid tumour survival and neovascularisation.  Whilst the expression of 
hexokinase 2, pyruvate dehydrogenase and VEGF have been shown to be 
induced via the two transcription factors working in co-operation (Kim et al, 
2007), the expression of other target genes such as lactate dehydrogenase and 
glyceraldehyde-3-phosphate dehydrogenase show no such co-operation and 
therefore are up-regulated independently by the two transcription factors 
(reviewed in Dang et al, 2008).  The up-regulation of respiration induced via 
deregulated c-myc activity (in co-operation with HIF-1α), leads to the 
increased uptake of glucose and corresponding production of lactate, even in 
the presence of oxygen.  This is known as ‘The Warburg Effect’, which is 
defined as “the propensity for cancer cells to convert glucose to lactate in the 
presence of adequate oxygen levels” (Dang et al, 2008).  Tumour cells take up 
higher levels of glucose in an attempt to keep up with their increased metabolic 
demands.  This altered glycolysis can be further enhanced via over-expression 
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of either c-myc or HIF-1α (as a result of oncogenic mutations), and would 
result in increased tumour survival.  To determine whether the increase of 
deregulated c-myc was gastrin-dependent, the expression of c-myc under 
hypoxic condition should be investigated, in the presence of anti-gastrin 
agents, such as gastrin siRNA, CCK-2 receptor antagonists or gastrin 
immunogens. 
 
The presence of hypergastrinemia is a common occurrence in patients with GI 
cancer (Bombski et al, 2003; D’Agostino et al, 1995; Hartwich et al, 2001; 
Konturek et al, 2000; Mihas et al, 1995; Seitz et al, 1991; Thorburn et al, 
1998), which would aid increased tumour growth and survival (Chu et al, 
1995; McGregor et al, 1982; Watson and Smith, 2001), by inducing pro-
survival characteristics, including cell growth (Colucci et al, 2005; Haigh et al, 
2003; Smith et al, 2004; Tsutsui et al, 1997), angiogenesis (Clarke et al, 2006; 
LeFranc et al, 2004), and invasion (Clarke et al, 2006; Wroblewski et al, 2002; 
Yu et al, 2006), producing a tumour that is solid in nature.   
 
As the tumour expands, aided by the pro-survival actions of gastrin, the 
existing vasculature is unable to supply the entire tumour with its oxygen and 
nutrient requirements (reviewed in Vaupel et al, 1989), which would lead to 
the generation of areas of hypoxia.  The induction of hypoxia would further 
increase the expression of gastrin, as shown using both gene and protein 
expression, which could further aid cell survival and possibly induce 
metastasis of the tumour to other sites.   
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The induction of tumour hypoxia is known to increase resistance to both 
radiotherapy (Brizel et al, 1997; Nordsmark et al, 1996) and chemotherapy 
(Hussein et al, 2006; Sermeus et al, 2008; Teicher et al, 1981; Teicher et al, 
1990) in cancer patients.  The increased presence of gastrin within hypoxic 
regions of tumours may further increase resistance to both chemotherapy and 
radiotherapy (Wang and Semenza, 1993; Wang et al, 1995).   
 
As gastrin may play a role in the development and progression of GI tumours, 
it may be beneficial to include anti-gastrin therapies in the treatment strategies 
of patients.  These could include CCK-2-receptor antagonists, such as YM022 
(Kitano et al, 2000) or Z-360 (Grabowska et al, 2008; Kawasaki et al, 2008), 
which would act at the gastrin receptor, blocking the transmission of any pro-
survival processes.  Alternatively, the addition of an immunogen that induces 
the production of antibodies against gastrin, such as G17DT (Gilliam et al, 
2004), would allow for gastrin to be sequestered (via binding at their N-
terminus (Watson et al, 1999)), therefore neutralising any trophic effects it 
may induce.  The addition of a bioreductive, such as tirapazamine, would 
sensitise the hypoxic component of the metastatic tumour to both radiotherapy 
and chemotherapy (Adams et al, 2008; Masunaga et al, 2000) and therefore 
may increase the efficiency of the anti-gastrin agent. 
 
Thus in conclusion, this study has further clarified the prevalence and potential 
importance of hypoxia in GI cancer, and shows a link to a common de-
regulated hormone implicated in GI carcinogenesis.  The study has therefore 
identified a new therapeutic approach for the treatment of GI cancer patients, 
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(by combining anti-gastrin agents with bioreductive drugs), which is urgently 
required, and includes a possible mechanisms to overcome radio and 
chemotherapeutic resistance.   
 
7.10 Summary of future work 
Firstly, the hypoxic expression of gastrin would be examined, using either 
mouse models or human tumour samples, to confirm that gastrin is up-
regulated under hypoxic conditions within a true pathological situation.  
Regions of hypoxia / HIF-1α expression would be correlated with gastrin 
expression (using in situ hybridisation), ensuring that the samples were fixed 
quickly after tissue harvesting to preserve the presence of HIF-1α, which has a 
half-life of less than 5minutes under normoxic conditions (Wang et al, 1995). 
 
Next, the putative gastrin HRE sequence DNA should be rescreened for the 
presence of an adjacent, downstream Sp-1 binding site, as this is suggested to 
augment HIF-1 transcriptional activity (Welford et al, 2006).  The presence of 
a Sp-1 site, plus the use of an alternative positive control (i.e. the VEGF-
promoter plasmid) may prove one or more of the putative gastrin HRE 
constructs successful.  Also the HRE sequence within the alternative gastrin 
transcript should be cloned into a luciferase reporter plasmid and investigated.  
Multiple carcinoma cell lines have been shown to express this alternate 
transcript (Grabowska et al, 2008) and therefore would express the alternative 
putative gastrin HRE sequence. 
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Next, the other possible mechanisms that may explain the increase in gastrin 
gene under hypoxic conditions require investigation.  These included: 
 
• The role of the HIF-2 transcription factor.  As the HIF-1 transcription 
factor was shown to be only partially responsible for the induction of 
gastrin under hypoxic conditions, it is possible that the gastrin gene is at 
least partially regulated by the HIF-2 transcription factor.  Whilst the HIF-1 
and HIF-2 transcription factor share a level of redundancy in their target 
gene expression, they are also responsible for the regulation of unique 
genes.  For example, HIF-2 is solely responsible for cyclin D1 and Oct4 
expression regulation under hypoxic conditions (reviewed in Gordan and 
Simon, 2007).  Therefore, gastrin gene expression should be investigated 
after transfection of HIF-2α siRNA (alone and in combination with HIF-1α 
siRNA).  Also, hypoxic gastrin expression should be investigated in a HIF-
2α-dominant cell line, such as RCC4.   
 
• The need for a second, unrelated transcription factor.  The protein β-
catenin was suggested to act in synergy with HIF-1α to up-regulate target 
gene expression (Kaidi et al, 2006) and has also been implicated in the 
regulation of gastrin gene expression itself (Koh et al, 2000).  Therefore, to 
investigate whether HIF-1α and β-catenin dually regulate the expression of 
gastrin gene under hypoxic conditions, GI carcinoma cell lines could be 
either transfected with a constitutively active β-catenin or treated with a β-
catenin inhibitor, such as glycogen-synthase kinase 3β, prior to gastrin 
expression being determined.   
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 Also, the Notch transcription factor has been shown to interact directly 
with HIF-1, further augmenting the expression of HIF-1 target genes 
(Sahlgren et al, 2008 Zheng et al, 2008).  To determine whether Notch 
plays a role in the up-regulation of gastrin gene expression, GI carcinoma 
cells could be transfected with a dominant-negative Notch, prior to 
incubation under hypoxic conditions.   
 
• The role of the transcriptional co-activator PGC-1α should also be 
investigated. PGC-1α independently up-regulated the expression of VEGF 
under hypoxic conditions, without any interaction with the HIF-1 
transcription factor (Arany et al, 2008).  Therefore, it may be responsible 
for the up-regulation of the gastrin gene via a similar mechanism.  Firstly, 
the DNA upstream of the coding region should be screened for the 
presence of the PGC-1α-dependent ERR-α binding site (Arany et al, 2008).  
If this proves successful, GI carcinoma cell lines could be pre-treated with 
a PGC-1α inhibitor prior to exposure to hypoxia to determine its affect on 
gastrin gene expression.  
 
• The role of P-bodies and RNA-binding proteins.  The expression of both P-
bodies and RNA binding proteins should be determined under hypoxic 
conditions, before being correlated with the gastrin gene expression.  The 
3’-untranslated region of the gastrin gene should also be screened for AU-
rich regions, which is a key feature for RNA sequestration by RNA binding 
proteins.  RNA binding proteins have previously been shown to be 
expressed adjacent to areas of necrosis and have been correlated with 
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expression of pro-angiogenic factors (Nabors et al, 2001), therefore hold 
similar properties to the HIF-1 transcription factor. 
 
Finally, the relationship between gastrin, HIF-1α, β-catenin and c-myc requires 
further investigation.  The actions of gastrin may increase the level of c-myc 
expression, by acting via the β-catenin/TCF signalling pathway.  Whereas, 
HIF-1α has been linked to c-myc inhibition under physiological conditions, via 
both direct and indirect mechanisms (reviewed in Dang et al, 2008).  Under 
pathological conditions, such as cancer however, HIF-1α has been suggested to 
interact with c-myc, and as a result enhances glycolysis (reviewed in Dang et 
al, 2008).  This c-myc may have been induced via the actions of gastrin 
signalling, whose expression was increased under hypoxic conditions. 
 
The full role of gastrin in this relationship has not been investigated; by 
determining the role of gastrin, answers may be found that could solve this 
conundrum of the c-myc/HIF-1α interaction. 
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